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ABSTRACT
For most cancers, the formation of distant metastasis is the point at which clinical
treatment shifts from curative intent to extending progression free survival. Physi-
cians are currently unable to diagnose metastasis until disseminated tumor cells affect
the function of a target organ as a secondary tumor. This dissertation describes a
novel approach where implantable biomaterial scaffolds are used to recruit metastatic
tumor cells for early detection prior to colonization of solid organs. This recruitment
of tumor cells to a defined site can not only serve as a platform for detection, but can
also have therapeutic effects and be used as a platform to study metastatic processes.
This dissertation describes work in each of these three areas including using an im-
plantable biomaterial scaffold for early detection, therapeutic benefit, and a platform
to study metastasis. The therapeutic benefit of scaffolds was demonstrated by scaffold
implantation significantly enhancing disease-free survival in a murine model of triple
negative breast cancer. Myeloid derived suppressor cells were the key population of
immune cells whose capture at the scaffold and reduction in the spleen and primary
tumor lead to enhanced survival. In an effort to probe the contributions of vari-
ous immune cell types to the formation and maintenance of the pre-metastatic and
metastatic niche in vivo, a gene delivery approach was utilized to alter the immune
microenvironment of the scaffold and investigate the recruitment of tumor cells, find-
ing reduced immune and tumor cell recruitment with IL-10 delivery and developing
a model of tumor cell recruitment that is dependent upon the proportion of each im-
mune cell type in the niche. Additional efforts to use the scaffold to study metastasis
included studying scaffold captured tumor cells relative to tumor cells derived from
xxvi
other locations. Scaffold captured tumor cells were a highly aggressive population of
metastatic tumor cells similar to those found in a metastatic lung, underscoring the
use of the scaffold as a sampling location for metastatic disease that is reflective of
tumor cell phenotype in solid organs. Next, biomaterial scaffolds were also validated
in transgenic models of both breast and pancreatic cancer to identify immune dys-
regulation as a function of tumor burden, recruit tumor cells, and to reduce tumor
burden. Finally, non-invasive ultrasound imaging and subsequent spectral analysis
techniques were applied to identify changes in the scaffold associated with tumor
burden and tumor cell recruitment. Taken together, this body of work supports that
the implantable biomaterial scaffold technology provides a robust and novel approach
for the early detection of metastatic disease in both breast and pancreatic cancer,
therapy to divert both pre-metastatic niche forming immune cells and tumor cells
themselves to an ectopic site and away from solid organs, and as a platform to study





Cancer metastasis is responsible for 90% of cancer related deaths. As the second
most common cause of death in the United States, an estimated 1.7 million new cases
will be diagnosed in 2018 and 610,000 patients will die from the disease. Metastasis is
deadly, not only because tumor cells colonize a vital organ and prevent normal func-
tion, but also because there are no proven detection methods to identify either an
increased risk for metastasis or metastasis at it’s earliest stages before organ function
is compromised. The research presented in this dissertation exists at the intersec-
tion of biomaterials, tissue engineering, immunoengineering, and cancer biology and
aims to develop novel detection strategies for metastasis, use the biomaterial plat-
form to study metastasis and the pre-metastatic niche, and to investigate the use of
biomaterials as a therapeutic for metastasis.
1.2 Contents
Chapter 1 provides a general introduction to the concept of engineering the
pre-metastatic niche and the research topics explored in this dissertation.
Chapter 2 establishes an intellectual framework for the dissertation and sum-
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marizes the relevant history of the pre-metastatic niche, cancer metastasis, and engi-
neering approaches to study these phenomena.
Chapter 3 introduces the concept of using implantable biomaterial scaffolds for
early detection of metastasis and therapeutic benefit in combination with a resection
of the primary tumor. The central goal of this work was to develop a slowly degrading
biomaterial scaffold that is capable of recruiting metastatic tumor cells in a chronic
implantation setting. The scaffold microenvironment was found to be dynamic with
primary tumor progression, demonstrating an increase in myeloid derived suppressor
cells with concordant with metastasis development in the scaffold. We demonstrate
that in combination with resection of the primary tumor after detection of tumor cells
in the implant, scaffold implantation enhances survival relative to a mock surgery.
Chapter 4 discusses the use of the scaffold technology as a platform to investigate
the role of various cytokines and immune cell populations in tumor cell recruitment
to a metastatic site. Lentivirus encoding for immunomodulatory factors including
CXCL12, Il10, and CCL2 was delivered from the scaffold and investigated for its
ability to alter the immune cell populations present within the scaffold and subse-
quently alter tumor cell recruitment. Delivery of CXCL12 was found to enhance
immune cell recruitment while delivery of IL10 reduced immune cell recruitment. Tu-
mor cell recruitment to the engineered niche was also investigated and IL10 was found
to significantly reduce tumor cell recruitment to the scaffold. The role of individual
immune cell populations was investigated by developing a multiple linear regression
model for tumor cell recruitment across all lentiviral conditions. Finally, the effect
of immunomodulated microenvironments were evaluated by treating tumor cells with
conditioned media generated from explanted scaffolds with the lentivirus of interest.
This chapter demonstrates that the scaffold may be used as a platform to validate
key contributors to tumor cell recruitment and phenotype at a metastatic site.
Chapter 5 describes the investigation of the tumor cells recruited to biomaterial
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scaffolds in vivo and comparison to the primary tumor and lung metastasis. Tumor
cells were isolated from various metastatic locations in vivo and expanded into cell
lines. These locations included the primary tumor (PT), scaffold (SCAF), and lung
(LUNG). Following the generation of cell lines from each location, the phenotype of
these tumor cell lines were compared both in vitro and in vivo. SCAF cells were found
to be more aggressive in vitro including higher migration, mammosphere formation,
cancer stem cell surface marker and 30 times more metastatic to the lung compared to
the PT line when inoculated in vivo. The molecular differences accounting for differ-
ential metastatic behavior and phenotype were investigated using RNAseq and Hi-C
techniques for function and structure of the genome respectively. RNAseq identified
key differentially expressed pathways including TNFα signaling via NFκB which was
enriched in SCAF relative to PT. This finding was supported by an alteration in both
structure (Hi-C) and function (RNAseq) in genes with NFκB binding sites between
SCAF and PT cells. Additionally TNFα via NFκB was also enriched in LUNG rel-
ative to PT indicating this may be a common mechanism of metastatic phenotype
between these two cell lines. This chapter demonstrates that the scaffold may be used
as a sampling location for metastatic tumor cells that are reflective of those found in
the lung.
Chapter 6 describes the use of biomaterial scaffolds in spontaneous models of
tumorigenesis and metastasis. All previous models of metastasis described in this
dissertation relied upon orthotopic injection of tumor cells into the mammary fat pad
of healthy mice. In this chapter we investigated the ability of the scaffold to recruit
metastatic cancer cells in two models of spontaneous tumorigenesis and metastasis.
We first started with the spontaneous breast cancer model MMTV-RFP-PyMT. We
found the scaffold recruits tumor cells and displays tumor-burden dependent immune
dynamics. We next investigated the spontaneous model of pancreatic cancer KPCY.
In this model we again found that the scaffold recruits tumor cells and displays tumor-
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burden dependent immune dynamics. We also found a reduction in metastatic burden
in the KPCY model with scaffold implantation relative to mock surgery. Finally, we
investigated the ability of the immune signature in the scaffold to differentiate between
these two tumor types and found differential tumor-dependent immune modulation
in these two cancers. The recruitment of tumor cells and tumor-dependent immune
dynamics by biomaterial scaffolds in two very different tumor models in two cancers
with very different clinical outcomes highlights the versatility and translatability of
this platform technology.
Chapter 7 discusses the use of high frequency spectral ultrasound imaging or
SUSI to detect metastasis to biomaterial scaffolds. Biomaterial scaffolds that recruit
tumor cells in vivo are a promising platform technology for the early detection of
metastasis in patients with breast cancer. However, a key need for this platform to
be implemented in patients is a non-invasive monitoring system. In this chapter the
use of SUSI as a non-invasive monitoring tool is detailed in both human xenograft and
mouse syngeneic models of breast cancer metastasis. Tissue parameters identifying
alterations associated with metastasis were discovered that are consistent across both
human and mouse tumors. The biological mechanism of these alterations was also
investigated via SUSI analysis of decellularized scaffolds from tumor free and tumor
bearing mice as well as analysis of scaffold infiltrating cells from tumor free and tumor
bearing mice. Finally, classification algorithms were designed and applied to the data
to stratify SUSI signatures from tumor free and tumor bearing mice. This chapter
highlights the potential avenues for translation of the scaffold not only as a site to
collect tumor cells but also as a site to monitor both non-invasively and longitudinally
to identify tissue parameter alterations associated with development of metastasis.
Chapter 8 concludes the dissertation and summarizes the presented findings.
The significance and impact of the work described herein are discussed and proposed
future directions are detailed.
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Figure 1.1: Overview of dissertation contents.
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CHAPTER II
Engineering the Pre-metastatic Niche
2.1 Authors
Brian A Aguado*, Grace G Bushnell*, Shreyas S Rao, Jacqueline S Jeruss, Lonnie
D Shea * These authors contributed equally to this work
2.2 Abstract
The pre-metastatic niche forms during metastatic progression, in which the pri-
mary tumor drives the aberrant accumulation of immune cells in target organs to
prime the microenvironment for tumor cell colonization. Since the discovery of the
pre-metastatic niche, there has been great interest in deconstructing the complexity
of the niche and identifying the roles of individual niche components in mediating
tumor cell homing, colonization, and proliferation. Technological advances in bio-
materials engineering have enabled various iterations of pre-metastatic niche mimics,
in which the immune response, soluble factors, extracellular matrix proteins, and
other niche cells have been used to mimic the niche both in vitro and in vivo with
user-defined parameters. Given the newfound ability to manipulate metastatic cell
trafficking in vivo, engineered pre-metastatic niche mimics have also been used as
oncomaterials, demonstrating both diagnostic and therapeutic capabilities. In sum,
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the juxtaposition of pre-metastatic niche biology and biomaterials engineering have
enabled unique discoveries of how tumor cells interact with pre-metastatic niches,
which may offer insights for future strategies to block pre-metastatic niche formation
and cellular interactions in metastatic cancer patients.
2.3 Introduction
Diagnosing a patient with metastasis often indicates the disease has become in-
creasingly difficult to treat effectively, since metastasis is responsible for 90% of
cancer-associated deaths [1, 2]. The journey of a metastatic cell from a primary
tumor to a secondary target organ is a progressive cascade of multiple events, involv-
ing numerous microenvironmental signals at each stage of disease progression [3–5].
Briefly, the metastatic cascade begins with invasion, where primary tumor cells un-
dergo a phenotypic change termed the epithelial-mesenchymal transition (EMT) to
degrade the tumor basement membrane and move into the surrounding tumor vascu-
lature to become a circulating tumor cell (CTC). CTCs are attracted via chemokine
gradients to organ microenvironments through a process known as homing. Once a
CTC encounters the target organ microenvironment, the CTC escapes the vasculature
via extravasation and is then classified as a disseminated tumor cell. During colo-
nization, the disseminated tumor cell encounters an attractive and permissible niche
at a target organ, where the tumor cell adheres, proliferates, and begins to form a
secondary tumor. At this point in the cascade, secondary tumors begin to negatively
affect organ function and dramatically decrease chances of survival. In 1889, Steven
Paget developed the seed and soil hypothesis, positing that the spread of tumors is
not random but governed by regulated processes where the metastatic tumor cell, or
seed, grows more optimally in organ soils primed for tumor cell arrival [6]. Pagets
observations were the first to describe cancer cell dissemination as pre-determined,
and that cancer cells tend to colonize specific tissue types. For example, in the case
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of breast cancer, metastases tend to form primarily in bone tissues, liver, lung, and
brain, indicating a tropism for specific microenvironments [3]. This primed microenvi-
ronment located at target organs has been termed the pre-metastatic niche (Figure
2.1) and is involved in promoting tumor cell homing, colonization, and growth at
a target organ. The pre-metastatic niche is a complex microenvironment, which in-
cludes inflammatory immune cells, stromal cells, extracellular matrix (ECM) proteins,
tumor-secreted exosomes, and homing factors. In brief, niche formation is a function
of primary tumor microenvironment formation and evolution. Tumor secreted fac-
tors and tumor-derived exosomes (Figure 2.1A) mobilize and recruit bone marrow
derived cells (BMDCs) to niches in secondary organs (Figure 2.1B) where they inter-
act with the local stroma to create permissive and attractive sites for metastatic cells
(Figure 2.1C, 2.1D) [7]. The niche was first described by Kaplan et al. through the
arrival of VEGFR1+ BMDCs to the metastatic site, which preceded and predicted
the arrival of tumor cells [8]. Additional BMDC populations have been implicated in
the formation of the pre-metastatic niche including CD11b+ myeloid cells, myeloid
derived suppressor cells (MDSCs), neutrophils, tumor-associated macrophages, and
regulatory T cells [9–16]. Tumor-secreted factors and exosomes can also directly mod-
ify the host stroma to establish a supportive microenvironment [17, 18]. Additionally,
fibroblasts, endothelial cells, and lung epithelial cells have been associated with the
establishment of the pre-metastatic niche via secretion of inflammatory cytokines and
chemokines [10, 13, 19]. Though there is evidence that pre-metastatic niche formation
leads to metastases, there is an urgent need to further elucidate the individual and
combinatorial cues that promote tumor cell homing, colonization, and proliferation at
the pre-metastatic niche, with the goal of developing novel therapeutic interventions.
Due to biological complexity and commonalities with primary tumor progression, the
contributions of individual components leading to metastasis have been challenging
to study in vivo. Biomaterial-based strategies have been developed to deconstruct
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these complex environments and focus on distinct metastatic processes, including pri-
mary tumor formation [20–22], invasion [23], and extravasation [24, 25], as well as
metastatic cell homing [26], colonization [27], and proliferation [28]. Tissue engineer-
ing principles are being applied to model the pre-metastatic niche environment as a
means to identify and study the key factors driving tumor cell activity at an organ
site. Compared to more traditional genetic or transgenic animal models for evaluat-
ing metastatic progression, studying these processes using an engineered ectopic site
in vivo avoids the need for biologically modifying the tumor or host (Table 2.1).
As a result, the progression of the tumor, formation of metastases, and phenotype
of the host are kept constant, thus reducing numerous confounding biological fac-
tors. The design of artificial, user-defined niches using biomaterials may facilitate the
identification of components of the pre-metastatic niche in vivo, which may lead to
strategies that efficiently prevent niche formation, divert metastatic cells away from
target organs, or develop early detection strategies [29, 30]. Several factors should
be considered when implementing biomaterials to engineer a pre-metastatic niche, in-
cluding choice of material (synthetic and/or natural), fabrication method, inclusion of
bioactive cues, degradability, and porosity (Table 2.2). Furthermore, biomaterials-
based tools that mimic the pre-metastatic niche have recently been shown to have
translational opportunities, enabling novel detection and therapeutic strategies in an-
imal models that have been previously unattainable using conventional approaches
[31]. The strategies for engineering mimics of the pre-metastatic niche are described
in this review, with a focus on (i) how biomaterials have been used to probe ques-
tions regarding tumor cell recruitment to an engineered niche, (ii) tumor cell behavior
upon arrival to a niche, and iii) how engineered niches may be used for detection and
therapeutic strategies.
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Figure 2.1: Formation of the pre-metastatic niche. (A) Hypoxic tumor sheds
exosomes (yellow dots) to simultaneously prepare the niche at a target
organ and to stimulate mobilization of BMDCs. Other tumor-secreted
factors (e.g. lysyl oxidase) crosslink ECM proteins (purple curves). (B)
BMDCs (green cells) accumulate at prepared sites, adhering to accumu-
lated ECM. (C) BMDCs and other immune cells (e.g. myeloid derived
suppressor cells) secrete factors (orange dots) to induce metastatic cell
(blue cells) homing to niche sites. (D) Metastatic cells colonize and pro-
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-Direct evidence for the
role of a factor or cell type
in metastasis
-Ability to knock-out and
knock-in specific genes
-Costly and time intensive
-Potential for off-target ef-
fects on health of the an-
imal or on tumor progres-
sion
Table 2.1: Strategies for characterizing the pre-metastatic niche and the for-
mation of metastasis
2.4 Cancer Cell Recruitment to an Engineered Niche
Numerous tissue engineering approaches have been utilized to create biomaterial
platforms to mimic properties of the pre-metastatic niche (Table 2.2). Material op-
tions include synthetic degradable materials (e.g. poly(lactic-co-glycolic acid), PLG),
synthetic non-degradable materials (e.g. polyacrylamide), and natural materials (e.g.
silk). Each of these substances can be formed into a porous scaffold structure capable
of (i) supporting retention of loaded factors or cells, (ii) facilitating integration with
a host tissue upon implantation, (iii) facilitating formation of a defined microenvi-
ronment in vivo and (iv) ultimately providing an ectopic site for the recruitment of
metastatic tumor cells. The choice of material depends on the desired application
and feature of the pre-metastatic niche to mimic. For example, in applications where
the desired goal is to simulate the bone microenvironment, relatively stiff biomate-
rials with similar mechanical properties to bone may be advantageous [32]. These
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Table 2.2: Materials and biological modifications for the engineering of the
pre-metastatic niche.
materials can be combined with appropriate factors implicated in organotropism to
specific sites to better emulate the properties of the target organ [33]. A platform
that provides facile and sustained delivery of the factor or cell type being investigated
can serve to examine the contribution of that factor to the homing and colonization
of cancer cells [31, 34]. This combination of biomaterials and biological modifications
provides a vast toolkit for dissecting the molecular components of the pre-metastatic
niche and discovering novel contributors to pre-metastatic niche formation and func-
tion in vivo.
2.4.1 Immune cell trafficking
Multiple immune cell types are involved in pre-metastatic niche formation, and the
complexity of the niche has confounded the analysis of the role for each cell type. In
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addition to VEGFR+ BMDCs playing a major role in establishing the pre-metastatic
niche, other myeloid cells including MDSCs [45, 46], macrophages [47], and monocytes
[15] contribute to niche formation and tumor cell homing. For instance, hypoxic tu-
mor cells secrete lysyl oxidase which crosslinks collagen IV in the lung and facilitates
the accumulation of CD11b+ monocytes, ultimately leading to pre-metastatic niche
formation [10, 48]. T-cells have also been shown to be involved in assembling the
pre-metastatic niche [49, 50]. The role of hematopoetic stem and progenitor cells
(HSPCs) has also been elucidated in pre-metastatic niches. Purified populations of
HSPCs were tracked in vivo using an orthotopic E0771 adenocarcinoma breast tu-
mor model, and HSPCs were shown to differentiate readily into immunosuppressive
myeloid cells [11]. Once immune cells accumulate at distal organs, they secrete a
multitude of factors facilitating the subsequent recruitment and colonization of dis-
seminated tumor cells [51, 52]. Recent studies have shown the real-time interactions
of immune cells and disseminated tumor cells undergoing colonization at target or-
gans using intravital imaging, further elucidating the role of myeloid cell populations
in providing a primed harbor for tumor cells at target organs [53]. While these stud-
ies identify the importance of immune cells in the pre-metastatic niche, few studies
have investigated the interplay between tumor cell and immune cells within the pre-
metastatic niche. This lack of investigation is partially due to a lack of tools to probe
the pre-metastatic niche without significant off-target effects on tumor, metastatic
progression, or immune function. Monitoring and evaluating tumor cell interactions
with immune cells at the pre-metastatic niche represents an opportunity to probe the
mechanisms governing metastasis.
Understanding cellular interactions at the pre-metastatic niche would lead to op-
portunities to exploit immune cells to capture metastatic tumor cells for detection
and therapy. Upon implantation, biomaterial scaffolds elicit an acute inflammatory
response in the host. The host response to an implanted biomaterial includes several
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blood-material interactions, including the formation of a fibrous capsule consisting
of inflammatory immune cells and fibroblasts around the border of the implant. Al-
though several other reviews discuss the inflammatory response to implanted bioma-
terials [54–57], more recent studies elucidate a connection between the immune cells
recruited to a biomaterial and the immune cells required to establish a pre-metastatic
niche site (Figure 2.2). For example, in an immune competent Balb/C mouse, a
variety of inflammatory immune cell populations are recruited to a subcutaneously
implanted poly(ε-caprolactone) (PCL) micro-porous scaffold (Figure 2.2A, 2.2B).
During a four-week implantation period prior to 4T1 breast tumor cell inoculation,
Ly6C+F4/80- inflammatory monocytes and CD11c+F4/80- dendritic cells accumu-
late at the implant site. However, following tumor inoculation, inflammatory mono-
cytes further increased and Gr1hiCD11b+Ly6C- MDSCs accumulated at the scaffold
(Figure 2.2C), while dendritic cell and F4/80+CD11b+ macrophage populations
decreased, thus recapitulating elements of the pre-metastatic niche [30]. Immune cell
dynamics at the scaffold correlate with tumor cell recruitment, indicating the bio-
material implant is able to recapitulate characteristics of a natural pre-metastatic
niche. In another approach, poly-L-lactic acid (PLA) microspheres have also been
shown to recruit CD11b+ monocytes to the implant location [26]. B1F10 melanoma
cells home to implanted PLA microspheres due to the prior arrival of inflammatory
immune cells. The recruitment of tumor cells without chemokine delivery indicates
that tumor cells can home to an implant due to the local foreign body response alone.
Importantly, the composition of the immune cells in the foreign body response may
differ in tumor-bearing relative to healthy animals, with the foreign body response
in a tumor-bearing host facilitating formation of a pre-metastatic niche at an ectopic
location. The emerging concept of immune cells mediating tumor cell recruitment to
an implanted biomaterial has significant implications in the study and modulation of
metastatic cell trafficking, as well as enabling detection and study of tumor cells at
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user-defined, ectopic locations.
2.4.2 Soluble factors and exosomes
The pre-metastatic niche microenvironment also consists of chemokines and cy-
tokines that actively influence immune cell and metastatic cell behavior. Various
secreted factors from stromal cells have been implicated in recruiting immune cells as-
sociated with the pre-metastatic niche including SDF-1, TGF-β, S100A-8/9, IL-1, and
caveolin-1 [13]. Similarly, immune factors including VEGF, IL-6, IL-1, TNF, CCL17,
G-CSF, Bv8, S100 proteins, CCL2 and CCL22 were shown to be over-expressed at
target organs during metastatic progression, suggesting a role in pre-metastatic niche
formation and tumor cell recruitment [14, 52, 58]. The function of each of these
factors has been described in detail by Liu et al [59]. In brief, VEGF was found
to recruit VEGFR1+ BMDCs [8], TNF induces S100A8/9 expression which attracts
Mac1+ myeloid cells and tumor cells to the niche [60, 61], G-CSF mobilizes MD-
SCs to the lung niche [9], Bv8 promotes angiogenesis and mobilization of myeloid
cells to the niche [12], IL-6 is responsible for tumor promoting inflammation [61],
and finally CCL2 recruits monocytes and BMDCs and facilitates the extravasation
of cancer cells [16]. Immature Gr1+CD11b+ MDSCs are responsible for suppressing
IFN-γ and increasing inflammatory cytokine expression, and induce the expression
of MMP9 in cells to allow for matrix remodeling at the niche [62]. Additionally, the
role of soluble factors in mediating metastasis to bone tissue has been characterized
using 3D models, where tumor cells actively prepare the bone tissue for coloniza-
tion through the release of cytokines such as IL-8 [35, 63]. Colonizing breast tumor
cells must produce osteoclast-activating factors including IL-6, IL-11, and TNF to
initiate bone resorption in an effort to create space for the metastatic lesion [64].
Additionally, inflammatory Mac1+ monocytes and lung endothelial cells are known
to secrete calcium-binding S100A8 and S100A9 factors in the presence of a primary
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Figure 2.2: Myeloid derived suppressor cell (MDSC) dynamics in a breast
tumor bearing mouse implanted with a biomaterial scaffold. (A)
Photographic (scale = 1 mm between black tick marks) and (B) Scan-
ning electron microscope images (scale = 1 mm) of a microporous PCL
scaffold. (C) Tumor progression influences Gr1hiCD11b+Ly6C- MDSCs
at the PCL scaffold implanted subcutaneously in a Balb/C mouse inoc-
ulated with 4T1 triple negative breast tumor cells. (D) PCL scaffolds
reduce MDSC burden in the spleen, which indicates a reduction in sys-
temic MDSC burden.
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tumor, which initiates the recruitment of additional monocytes to pre-metastatic sites
[19, 60]. S100A8 and S100A9 are also known to increase formation and activation
of invadopodia via p38 signaling, which may promote tumor cell adhesion at a pre-
metastatic niche [65]. Soluble factors have a clear role in mediating the recruitment of
different immune cell populations, which subsequently impact tumor cell recruitment
to the niche. While many soluble factors have been implicated in the pre-metastatic
niche, these have been difficult to study in a controlled manner due to the common-
ality of many of these chemokines and cytokines with processes in tumor progression.
The release of chemotactic factors from biomaterials has been used to manipu-
late immune and tumor cell trafficking to implant sites. Chemokine releasing scaf-
folds have recruited metastatic melanoma tumor cells [26]. Stromal-derived factor 1
(SDF-1) and erythropoietin (EPO) releasing scaffolds implanted subcutaneously have
been compared, with EPO scaffolds having increased tumor cell recruitment (Figure
2.3A). The delivery of viruses from biomaterials that encode for chemokines has also
been employed to modulate immune cell trafficking [66]. Similarly, PLG scaffolds
with an immobilized lentivirus encoding for CCL22 modulated the immune cell com-
position within the scaffold [31]. An increase in MDSCs at the niche was observed,
which enhanced tumor cell recruitment to the scaffold, similar to the mechanism of
pre-metastatic niche formation and completion by tumor cells [45, 46]. These factors
are thought to modulate the chemokines at the local environment; however, altering
the trafficking of immune cells locally may potentially have an impact systemically.
Collectively, these studies indicate that individual secreted factors have distinct cell
recruitment abilities and direct release from the material may enable studies of im-
mune and metastatic cell trafficking.
Tissue engineered constructs have delivered a variety of soluble factors to in-
vestigate their role in tumor cell homing [41]. Silk biomaterial scaffolds have been
developed to study the impact of BMP-2 on bone metastasis [67]. BMP-induced
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transcriptional pathways are activated during breast and prostate cancer invasion and
bone metastasis [68, 69]. Using a layered scaffold system, BMP-2 release stimulates
adhesion of PC3 prostate cancer cells to the scaffold and enhanced the attached cells
expression of osteogenic markers in response to BMP-2. More recently, the immune
cell secretome that may attract MDA-MB-231 breast cancer cells was characterized
using systems biology and biomaterial techniques [34]. Using mass spectrometry
proteomics, 115 proteins were identified as secreted by the immune cells, and were
considered candidate mediators of metastatic cell homing. Using a complementary
systems biology approach that measures large-scale transcription factor activity, the
list of candidate factors was narrowed to five. Haptoglobin was identified as a critical
mediator of homing and PLG scaffolds were engineered to locally release haptoglobin
upon implantation in orthotopic breast cancer mouse models. The protein-releasing
scaffolds were able to recruit significantly more metastatic tumor cells to the syn-
thetic scaffold site relative to blank scaffolds, indicating a role for haptoglobin in
tumor cell homing to a niche. Taken together, elucidation of the ability of EPO
[26] and haptoglobin [34] to recruit tumor cells to engineered niches indicates that
these platforms can serve to validate components of the pre-metastatic niche, and
also facilitate discovery of novel contributors to pre-metastatic niche formation and
function. Tumor-shed exosomes, which contain a variety of soluble factors that elicit
dramatic changes in immune cell trafficking and the target organ ECM, have simi-
larly been delivered locally as a means to promote tumor cell recruitment. Typically
50-90 nm in diameter, exosomes are small membrane vesicles shed from cells via
fusion of multi-vesicular bodies to the cell membrane [70, 71]. The multi-vesicular
bodies carry signaling molecules from the cytoplasm, and once secreted from a cell,
the newly-formed exosome participates in cell-cell communication after internaliza-
tion by another cell type [72]. Exosomes were shown to prepare organs for tumor
cell colonization and mobilize BMDCs to pre-metastatic niche sites [7, 18]. For pre-
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metastatic niche formation in the lung, RNA molecules from tumor-shed exosomes
activate TLR3 in alveolar type II cells, which stimulates neutrophil recruitment to a
target site [59]. As such, using tumor derived exosomes in engineered pre-metastatic
niches may further elucidate their role during metastasis progression [73]. With this
concept in mind, de la Fuente et al embedded exosomes in a 3D biomaterial scaf-
fold to serve as a metastatic trap (M-Trap) [29]. The authors found that in both
peritoneal and orthotopic models of ovarian cancer, the M-Trap device preferentially
captured metastatic cells (Figure 2.3B). As a result, mice implanted with M-Trap
scaffolds survived significantly longer than those without implants, with a greater
survival benefit demonstrated with removal of the implant after focalization of the
metastatic disease.
2.4.3 Extracellular matrix
The pre-metastatic niche microenvironment assists with immune cell and tumor
cell colonization to a target tissue. As early as 1999, it was demonstrated that intra-
venously delivered human prostate cancer cells would arrive and engraft to implanted
human bone fragments but not implanted human lung or intestinal tissues [39]. Simi-
larly, human SUM1315 cells, derived from a patient bone nodule of metastatic breast
cancer, preferentially colonize engrafted human bone sample when co-injected with
human bone marrow stem cells and did not metastasize to mouse bone [39]. Fur-
ther studies using a similar humanized bone metastasis model in SCID mice have
shown disparities in gene expression profiles of cell lines that metastasize sponta-
neously at typical metastatic sites in control mice compared to cells that preferentially
metastasized to human bone implants [40]. These studies show the preferential col-
onization of tumor cells to species-specific microenvironments. More broadly, these
early studies pioneered the concept that tumor cell colonization can be controlled
with the proper design and presentation of a specific microenvironment primed for
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tumor cell recruitment. Tissue engineering strategies have been utilized to model
organ-specific colonization in vitro using organ ECM mimics. To address this need,
a high-throughput strategy to rapidly screen tumor cell adhesion and migration on a
biomaterial-screening platform has recently been reported. Specific tumor cell lines
have a certain proclivity for ECM protein compositions due to integrin expression [74].
Barney et al. suggest that integrin binding dictates organotropism, with β1, 2, and
6 integrin subunit expression determining cellular adhesion to lung, liver, and brain
ECM mimics [75]. By taking advantage of the cell surface receptors expressed on
tumor cells, cells can be cultured on tissue-inspired biomaterials, such as bone, brain,
and lung ECM. Integrin-mediated phenotypes observed on these ECM materials pro-
vided an in vitro fingerprint for cell lines with predictable metastatic targets. After
identifying these fingerprints, heterogeneous tumor cell lines were cultured on the bio-
material ECMs to accurately predict the in vivo metastatic targets. Further studies
have determined that tumor-derived exosomes display distinct integrin patterns that
preferentially bind to organ-specific cells, thus demonstrating that organotropism is
mediated through multiple extracellular signals [18].
Tumor cell adhesion has also been tested using decellularized lung and liver matrix
to coat biomaterial scaffolds [42]. Organ decellularization is a commonplace tissue
engineering method used to obtain tissue-specific matrix [76], and has been recently
used to assess tumor cell activity on primary tumor [77], lung [78], and bone-derived
matrices [79]. Using this approach in vivo, lung and liver decellularized organ ma-
trix obtained from tumor-bearing mice was used to coat micro-porous PCL scaffolds,
and upon subcutaneous implantation, was shown to enhance tumor cell coloniza-
tion at the scaffold relative to healthy decellularized organ matrix (Figure 2.4A,
2.4B). Interestingly, proteomics was used as a technique to evaluate the composi-
tion of lung and liver matrix to identify the unique components of organ-specific pre-
metastatic niches. In this example, myeloperoxidase was determined using proteomics
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and validated as a factor that mediates tumor cell colonization using an engineered
myeloperoxidase-coated PCL scaffold. Taubenberger et al. have investigated this
with engineered mineralized ECM-based scaffolds seeded with osteoblasts. Scanning
electron microscopy was utilized to characterize the myofibrillar network produced by
seeded osteoblasts, which was comparable to the assembly of trabecular bone tissue.
Atomic force microscopy was also used in this study to measure the detachment force
of various breast cancer cells as a measure of tumor cell adhesion to the engineered
sites. Tumor cells seeded on the human bone mimic revealed gene expression changes
in osteopontin, which are consistent with tumor cells colonizing bone tissue in vivo.
This study demonstrated the ability of combinatorial approaches to help identify and
characterize the interaction between many elements in the in vivo niche [43]. Taken
together, these results demonstrate the ability of tissue engineered constructs to re-
capitulate elements of bone-specific colonization, and represent a highly controllable
platform to study these interactions for any organ in vitro.
2.4.4 Cell delivery
While specific cell types have been implicated in pre-metastatic niche formation,
de-convoluting the role of each cell type has been elusive due to the off-target effects
of altering a cell population globally via transgenic strategies, antibody depletion,
or adoptive transfer. Biomaterials provide a practical strategy to evaluate the func-
tion of a specific cell type in recruiting tumor cells to the pre-metastatic niche, as
cells can be seeded directly onto a biomaterial scaffold and implanted into a mouse
model of metastatic cancer. The most frequently reported approach involving cell
transplantation to enhance cancer cell recruitment has attempted to mimic the bone
marrow niche through transplantation of human bone marrow stromal cells (Figure
2.5A) [33, 36], BMDCs [27, 36], or mesenchymal stem cells [37]. These cells were
seeded on a biomaterial scaffold and cultured in vitro prior to implantation. Upon
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Figure 2.3: Soluble factors and exosomes mediate tumor cell homing. (A)
Control, EPO and SDF-1α loaded scaffolds recruit labeled B16F10
melanoma cells, quantified using bioluminescence imaging (*P <0.05).
(B) Exosome-laden scaffolds (M-trap) capture SKOV3 ovarian cancer cells
delivered into the peritoneal cavity. Bioluminescence imaging shows con-
trol mice with metastasis to the pancreas and gonadal fat pads 1 week
after inoculation. Blank scaffolds were able to redirect tumor cells, al-
though abdominal metastases were still detected. M-trap scaffolds were
able to recruit tumor cells with no visible metastases at 1 week after
inoculation.
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implantation, engineered bone marrow niches were able to recruit human breast can-
cer [27, 33, 41], erythroleukemia (Figure 2.5B, 2.5C) [36], acute myeloid leukemia
[37], and prostate cancer cells [27, 80] to the implant site. Interestingly, studies sug-
gest the frequency of capturing tumor cells using scaffolds seeded with BMDCs may
correlate with the frequency of CTC capture in the blood [27]. In sum, bone marrow
mimics are capable of capturing tumor cells at an ectopic site using animal models
of both hematological malignancies and carcinoma metastasis, further demonstrating
that cell-laden materials are capable of mimicking metastatic niches.
Aside from bone marrow mimics, tissue engineered constructs have been used to
deliver cells found at pre-metastatic niche sites to generate a more accurate model.
Stromal cells (e.g. neutrophils, fibroblasts, lymphatic endothelial cells) at target or-
gans provide the microenvironment necessary for human breast tumor cell coloniza-
tion [81, 82]. Local fibroblasts participate in the formation of pre-metastatic niches
and become cancer-supportive through the secretion of growth factors and ECM re-
modeling proteins [83]. In a model of ovarian and colorectal peritoneal metastasis,
De Vlieghere et al. designed cancer-associated fibroblast (CAF) loaded micropar-
ticles (MP-CAF) to divert peritoneal metastasis. Human CAFs were encapsulated
within alginate/gelatin microparticles (500-700 µm in diameter), and the particles
were coated with a membrane composed of polyelectrolytes to retain CAFs within
the microparticle and prevent degradation. Once implanted in the intraperitoneal
space of nude mice, CAFs and CAF-secreted ECM were found to be key in the for-
mation of peritoneal niches for metastasis, and as a result, can serve as a biomimetic
trap for cancer cells [84]. Injection of MP-CAFs into the peritoneal cavity redi-
rected cancer cells to the microparticles and resulted in prolonged animal survival
[38]. Similarly, MDSCs have been harvested from spleens of mice and seeded onto
PLG scaffolds prior to implantation in an orthotopic model of breast cancer using
highly metastatic, brain-tropic MDA-MB-231BR cells [31, 85]. MDSCs were retained
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on the scaffold after implantation, and recruited significantly more tumor cells to the
implant site relative to blank scaffolds. Collectively, implantable bone marrow niches
and other cell-laden scaffolds represent a powerful tool to investigate the contribution
of specific cell types to metastatic cell homing and colonization of tissues and organs.
2.5 Tumor cell behavior at engineered niches
Once a disseminated tumor cell adheres to and grows within a niche present in the
target organ, the cell is said to have colonized the organ. Colonization has been as-
sociated with specific genetic changes, including a mesenchymal-to-epithelial (MET)
transition. In contrast to the EMT transition during invasion, MET is the process
by which tumor cells return to their epithelial-like state to form a distant tumor
mass. MET is typically characterized with gene expression studies, generally showing
a return to expressing E-cadherin and down-regulating vimentin [86]. Metastatic col-
onization is also mediated by the activity of specific transcription factors, including
decreased activity of TGFβ/SMAD3 activity and increased PRRX1 activity [87, 88].
As disseminated tumor cells successfully colonize the target organ, proliferation at
the metastatic site may occur based on cues received from the pre-metastatic niche
[3]. The cues involved in activating dormant metastatic cells to a proliferative state
are still largely unknown. However, there is evidence that the perivascular niche and
sprouting versus stable endothelial networks are able to regulate dormancy through
control of TSP-1, TGF-β, periostin, tenascin, versican, and fibronectin, all factors
previously implicated in the pre-metastatic niche [89]. Alternatively, tumor cells may
also reside in a dormant state where the tumor cells do not divide or the rate of
proliferation is equal to the rate of cell death [90]. The pre-metastatic niche has been
shown to be involved in transitioning dormant disseminated tumor cells into an active
state and initiating their proliferation [89]. Metastatic inefficiency is defined as the
inability of tumor cells to grow at a metastatic site [91–93]. Without proper acti-
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Figure 2.4: Modeling organotropism using ECM- or BMSC-functionalized
scaffolds. (A) Decellularized lung and liver matrix from healthy and
diseased mice inoculated with tdTomato-tagged LM-2 lung/liver target-
ing breast tumor cells was used to coat PCL scaffolds, and scaffolds were
implanted subcutaneously in tumor-inoculated mice to detect differences
in tumor cell colonization as a function of matrix coatings. (B) Matrix-
coated scaffolds from diseased lungs and livers recruited more cells relative
to blank and healthy coating controls as assessed by flow cytometry.(C)
Delivery of multipotent BMSCs (CD44+, CD106+, CD14-, CD34-, CD45-
, CD73+, and CD105+) on scaffolds recruit leukemia tumor cells to an
implant site. (D) Images of hematoxylin and eosin stained tissue sections
of subcutaneously implanted 3D microfabricated polyacrylamide scaffolds
(unseeded vs. BMSC seeded, scale bars = 250 µm). (E) Homing of intra-
venously transplanted human TF-1A cells to unseeded vs. BMSC seeded
scaffolds. Confocal images of scaffolds show significantly more stained
TF-1A cells arriving to BMSC-seeded scaffolds 6 hours after injection
(scale bars = 250 µm). (F) Flow cytometric analysis of labeled TF-1A
cells at the bone marrow vs. implanted scaffolds. FACS analysis suggests
there were approximately twice as many cells at BMSC-seeded scaffolds
relative to unseeded scaffolds.
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vation, disseminated tumor cells may undergo apoptosis at the target organ, remain
dormant at the metastatic site for up to several years, or continue circulating through
the body [94–96].
In vitro biomaterial models of colonization, including models of the pre-metastatic
niche, have proved to be useful to model critical cues that enable sustained tumor
cell proliferation. The accumulation of ECM proteins and inflammatory immune cells
have been implicated in their ability to activate dormant CTCs into a proliferative
state. These effects have been investigated using materials such as a 3D basement
membrane culture model. Barkan et al. demonstrated that solitary tumor cells re-
main dormant due to cell cycle arrest through elevated p16 and p27 activity [28, 97].
The proliferation rates of multiple cell types in 2D and 3D basement membrane gels
have been tested, and a variety of breast tumor cell lines had signs of dormancy in
3D in vitro culture with increased activity of p16 and p27 cell cycle regulators. These
results were comparable to in vivo dormancy typically exhibited by these cell lines.
However, the introduction of fibronectin to the 3D culture environment enhanced pro-
liferation rates of dormant cells and increased cytoskeletal rearrangements, indicating
a dormant/static to proliferative/dynamic switch in phenotype. These results imply
that ECM components typically found in the pre-metastatic niche, i.e. fibronectin,
are greatly involved in initiating the dormant-to-proliferative switch.
Metastatic cells at the pre-metastatic niche experience paracrine signals from
neighboring cells. Consequently, 3D co-culture systems are currently being utilized
to more accurately model the pre-metastatic niche in vitro [98]. For instance, to
model MDA-MB-231 tumor cell extravasation, the bone pre-metastatic niche was re-
cently modeled in 3D using a microfluidic platform consisting of osteo-differentiated
mesenchymal stem cells embedded in a collagen gel lined with endothelial cells [44].
Likewise, 3D collagen gels containing human lung adenocarcinoma cells, lung fibrob-
lasts, and macrophages were used to track MMP-1 and VEGF production in different
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culture conditions (e.g. hypoxia) [13]. Co-culture systems in which cancer cells,
osteoblast-like cells, and/or mesenchymal stem cells are placed in a matrix are be-
ing employed to generate a microenvironment in vitro that models elements of the
in vivo metastatic bone niche. These systems have imparted enhanced migration,
adhesion, angiogenicity, and drug resistance to human breast adenocarcinoma cells
when co-cultured with osteoblast-like cells and mesenchymal stem cells on a silk scaf-
fold compared to indirect co-culture models [99]. Phenotypic changes were reported
for osteoblasts in the metastatic niche including decreased proliferation and miner-
alization as tumor cell activity was enhanced [99]. A similar study was performed
with LNCaP prostate cancer cells and human osteoblasts [100]. However, in this
approach the authors were interested in paracrine signaling pathways and instead of
direct co-culture, the LNCaP cells were embedded in PEG hydrogels and co-cultured
with PCL scaffolds pre-seeded with osteoblasts. Microarray analysis demonstrated
that paracrine signaling between cancer cells and osteoblasts in two separate tissue
engineering constructs alter gene expression patterns associated with homing and col-
onization (such as S100A6) compared to mono-culture controls. As in vitro strategies
continue to evolve the inclusion of multiple cell types in a 3D culture system will be
critical for generating more robust niche platforms for study. Engineered biomaterial
models that use multiple cell types may allow for a more accurate mimic of the pre-
metastatic niche and may provide a platform to evaluate the cues critical for tumor
cell behavior decisions within the niche.
2.6 Translational opportunities for pre-metastatic niche mim-
ics
In this section, we demonstrate that implantable niches may serve as oncomate-
rials, defined as biomaterials that enable detection and/or treatment of cancer. The
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juxtaposition of biomaterials and oncology principles to enable detection and treat-
ment of cancer metastasis may provide more effective therapies (Figure 2.6A, 2.6B).
In a clinical setting, the probability of a tumor spreading to target organs has been
shown to correlate with tumor size. Tumors less than 2 cm diameter have a lower
risk of metastasis, compared to tumors greater than 2 cm in diameter [101]. Detec-
tion strategies for metastasis are often limited to CT and MRI scans, and tumors
must be at least 1 cm in size to distinguish from surrounding tissue [101]. These size
limitations are particularly problematic for highly aggressive cancers such as pancre-
atic that disseminate at very early stages of the disease [102]. Technologies for the
early detection of metastatic disease combined with an early intervention prior to the
spread of metastatic tumor cells to solid organs provide an opportunity to improve
patient outcomes.
2.6.1 Materials for metastatic cell detection
The probability of patient survival increases with early detection of rare CTCs
in the blood [103], which has motivated the continued development of these tech-
nologies. Nanomaterial strategies have been employed to isolate and characterize
CTCs for developing personalized therapies for cancer patients [104]. The traditional
approach to developing personalized therapies is to analyze the genetic aberrations
of tumor biopsy samples from patients. As cancer progresses to metastasis, tumor
cells constantly evolve at a molecular level, and the turnover of tumor cell molecular
targets and emergence of therapeutic-resistant clones challenges the development of
personalized therapies. For these reasons, techniques to capture, characterize, and
culture CTCs are being developed to complement primary tumor biopsy analysis and
provide a more comprehensive study of tumor genomics for individual patients [104–
106]. CellSearch, an FDA approved, commercially available CTC enrichment system,
enables reliable detection of CTCs in blood samples from metastatic cancer patients
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[107]. Most notably, ex vivo culture of CTCs in conjunction with in vitro biomaterial
mimics of the pre-metastatic niche have facilitated the capture, culture, and study of
CTCs [108–110].
CTCs are isolated from blood, whereas cells found within the pre-metastatic niche
mimics have left the vasculature and may represent a distinct cell type with distinct
prognostic value. Despite advances in ex vivo CTC detection, CTCs captured in blood
samples may remain in the circulation for years, and may not be representative of
tumor cell populations capable of colonization [95, 105, 111]. Additionally, detection
of CTCs does not indicate that permissive niches for tumor cells to home, colonize
and proliferate exist. Recently, Azarin et al. reported biomaterial scaffolds for the
early detection of cancer metastasis [31]. Using an orthotopic mouse model of breast
cancer, micro-porous PLG scaffolds were implanted either subcutaneously or in the
intraperitoneal fat. Tumor cells populated the scaffolds prior to their colonization
at common organ sites (i.e. lung, liver, and brain). Interestingly, using inverse
spectroscopic optical coherence tomography (ISOCT) [112], unique microstructural
alterations were detected at the scaffold due to tumor cell arrival, allowing for a
non-invasive method of metastasizing tumor cell detection. The scaffold technology,
coupled with ISOCT or other imaging techniques, may enable a viable method for
early metastasis detection while overall metastatic tumor burden remains low (Figure
2.6C). In a future clinical setting, these scaffolds, either alone or modified with ECM
proteins or cytokine delivery, may provide a practical source of actively colonizing
tumor cells for phenotypic and genomic analyses of patient-specific metastatic tumor
cells and their heterogeneity.
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2.6.2 Early detection, early intervention, and metastatic cell capture can
enhance survival
Recently, implantable scaffolds have been shown to significantly impact survival
in mouse models of metastasis. For instance, micro-porous PCL scaffolds have re-
cently increased survival of immune competent mice inoculated with 4T1 metastatic
breast tumor cells [30]. The scaffold provides a site for early detection and acts as
a sink for metastatic tumor cells and pre-metastatic niche immune components. As
a result, the scaffold reduced the average tumor burden in the liver and brain. A
post-surgical model of breast cancer metastasis was used to investigate the impact of
the scaffold on survival. In this model the primary tumor was removed after the time
point where tumor cells were detectable in scaffolds. Results show 40% of scaffold-
implanted mice survived the tumor resection procedure past 200 days relative to sham
controls where survival did not exceed 30 days. The study suggested that increased
survival may result from a decreased burden of MDSCs present at the primary tumor
and spleen of scaffold-implanted mice (Figure 2.2D). Therefore, the study impli-
cates that biomaterials designed to reduce the overall generation of MDSCs during
metastatic disease progression or divert them to an ectopic location may impact sur-
vival. Similarly, exosome impregnated scaffolds drastically changed the pattern of
peritoneal ovarian cancer metastasis by redirecting the vast majority of tumor cells
to the implant (Figure 2.3B) [29], which resulted in a significant survival benefit
for mice that receive an implant versus those that did not (mean survival of 200 days
compared to 120 days). Additionally, removal of the implant after focalization of
much of the disease to the biomaterial further enhanced survival ( 310 days mean
survival). These studies have demonstrated that by taking advantage of the natural
biological cues that form the pre-metastatic niche in distant organs, vast numbers of
pre-metastatic niche forming cells and/or metastasizing cancer cells themselves can
be captured, which combined with a treatment can provide a substantial survival
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advantage.
2.6.3 Opportunities for metastasis detection platforms
Although recent evidence suggests pre-metastatic niche models enable early detec-
tion and treatment of metastatic disease, open questions remain regarding the efficacy
of these platforms when compared to other emerging metastasis detection technolo-
gies. Additional technologies for metastasis detection include exosome detection and
CTC enumeration Table 2.3. Both of these platforms are part of a larger initiative to
utilize liquid biopsies to gain more information about a patients disease state, evolv-
ing molecular features, and response to therapy. While liquid biopsies have shown
promise in these areas they also have distinct disadvantages that could potentially
be circumvented by pre-metastatic niche mimics. For example, exosome detection is
likely to be less sensitive than CTC detection due to exosome heterogeneity and the
presence of large numbers of exosomes in healthy patients [70, 113]. Similarly, the
presence of CTCs indicates the risk for metastasis but does not indicate that there are
permissive microenvironments in organs for these cells to home and colonize. These
considerations show specific advantages for the use of pre-metastatic niche mimics,
however, there are also potential issues associated with the clinical use of these de-
vices. The safety of creating a site for metastatic cells to home will be evaluated
in clinical trials, however current preclinical work has demonstrated reduced tumor
burden and enhanced survival associated with focalization of disease at an implant
[29–31].
In a clinical setting, the choice of material (Table 2.2) is critical for designing a
functional implantable device for recruiting and detecting metastatic cells. For exam-
ple, materials such as PLG are susceptible to hydrolytic degradation, thus limiting
the amount of time the material can remain in a patient. The scaffold should ideally
not degrade rapidly and maintain its structure for several months during the course
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of a patients treatment, given that metastasis may occur on a timescale from months
to years [114]. Polymer scaffold degradation is desired for many tissue engineering
applications where tissue growth eventually replaces the material, but degradation is
likely undesirable for long-term implantable metastasis detectors in patients. Non-
or semi-degradable materials could be used to fabricate implantable scaffolds less
susceptible to hydrolytic degradation [80]. The material must also elicit an appropri-
ate inflammatory response at the implant site in order to initiate the recruitment of
metastatic cells, and should be amenable to harvesting intact populations of tumor
cells for downstream analysis. Additionally, scaffold porosity increases the interior
surface area for blood vessel and immune cell infiltration, in order to provide tu-
mor cells access to the scaffold. In a future clinical setting, material selection will be
paramount for successful translation of pre-metastatic niche mimics as oncomaterials.
Thus far, no clinical trials have been initiated for the application of biomaterial
pre-metastatic niche mimics as devices to detect metastasis. Although several bioma-
terials utilized as pre-metastatic niche mimics are already FDA approved for use in
human patients (Table 2.2), limitations in imaging tumor cell arrival to the implant
remain. ISOCT is a practical approach for detecting the nanostructural alterations
due to tumor cell arrival [112], however, the penetration depth that is associated with
this optical technique will need to be enhanced for translation to a clinical setting.
Future iterations of pre-metastatic niche mimics may implement alternative methods
for tumor cell detection. Imaging technologies already available in the clinic such as
ultrasound may be implemented for tumor cell detection. In order for translation to
move forward, the safety of biomaterial devices in large animal and human subjects
needs to be assessed. Even though safety remains an open question, the future for
pre-metastatic niche mimics as oncomaterials remains promising, given the ability to
detect and treat metastasis at early stages of disease in pre-clinical studies.
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Platform Stage Safety Sensitivity Specificity Therapy Refs
Exosome detection Primary + - + - [83]
CTC detection Circulation + + + - [107,
115]
Biomaterial mimic Dissemination ? + ++ + [30,
31, 34,
42]
Table 2.3: Risks and opportunities of detection technologies for metastasis
Figure 2.5: Proposed detection strategy for metastatic breast cancer. (A)
Pre-metastatic niche oncomaterials may be designed from a variety of pa-
rameters, including the natural immune response to the implant, soluble
factor delivery, extracellular matrix, and cell delivery. Parameters may be
tuned depending on the cancer or the needs for a specific patient for de-
signing the most effective oncomaterial. (B) After removal of the primary
tumor, a biomaterial scaffold may be implanted subcutaneously, ideally
before metastasis occurs. (C) Regular imaging at check-ups may be per-
formed during the patients course of treatment. When using ISOCT, the
shape factor (D) may be used to quantify microstructural alterations at
the scaffold due to the arrival of metastatic tumor cells (scale bar = 200
µm). Illustrations courtesy of Katie Aguado.
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2.7 Opportunities and Conclusions
Pre-metastatic niche mimics offer the ability to identify and validate critical fac-
tors leading to metastatic cell colonization in an ectopic site. Roles of inflammatory
immune cells, secreted factors, ECM proteins, and delivered cells have been evaluated
using niche mimics to determine contributions to metastatic cell homing and colo-
nization. Furthermore, the capture of early metastatic cells at a pre-defined site may
enable early detection of metastatic cell dissemination. The development of novel
imaging modalities, or the engineering of probes to label colonizing tumor cells may
enable real-time tracking of tumor cells or vascular leakiness at the niche during the
evolution of the disease. This capture can reduce the burden of disease in solid organs,
and provides an extended window of time over which a therapeutic intervention may
improve outcomes. The use of oncomaterials supplemented with current therapeu-
tic strategies such as surgery and chemotherapy may serve as a disruptive technique
for combating metastasis. Extending beyond the concept of capturing tumor cells,
scaffolds may be bioengineered to capture and manipulate other types of circulating
niche components, including exosomes and immune cells that reflect disease (e.g.,
MDSCs). Furthermore, future work in the genetic profiling of captured metastatic
cells at implanted niches may lead to the identification of the types of cells arriving at
the scaffold (e.g. tumor stem cells, EpCAM+ cells), which may guide the discovery
of precision targets to treat metastasis based on the disease biology. In sum, the
successful integration of pre-metastatic niche components in biomaterials can enable
the discovery of novel cues leading to metastasis, as well as provide novel detection
and therapeutic strategies to combat disease progression.
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CHAPTER III
Therapeutic Benefit of Scaffold Implantation
3.1 Authors
Shreyas S Rao, Grace G Bushnell, Samira M Azarin, Graham Spicer, Brian A
Aguado, Jenna R Stoehr, Eric J Jiang, Vadim Backman, Lonnie D Shea, Jacqueline
S Jeruss
3.2 Contributions
I worked closely with Shreyas for the latter half of this study including validation of
early detection and ISOCT, reduction of tumor burden in liver and brain with scaffold
implantation, post-surgical survival model, and reduction of CD11b+Gr-1hiLy6C-
cells in the spleen and primary tumor of mice with scaffolds. Additionally, I performed
Gr-1 depletion and survival studies independently to confirm the role of CD11b+Gr-
1hiLy6C- myeloid derived suppressor cells in the survival benefit associated with
scaffold implantation.
3.3 Abstract
The onset of distant organ metastasis from primary breast cancer marks the tran-
sition to a stage IV diagnosis. Standard imaging modalities often detect distant
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metastasis when the burden of disease is high, underscoring the need for improved
methods of detection to allow for interventions that would impede disease progres-
sion. Here, micro-porous poly(ε-caprolactone) scaffolds were developed that capture
early metastatic cells and thus serve as a sentinel for early detection. These scaffolds
were used to characterize the dynamic immune response to the implant spanning the
acute and chronic foreign body response. The immune cell composition had stabilized
at the scaffold after approximately 1 month, and changed dramatically within days
to weeks after tumor inoculation, with CD11b+Gr1hiLy6C- cells having the greatest
increase in abundance. Implanted scaffolds recruited metastatic cancer cells that were
inoculated into the mammary fat pad in vivo, which also significantly reduced tumor
burden in the liver and brain. Additionally, cancer cells could be detected using a
label-free imaging modality termed inverse spectroscopic optical coherence tomogra-
phy, and we tested the hypothesis that subsequent removal of the primary tumor
after early detection would enhance survival. Surgical removal of the primary tumor
following cancer cell detection in the scaffold significantly improved disease-specific
survival. The enhanced disease-specific survival was associated with a systemic re-
duction in the CD11b+Gr1hiLy6C- cells as a consequence of the implant, which was
further supported by Gr-1 depletion studies. Implementation of the scaffold may pro-
vide diagnostic and therapeutic options for cancer patients in both the high-risk and
adjuvant treatment settings.
3.4 Introduction
The oncogenic progression of breast cancer from the primary tumor to distant
metastatic sites is the critical event that defines stage IV disease [5, 116, 117]. Cur-
rently, metastatic disease is detected through radiologic imaging modalities after the
burden of distant disease has become destructive to the host organ [118–120]. A lim-
itation to the development of life-preserving timely interventions is the striking lack
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of robust technologies capable of early detection of metastatic events. Additionally,
experimental model systems are needed that permit systematic screening and ex-
amination of factors contributing to breast cancer metastasis in a controlled setting.
Detection of circulating tumor cells (CTCs) is being pursued in both the experimental
and clinical settings. While promising [121, 122], the widespread use of CTC capture
is not without challenges, given the high biomarker sensitivity and specificity required
to capture a low number of circulating CTCs [123, 124]. Furthermore, CTCs may not
represent the population of cells capable of metastasis or these cells could circulate
for long periods before invading distant organs. The capacity to identify metastatic
cells or foci at the earliest possible time-point may permit the delivery of targeted
treatment interventions prior to the compromise of distant organs, potentially trans-
lating into prolonged distant metastasis free outcomes. Thus, there is an urgent need
for development of novel technologies to aid in the detection of metastatic events in
the nascent setting.
An emerging approach for early detection lies with the implantation of a bioma-
terial scaffold that can capture metastatic cells [31]. These scaffolds were modeled
after the concept of the pre-metastatic niche [8, 125], echoing Pagets seed and soil
hypothesis proposed over a century ago [4, 6, 51, 125, 126]. This paradigm proposes
that, prior to colonization by metastatic cells, supportive cells (e.g., fibroblasts, im-
mune cells, endothelial cells), soluble factors, and extracellular matrix (ECM) compo-
nents establish a microenvironment conducive to tumor cell homing and colonization
[4, 6, 51, 126, 127]. Importantly, these studies indicate that metastasis to specific
organs is not random, but is influenced by the properties of the local environment
[8, 125, 127]. The initial translation of these principals led to the development and im-
plementation of micro-porous poly(lactide-co-glycolide) (PLG) biomaterial scaffolds,
which recruited metastatic breast cancer cells through the local immune response
in vivo, resulting in decreased tumor burden at metastatic sites [31]. However, PLG
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scaffolds were degradable over time scales considered too short for clinical translation.
In this report, we developed micro-porous poly(ε-caprolactone) (PCL) scaffolds
with greater stability than the PLG scaffolds, to investigate the dynamic immune
response and cellular events associated with PCL-scaffold-mediated recruitment of
metastatic breast cancer cells. Specifically, utilizing PCL scaffolds in metastatic
breast cancer murine models we examined if (a) metastatic cells could be recruited
to the scaffold (b) metastatic cells could be detected in the scaffold at a nascent
stage, prior to cancer cell colonization of other major organs, using label-free imaging
modalities and (c) scaffold implantation could influence survival following detection
of cancer cells in the scaffold and then subsequent surgical removal of the primary
tumor. The favorable translational endpoints from these studies could lead to the in-
tegration of scaffold implants, fabricated using FDA approved materials, into breast
cancer disease management plans. Moreover, scaffolds could be recovered to exam-
ine the biology of metastatic tumor cells in conjunction with niche cells enabling the
development of patient-specific treatments.
3.5 Results
3.5.1 Micro-porous PCL scaffolds for in vivo recruitment of metastatic
cells
We developed micro-porous PCL scaffolds (Figure 3.1A, 5 mm diameter and 2
mm height) to create microenvironments in vivo and subsequently examine their abil-
ity to recruit metastatic tumor cells. The porous interconnected architecture of the
scaffold was confirmed using SEM imaging (Figure 3.1B). Micro-structural features
such as porosity, pore volume, and mechanical properties (i.e., elastic modulus) were
similar for PCL and previously reported PLG scaffolds [31] (Supplemental, Table
3.1). The ability of PCL scaffolds to persist and create a defined space in vivo was
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investigated by implantation into the subcutaneous dorsal space of BALB/c and NSG
mice. The subcutaneous site was selected for its accessibility and amenability to non-
invasive imaging. Furthermore, neither 4T1 nor MDA-MB-231BR breast cancer cells
typically metastasize to the subcutaneous space, thus the presence of cancer cells in
the metastatic site would likely be associated with the presence of the scaffold. PCL
scaffolds retrieved after 3 months experienced minimal degradation when compared
to day 0 as opposed to PLG scaffolds, which had previously been employed for in vivo
recruitment of tumor cells [31]. PLG scaffolds showed significant degradation over
this time period as quantified by scaffold area (i.e., 66% in NSG and 77% in BALB/c
mouse; Supplemental, Figure 3.8).
The dynamic immune response to the biomaterial implant was investigated through-
out the acute and chronic phases. Implantation of the PCL scaffold into healthy
BALB/c mice resulted in infiltration of CD45+ leukocytes by day 3. The number of
CD45+ leukocytes remained relatively unchanged after day 14 post scaffold implan-
tation (Figure 3.1C). However, the relative distribution of leukocyte populations
examined, including innate and adaptive immune cells, changed dynamically follow-
ing scaffold implantation. The percentage of inflammatory monocytes, identified as
Ly6C+F4/80- cells, decreased after day 3 and remained relatively stable at later time
points, whereas the percentage of dendritic cells, identified as CD11c+F4/80-, in-
creased after day 3 and remained stable at later time points (Figure 3.1D). These
two cell populations constituted the majority of cells (i.e., approx 65%) observed at
the PCL scaffold at later time points. The percentage of macrophages, identified as
CD11b+F4/80+ cells, significantly increased through day 14 (e.g., 8.8% at day 14
vs. 1.7% at day 3, Figure 3.1D, p <0.05) and then returned to levels observed at
day 3 (e.g., 1.4% at day 60, Figure 3.1D, p = 0.99 compared to day 3). In contrast,
the levels of CD11b+Gr-1hiLy6C- cells remained low at all time points examined at
0.15% (Figure 3.1D). In the adaptive immune cell population, the percentage of
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CD4+ helper T cells and CD8+ cytotoxic T cells significantly increased over time
(e.g., 1% at day 3 to 9% at day 60 for CD4+ and 1.2% at day 3 to 3% at day 60
for CD8+ respectively, Figure 3.1D, p <0.05). The percentage of B cells, identified
as CD19+, and natural killer (NK) cells, identified as CD49b+, increased post day 3
and returned to day 3 levels at later time points (i.e., day 30 and 60; Figure 3.1D).
Importantly, the relative percentages of leukocyte subpopulations were similar be-
tween day 30 and day 60 post scaffold implantation in BALB/c mice (Figure 3.1D).
This trend was also observed in NSG mice (Supplemental, Figure 3.9). Based on
the stabilization of cell populations after day 30, we utilized day 30 as a time point
representing the chronic response to a scaffold implant in all following experiments.
We subsequently examined the recruitment of metastatic cells to a chronically
implanted microporous scaffold (i.e., a scaffold that had been implanted for 30 days
prior to tumor inoculation, a time corresponding to the chronic phase of the immune
response). Flow cytometry and fluorescence imaging (Figure 3.2) performed for
scaffolds retrieved at day 15 post tumor inoculation demonstrated the presence of
mouse 4T1 tumor cells in the scaffold, indicating that the local microenvironment
enabled recruitment of tumor cells. Total cell infiltration was significantly greater
within PCL scaffolds compared to PLG scaffolds (i.e., approximately 6e5 cells in the
PCL scaffold vs. approximately 1e5 cells in the PLG scaffold, p <0.0001, Figure
3.2A) and a similar trend was observed for tumor cell recruitment (Figure 3.2B, p
<0.01). Scaffolds were also able to recruit human MDA-MB-231BR cells in NSG mice
(Supplemental, Figure 3.11), indicating that such a system enabled recruitment
of mouse and human breast cancer cells in the context of both immune competent
and immune compromised mouse models, respectively.
Following tumor inoculation, the dynamics of immune cell populations at the PCL
scaffold was subsequently characterized, as tumor cells are known to influence the re-
cruitment of immune cells from the bone marrow (25). Flow cytometric analysis indi-
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Figure 3.1: Physical characteristics and dynamic immune cell response fol-
lowing implantation of micro-porous PCL scaffolds into the dor-
sal subcutaneous space of a BALB/c mouse. Photomicrograph (A)
and scanning electron micrograph (B) of a microporous PCL scaffold.
SEM image shows the interconnected porous structure. (C) CD45+ leuko-
cyte numbers and (D) Dynamics of CD11b+F4/80+, CD11c+F4/80-
, CD11b+Gr-1hiLy6C-, Ly6C+F4/80-, CD4+, CD8+, CD19+, and
CD49b+ immune cell populations expressed as a percentage of live
CD45+ leukocytes at day 3, 7, 14, 30, and 60 post PCL scaffold im-
plantation (N = 6 for each time point examined, *p <0.05 compared to
day 3 as determined by the Tukey-HSD test post ANOVA). Error bars
denote s.e.m.
41
Figure 3.2: Micro-porous scaffolds implanted for 30 days prior to tumor in-
oculation recruit metastatic cells. Number of (A) total cells and (B)
tumor cells (tdTomato+ cells) isolated from micro-porous PLG and PCL
scaffolds at day 15 post tumor inoculation analyzed via flow cytometry (N
= 10, *p <0.01 as determined by t-test for analysis of total cell numbers
and Wilcoxon rank-sum test for tumor cell numbers). Fluorescence image
of a PCL scaffold section shows the presence of a tumor cell (indicated by
white arrow) as identified using tdTomato (C) and DAPI (D) fluorescence
and their co-localization (E). Scale bar indicates 20 m. Error bars denote
s.e.m.
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cated an increase in Ly6C+F4/80- and CD11b+Gr-1hiLy6C- cells at the PCL scaffold
site (Figure 3.3C and 3.3D, p <0.0005). For example, the numbers of CD11b+Gr-
1hiLy6C- cells increased from 0.1% at day 0 to 17% at day 21 post tumor inoculation
(p <0.05), an increase of two orders of magnitude relative to their numbers at the
PCL scaffold site in tumor-free BALB/c mice (Figure 3.1D, Figure 3.3C). Both
cell types have been implicated in the pre-metastatic niche [15, 16, 19, 51, 128]. In
contrast, the percentages of CD11b+F4/80+ macrophages, CD11c+F4/80- dendritic
cells, and CD8+ cytotoxic T cells decreased at the PCL scaffold site (Figure 3.3A,
3.3C, 3.3F, e.g., 30% at day 0 vs. 14% at day 21 for dendritic cells, p <0.05). The
percentage of CD19+ B cells, CD49b+ NK cells, and CD4+ helper T cells increased
at day 3 and then decreased at later time points (Figure 3.3G, 3.3H, 3.3E). Specif-
ically, NK cells increased from 4% at day 0 to 8% at day 3, followed by a decrease to
2.5% at day 21 post tumor inoculation (Figure 3.3H, p <0.05). Interestingly, the
immune cell dynamics at the PCL scaffold site reflected the dynamics observed in
the spleen post tumor inoculation (Figure 3.3 vs. Supplemental, Figure 3.10).
In summary, the changing immune microenvironment at the PCL scaffold site post
tumor inoculation correlated with recruitment of 4T1 tumor cells, and is consistent
with prior literature reports on the role of the immune cells in the pre-metastatic
niche [10, 15, 16, 19, 51, 128, 129].
3.5.2 Early detection of metastatic cells at the PCL scaffold
The ability to detect the presence of metastatic disease at an early stage was
examined through evaluation of the percentage of tumor cells in the PCL scaffold
relative to the cancer cells detected in typical metastatic sites such as the lung, liver,
and brain, at day 5 post tumor inoculation. Flow cytometry analysis revealed that
the PCL scaffolds had a detectable percentage of tumor cells (i.e., 0.005 +/- 0.002%)
compared to the lung, liver, and the brain, none of which had detectable tumor cells
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Figure 3.3: Tumor progression influences dynamics of leukocyte popula-
tions at the PCL scaffold. Percentage of (A) CD11b+F4/80+ (B)
CD11c+F4/80- (C) Gr-1hiCD11b+Ly6C- (D) Ly6C+F4/80- innate im-
mune cell populations and percentage of (E) CD4+ (F) CD8+ (G) CD19+
and (H) CD49b+ adaptive immune cell populations in the total popula-
tion of live CD45+ leukocytes at day 0, 3, 7, 14, and 21 post tumor
inoculation (N = 8 for each time point examined, p <0.05 compared to
day 0 and p <0.05 compared to day 3 as determined by Tukey-HSD test
post ANOVA). Error bars denote s.e.m.
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(Figure 3.4A and 3.4B; N = 5 for lung, liver, and brain, N = 10 for PCL scaffolds,
p <0.05, Fishers exact test). The greater density of tumor cells observed at the PCL
scaffold site compared to other organ sites supports the use of this tool for detecting
metastatic disease at a nascent stage.
We subsequently investigated the feasibility of using a label-free imaging tech-
nique: inverse spectroscopic optical coherence tomography (ISOCT), for the early
detection of metastatic disease in a chronic model of scaffold implantation. The tis-
sue was modeled as a continuous random refractive index distribution, which enabled
the refractive index correlation function shape factor D to be computed from the
shape of the backscattering intensity spectrum obtained with ISOCT [130]. If D has
a value between 0 and 3, it has a physical meaning of a mass fractal dimension, re-
flecting a more clumped structure associated with higher D. Prior studies of early
carcinogenesis with ISOCT and a similar spectroscopic technique, low-coherence en-
hanced backscattering spectroscopy (LEBS), have revealed that D measured from
tissue increases with cancer progression [130–132]. Thus, similar ultra-structural tis-
sue modifications occurring in the pre-metastatic niche are likely to have an analogous
effect on D. D has previously been reported to reflect mass-density distribution fea-
tures at length scales of 35-350 nm [130]. In addition, D values from tissue have
been demonstrated as a robust biomarker of early-stage carcinogenesis [130]. Consis-
tent with these observations and data obtained via flow cytometric analysis (Figure
3.4A and 3.4B), a significant increase was observed in average D values obtained
from ISOCT measurements at the PCL scaffold site in tumor bearing mice (N =
7) compared to tumor free mice (N = 8; p <0.05, Figure 3.4C), confirming ultra-
structural alterations to the scaffold and further indicative of the presence of tumor
cells. The color map overlay of D values (Figure 3.4D and 3.4E) demonstrated
the distribution throughout the scaffold. These results suggest that ISOCT could be
employed for early detection of metastatic disease at the PCL scaffold.
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Figure 3.4: Micro-porous PCL scaffolds enable early detection of metastatic
cells in a chronic model of scaffold implantation. (A) Number of
mice with detectable tumor cells analyzed by flow cytometry in the lung,
liver, and brain in a group of 5 mice at day 5 post tumor inoculation (N
= 5 for lung, brain, and liver; N = 10 for PCL scaffolds, *p <0.05 as
determined using the Fishers exact test). (B) Percentage of tdTomato+
tumor cells isolated from the PCL scaffold at day 5 post tumor inocula-
tion analyzed via flow cytometry. (C) Average D value for PCL scaffolds
isolated from tumor free and tumor bearing mice. Scaffolds from tumor
bearing mice were isolated at day 5 post tumor inoculation. (N = 14
scaffolds for tumor free and N = 16 scaffolds for tumor bearing mice, *p
<0.05 as determined using the Wilcoxon rank-sum test). Representative
three dimensional maps of D generated via ISOCT analysis of PCL scaf-
folds in tumor free (D) and tumor bearing mice (E). Scale bars indicate
200 m. Error bars denote s.e.m.
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3.5.3 PCL scaffold implantation reduces tumor burden and improves
disease-specific survival
We subsequently investigated the hypothesis that the recruitment of metastatic
cells to the chronically implanted PCL scaffolds may reduce the tumor burden at
typical metastatic sites, such as the liver, brain, and the lung at day 15 post tumor
inoculation. Flow cytometry analysis indicated that the percentage of tumor cells
in the liver and the brain was reduced in mice receiving a PCL scaffold versus mice
undergoing a mock surgery. As stated, the tumor burden was reduced by 64% for
the liver (Figure 3.5A, N = 15, p <0.05) and 75% for the brain (Figure 3.5B, N
= 8 for mock surgery, N = 6 for scaffold implant, p <0.05 as determined using the
Wilcoxon rank-sum test in both cases). However, in this immunocompetent mouse
model, a reduction in the tumor burden in the lung was not observed (Figure 3.5C,
N = 11, p = 0.7) distinct from our previous observations in an immune compromised
NSG mouse inoculated with human MDA-MB-231BR cells [31].
A post-surgical model of breast cancer metastasis was then applied to investigate
the potential for PCL scaffold implants to influence survival. In this model, the
primary tumor was resected at day 6 (Supplemental, Figure 3.12) or 10 (Figure
3.6A) post tumor inoculation, which corresponded to a time after which cancer cells
were detectable in the scaffold by label-free imaging (i.e., day 5, Figure 3.4). The
resected tumor weights were comparable for both groups, with tumors from the mock
surgery group weighing 0.423 +/- 0.035 g versus tumors from scaffold implanted mice
weighing 0.419 +/- 0.029 g at day 10 post inoculation (p = 0.93, t-test, Figure 3.6B).
Kaplan-Meier survival analysis demonstrated a significant improvement in survival in
mice receiving a PCL scaffold implant compared to mice receiving a mock surgery
with resection at day 10 (Figure 3.6C, N = 7 per group, p <0.05, Log-rank test).
The sacrifice end-points utilized for mice in both groups for data corresponding to
Figure 3.6 are described in Supplemental, Table 3.2. With resection at day 6
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Figure 3.5: Recruitment of 4T1 tumor cells to the PCL scaffold site reduces
tumor burden in metastatic sites such as the liver and brain
in a chronic model of scaffold implantation in BALB/c mice.
Normalized average tumor burden in the (A) liver, (B) brain, and the
(C) lung for the scaffold and mock surgery groups. The average burden
in the mock group was set to 1 (N = 6 for each group, * p <0.05 compared
to mock surgery as determined by the Wilcoxon rank-sum test). Tumor
burden in the lung was identical in both groups. Error bars denote s.e.m.
post tumor inoculation, 40% of both mock and scaffold groups survived indefinitely
(Supplemental, Figure 3.13) mirroring the 40% survival in the scaffold group with
day 10 resection (Figure 3.6C), indicating that the scaffold increased the time over
which a therapeutic intervention such as surgery can be performed and provide a
survival benefit.
Given the greatest increase in the abundance of CD11b+Gr-1hiLy6C- cells (2
orders of magnitude change) at the PCL scaffold site post tumor inoculation, we
hypothesized that the increased survival with scaffold implantation may reflect a
differential distribution of CD11b+Gr-1hiLy6C- cells at the primary tumor (local)
and the spleen (systemic). Flow cytometric analysis indicated that the abundance
of CD11b+Gr-1hiLy6C- cells was reduced in mice receiving a scaffold implant versus
mice receiving a mock surgery examined at day 10 post tumor inoculation. The bur-
den of CD11b+Gr-1hiLy6C- cells was reduced by 39% in the primary tumor (Figure
3.7A) and 30% in the spleen (Figure 3.7B, N >7, p <0.05 as determined by t-test
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Figure 3.6: Micro-porous PCL scaffolds improve survival in a post-surgical
model of breast cancer metastasis. (A) Schematic of experimental
design to examine the influence of scaffold implant on survival (B) Aver-
age resected tumor weights for mock and scaffold group were identical, p
= 0.93, t-test) (C) Kaplan-Meier survival curve for mice undergoing mock
surgery versus mice receiving a scaffold implant (N = 7 for each group, *p
<0.05 as determined using the Log rank test). Error bars denote s.e.m.
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Figure 3.7: Micro-porous PCL scaffolds reduce burden of CD11b+Gr-
1hiLy6C- cells in the (A) primary tumor and the (B) spleen in BALB/c
mice. The percentage of CD11b+ Gr-1hi Ly6C- cells in the CD45+ leuko-
cyte population was examined at day 10 post tumor inoculation via flow
cytometry and is reported as normalized burden. (N = 7 for mock surgery;
N = 8 for scaffold implant, *p <0.05 as determined using t-test). (C)
Anti-Gr-1 depletion of CD11b+Gr-1hiLy6C- cells enhances survival in
both mock and scaffold groups and diminishes the survival advantage ob-
served for PCL implanted mice (N = 4 per group). Error bars denote
s.e.m.
in both cases). This result suggests that, in part, presence of the scaffold contributes
to a reduction in the abundance of key niche cells locally (i.e., primary tumor site)
and systemically (i.e., spleen) that support metastasis. This observation was further
investigated via Gr-1 antibody depletion of CD11b+Gr-1hiLy6C- cells in vivo, which
was performed in the context of surgical resection (Supplemental, Figure 3.13).
Mice receiving a mock surgery with Gr-1 depletion demonstrated survival greater than
20% by day 40 (Figure 3.7C), with no survival observed at this time without Gr-1
depletion (Figure 3.6C). Furthermore, with Gr-1 depletion, the observed difference
in survival between mock and scaffold groups was not statistically significant (Figure
3.7C), further supporting the involvement of CD11b+Gr-1hiLy6C- cells in improv-
ing disease-specific survival in our model. Taken together, these results highlight the
potential for PCL scaffold in improving disease-specific survival outcomes.
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3.6 Discussion
In this study, micro-porous PCL scaffolds, implanted prior to tumor initiation,
recruited metastatic cells at an early time-point in disease progression. The novel
approach to this work was based on recapitulating some of the immunological as-
pects of the pre-metastatic niche, while prior reports have focused on materials to
mimic properties of target organs (e.g., bone [33, 133], bone marrow [41]). Previous
elegant studies of the pre-metastatic niche have identified some of the biological cues
involved in cancer cell recruitment, such as the cellular components (e.g., hematopoi-
etic and endothelial progenitor cells, immune cells), soluble factors (e.g., cytokines,
chemokines), and ECM proteins [4, 6, 51, 125, 126]. Importantly, as indicated by
Lyden [125, 127], the existence of the pre-metastatic niche implies that metastasis to
a particular site is not random, but is predetermined, which supports the idea that a
site could be engineered to attract metastatic cells. A synthetic scaffold provides an
opportunity to create a defined environment to investigate the role of specific compo-
nents involved in the colonization of metastatic cells. Scaffolds can be modified with
specific niche components, such as stromal cells, ECM molecules, and cytokines to
identify the key signals in the metastatic environment [27, 134], thereby providing a
tool with which to advance fundamental studies of the pre-metastatic niche and tu-
mor metastasis. Herein, the scaffold defines a site for immune cell infiltration, and we
characterize the dynamic immune response associated with cancer cell recruitment.
The immune cell populations at the PCL scaffold, which had stabilized prior to
tumor inoculation, were substantially altered post-tumor inoculation, suggesting that
the changing foreign body response to the implant may contribute to metastatic cell
recruitment. Immune cells are recognized as significant to the pre-metastatic niche
[10, 15, 16, 19, 51, 128, 129]. As such, chemokine CCL-2 recruits inflammatory mono-
cytes (Ly6C+F4/80- cells) to the pre-metastatic niche enabling metastasis of breast
cancer cells [15]. Similarly, CD11b+Gr-1hiLy6C- cells are recruited via inflammatory
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chemoattractants (e.g., S100A8 and S100A9) to pre-metastatic niches [135]. In addi-
tion, CD11b+Gr-1hiLy6C- cells are known to downregulate infiltration and suppress
the function of T cells (CD4+ and CD8+ T cells) and NK cells [135–138]. Consis-
tent with these observations, we found an increase in the levels of monocytes and
CD11b+Gr-1hiLy6C- cells at the scaffold site post tumor inoculation and an associ-
ated decrease in the abundance of CD4+ T cells, CD8+ T cells, and CD49b+ NK
cells, with the greatest change observed for CD11b+Gr-1hiLy6C- cells (i.e., more
than two orders of magnitude). Importantly, the changing immune composition as
a consequence of disease progression observed in the spleen largely reflected the dy-
namics at the scaffold site. Taken together, these results suggest that engineering
a local microenvironment may be used to identify and modulate key components of
cancer-associated immunogenicity in the pre-metastatic niche.
The implantation of PCL scaffolds enhanced disease-specific survival, which we
hypothesized to be related to the decreased tumor burden in major organ sites and
a reduction in systemic availability of key immune cells that support metastasis.
The implantation of PCL scaffolds in the subcutaneous space reduced tumor burden
in major organ sites (i.e., liver and brain) in an immunocompetent mouse model.
We previously reported a reduction in burden in the lung in an immunocompromised
mouse model using PLG scaffolds implanted in the intraperitoneal fat pad after tumor
inoculation [31]. The results of the current study extend our previous observation and
importantly suggest that a scaffold-based approach can contribute to the reduction
in disease burden in solid organs in both immunocompetent and compromised mouse
models and when implanted at different sites. Metastatic cells could be detected
within chronically implanted PCL scaffolds by day 5 following tumor inoculation using
ISOCT imaging, which allowed for label free detection of metastasis through changes
in the tissue ultrastructure (e.g., matrix organization) and the presence of cancer cells
that have a distinct nano-scale signature relative to normal cells [130]. In order to
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employ ISOCT analysis for diagnostic screening of early metastasis, ultrastructural
parameters measured with ISOCT (D, correlation length Ln, and refractive index
fluctuation Bn), which independently change in the presence of carcinogenic tissue
modification, would need to be investigated to establish a multivariate diagnostic for
patients with metastatic disease.
The resection of the primary tumor at day 10 post tumor inoculation resulted in
increased survival in mice that received a scaffold. The increased survival may result
from a decreased burden of CD11b+Gr-1hiLy6C- cells observed locally at the primary
tumor and systemically in the spleen of a scaffold-bearing mouse when compared to
a mouse that received a mock surgery. Gr-1 depletion studies further supported this
observation, as mice receiving a mock surgery survive longer in the context of Gr-1
depletion, and the difference between mock and scaffold groups was abrogated with
Gr-1 depletion. As stated, CD11b+Gr-1hiLy6C- cells or myeloid derived suppressor
cells (MDSCs) have been implicated in the pre-metastatic niche and the reduced
abundance of these cells systemically may contribute to the reduced burden in solid
organs and ultimately, to enhanced survival [134, 139, 140]. Finally, MDSCs have
been identified in high numbers in patients with metastatic disease, correlating with
clinical stage and metastatic disease burden and their levels are predictive of overall
survival [141–143]. Thus, a scaffold-based approach that reduces the abundance of
MDSCs could, in part, explain the survival benefit observed in our studies. Taken
together, the ability to detect metastatic disease at an early stage, in combination with
the survival benefit provided by the scaffold highlight the potential for this technology
in transforming the current detection and management of metastatic disease.
The recruitment of metastatic cells to the scaffold, combined with label-free imag-
ing for detection of nascent stage metastatic cells, and reduced burden of disease in
solid organs (i.e., liver and brain), may ultimately allow for interventions when the
disease burden is low that could translate to improved disease-specific outcomes. In
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the clinical setting, the scaffold may be integrated into disease management plans by
potentially serving as a sentinel site for detection of disease metastasis or recurrence.
For example, the scaffold could be implanted in patients with a diagnosis of invasive
cancer at the completion of adjuvant therapy, and monitored during scheduled follow-
up visits using the optical imaging technique. If metastatic or recurrent disease was
then detected, the scaffold could be explanted for cell retrieval and analysis to help
guide targeted treatment decisions. Furthermore, in the setting of metastatic disease,
given the potential survival benefit of the presence of the scaffold, patients may have
extended disease-specific survival with excision of the primary tumor and scaffold
implantation long-term. Finally, the scaffold may be implanted prophylactically to
help detect early onset metastatic disease in high-risk patients.
Our results provide the first evidence that a scaffold for capture and detection of
early metastatic cells, combined with an intervention shortly after detection of early
metastasis (i.e., primary tumor excision) can enhance survival. This biomaterial
approach is based on the host response to an implanted scaffold, thereby avoiding the
presence of potentially deleterious cellular or biological components. PCL material
is currently FDA approved for applications such as drug delivery, suture material,
and wound dressings, which may facilitate translation to the clinic for the capture
of metastatic cells [144]. Also, this material is biodegradable and would not need to
be retrieved unless cancer cells are detected; and the degradation rate is relatively
slow allowing the implant to be monitored for up to two years within a patient [145,
146]. Clinical studies would be necessary to appropriately integrate metastatic cell-
capturing scaffolds into existing breast cancer management plans. Taken together,
the results of this work showing prolonged survival with scaffold implantation, hold
promise for reducing breast cancer morbidity and mortality.
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3.7 Materials and Methods
3.7.1 Fabrication, characterization, and implantation of micro-porous scaf-
folds
Scaffold Fabrication and Characterization
For preparation of microporous PCL scaffolds, PCL microspheres were first pre-
pared by emulsifying a 6% (w/w) solution of PCL (Lactel Absorbable Polymers,
Birmingham, AL; Inherent viscosity = 0.65-0.85 dL/g) in dichloromethane in a 10%
poly(vinyl alcohol) solution followed by homogenization at 10,000 rpm for 1 min. The
solution was then stirred for 3 h. Microspheres were collected by centrifugation and
washed at least 5 times in deionized water, followed by lyophilization for 48 h. To pre-
pare micro-porous PCL scaffolds, PCL microspheres and salt particles (size range 250
425 m) were mixed in a 1:30 (w/w) ratio and pressed at 1500 psi in a steel die for 45 s.
Polymer-salt discs were heated at 60 C for 5 min on each side, followed by foaming in
high pressure CO2 at 800 psi for 24 h. Salt particles were removed by immersing discs
in water. For experimental studies, scaffolds were sterilized using 70% ethanol, rinsed
with sterile water, and dried on a sterile gauze pad. Microporous PLG scaffolds were
prepared as described previously [147]. Scaffolds were characterized using mechanical
testing, scanning electron microscopy, and calculation of porosity.
Scaffold Implantation
Microporous scaffolds were implanted in the subcutaneous space of either female
BALB/c or NOD/SCID-IL2R-/- (NSG) mice (8-10 week old). All animal studies
were performed in accordance with institutional guidelines and protocols approved
by Northwestern University and the University of Michigan Institutional Animal Care
and Use Committee. NSG mice were bred in house or purchased from the Jackson
laboratory. BALB/c mice were purchased from the Jackson laboratory. For the
implantation procedure, mice were anesthetized with an intraperitoneal injection of
55
Ketamine (10 mg/kg) and Xylazine (5 mg/kg). The upper back was shaved and
prepped using a betadine swab followed by an ethanol swab (3X). An incision was
made in the upper back and a subcutaneous pocket was created on each side, into
which the scaffolds were inserted (2 scaffolds per mouse). The skin was closed using
wound clips (Reflex 7mm, Roboz Surgical Instrument Co.) and surgical glue (3M
Vetbond Tissue Adhesive).
3.7.2 Tumor inoculation
Orthotopic tumor inoculation was performed one month after scaffold implan-
tation. MDA-MB-231BR-tdTomato-luc2 cells were obtained from the Northwestern
University Developmental Therapeutics Core and authenticated by short tandem re-
peat DNA analysis and comparison to the ATCC STR profile database in 2013 (DDC
Medical). 4T1-luc2-tdTomato cells were obtained from Perkin Elmer in 2014 and were
used directly without additional authentication. 2 106 4T1-luc2-tdTomato (Perkin
Elmer) or MDA-MB-231BR-tdTomato-luc2 cells in 50 L sterile phosphate buffer saline
(PBS) (Life Technologies) were injected into the fourth right mammary fat pad of
12-14 week old female BALB/c or NSG mice.
3.7.3 Flow cytometry
Mice were euthanized at indicated times and retrieved scaffolds and organs were
processed according to previously established procedures [31]. Flow cytometry stain-
ing and analysis were performed according to established procedures [31].
3.7.4 Scaffold sectioning and fluorescence imaging
Scaffolds retrieved from mice were rinsed in PBS and then immediately flash frozen
in pre-chilled isopentane. Frozen scaffolds were then embedded in optimal cutting
temperature (OCT; Cardinal Health) compound with 30% sucrose and sectioned using
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a cryostat (Microm HM 525; Microm International) at 14 m. Scaffold sections were
stored at -20 C until imaging. Cryosections were air-dried at room temperature for
30 min, fixed with 10% neutral buffered formalin, washed with tap water for 5 min,
DI water for 10 min (2X) and cover slipped with ProLong Gold antifade aqueous
mounting medium containing DAPI (Molecular Probes, Grand Island, NY). DAPI
fluorescence was visualized using an excitation wavelength of 358 nm, and tdTomato
fluorescence in cancer cells was visualized using an excitation wavelength of 532 nm.
Images were viewed using an Olympus BX43 microscope and an Olympus DP72
digital camera with CellSens Entry software (Olympus) used for image capture and
co-localization.
3.7.5 ISOCT imaging and analysis
ISOCT imaging and analysis was performed as described elsewhere [31, 112, 130,
148].
3.7.6 Post-surgical model of breast cancer metastasis and Gr-1 depletion
The influence of scaffold implant on survival was investigated using a post-surgical
model of breast cancer metastasis. In this model, the 4T1 primary tumor was resected
6 or 10 days post tumor inoculation. Briefly, the primary tumor area was prepped
using a betadine swab followed by an ethanol swab (3X). An incision was made
along the right side of the lower half of the dorsal skin exposing the primary tumor.
The tumor was picked up using needle nose-forceps and cut around the base using
curved tip scissors. The skin was closed using MONOCRYL (poliglecaprone 25) suture
(Ethicon, Inc.) and surgical glue (3M Vetbond Tissue Adhesive). Animal health was
monitored daily after the procedure for activity and responsiveness including posture,
mobility, body weight, grooming behavior, and respiratory conditions. Animals were






Porosity (%) Pore Volume
(mm3)
PLG 1004 +/- 112 96.7 +/- 0.001 38.1 +/- 0.04
PCL 664 +/- 97 94.7 +/- 0.005 37.2 +/- 0.18
Table 3.1: Characterization of micro-porous PLG and PCL scaffolds (N =
10)
that evidenced primary tumor re-growth were excluded from the analysis to avoid
confounding effects arising from the primary tumor. For Gr-1 depletion studies,
resection was performed at day 10 as described above and mice received 300 g anti-
Gr-1 (clone RB6-8C5, Bio X Cell) via intraperitoneal injection at day 13 and 17 post
tumor inoculation.
3.7.7 Data analysis
Data are presented as mean +/- standard error (s.e.m.). Animal studies were
performed with at least two independent replicates of 48 female 812-week-old mice
per group with random assignment. Multiple comparisons were performed using one-
way ANOVA. Comparisons post ANOVA was performed using the Tukey-HSD test.
For data that did not follow a normal distribution, comparison was performed using
the non-parametric Wilcoxon rank-sum test. For comparing the relative number of
mice containing detectable tumor cells in organs with scaffolds, a Fishers exact test
was used to determine the p-value. Statistical analysis was performed using JMP
Software (JMP Pro 11). For survival analysis, Kaplan-Meier curve was generated and




Figure 3.8: Micro-porous PCL scaffolds persist and maintain a space for ex-
tended times in vivo. (A) Representative photomicrographs of micro-
porous PLG and PCL scaffolds retrieved from tumor free BALB/c mice
at day 98 post scaffold implantation. Average scaffold area at day 0 ver-
sus day 98 for PLG and PCL scaffolds when tested in a BALB/c (B)
and NSG (C) mouse model. N = 4; *p <0.0001 compared to day 0 for
PLG scaffolds in BALB/c and NSG mouse; p = 0.22 compared to day 0
for PCL scaffolds in BALB/c mouse and p = 0.7 compared to day 0 for
PCL scaffolds in NSG mouse as determined by t-test. Scaffold area was
calculated using dimensions obtained from images of scaffolds taken at
day 0 and day 98 post implantation using Image J software. Error bars
denote s.e.m.
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Figure 3.9: Host response following implantation of micro-porous PCL scaf-
folds in the dorsal subcutaneous space of an NSG mouse in vivo.
(A) CD45+ leukocyte numbers and (B) Dynamics of CD11b+F4/80+,
CD11c+F4/80-, CD11b+Gr-1hiLy6C-, and Ly6C+F4/80- populations
expressed as a percentage of live CD45+ leukocytes at day 30 and day
60 post PCL scaffold implantation (N = 8 for each time point examined,
*p <0.05 compared to day 30 as determined by t-test). The relative dis-
tribution of immune cell populations was nearly identical between day 30
and day 60 post scaffold implantation. Error bars denote s.e.m.
Reason for sacrifice Mock Scaffold
Hunched posture, bad grooming, and
lethargy
2/7 1/7
Labored breathing 3/7 -
Hind limb paralysis 1/7 1/7
Forelimb paralysis - 1/7
Cause unknown - mouse found dead 1/7 1/7
Experiment terminated – mice were
healthy, no signs of disease observed
- 3/7
Table 3.2: Sacrifice and endpoints observed in the post-surgical model in
mock and scaffold groups
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Figure 3.10: Dynamics of immune cell populations in the spleen of BALB/c
mice with a PCL scaffold implant at day 0, 5, 10, and 15
post tumor inoculation. Percentage of (A) CD11b+F4/80+ (B)
CD11c+F4/80- (C) CD11b+Gr-1hiLy6C- (D) Ly6C+F4/80- innate im-
mune cell populations and percentage of (E) CD4+ (F) CD8+ (G)
CD19+ and (H) CD49b+ adaptive immune cell populations in the total
population of live CD45+ leukocytes. (N >5 for each time point exam-
ined, *p <0.05 compared to day 0 and #p <0.05 compared to day 5 as
determined by Tukey-HSD test post ANOVA). Error bars denote s.e.m.
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Figure 3.11: Micro-porous PCL scaffolds enable recruitment of human
MDA-MD-231BR cells in a chronic model of scaffold implan-
tation. (A) Total cell infiltration and (B) Tumor cell infiltration in
PLG and PCL micro-porous scaffolds. Scaffolds were retrieved at day
15 post tumor inoculation, which was performed 1 month post scaffold
implantation (N = 10 for each group, *p <0.05 as determined by t-test
for analysis of total cell numbers and Wilcoxon rank-sum test for tumor
cell numbers). Error bars denote s.e.m.
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Figure 3.12: Micro-porous PCL scaffolds do not significantly improve sur-
vival in a post-surgical model of breast cancer metastasis with
day 6 post tumor inoculation resection. (N >5 for each group).
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Figure 3.13: Anti-Gr-1 depletion significantly reduces the presence of
CD11b+Gr-1hiLy6C- MDSCs in the spleen (A) primary tumor
(B) and scaffold (C). The percentage of CD11b+Gr-1hiLy6C- cells in
the CD45+ leukocyte population was examined via flow cytometry at
day 15 post tumor inoculation after three 300 g antibody injections (day
5, 9, 13) (N=5 for spleen and primary tumor, N = 10 for scaffolds, per-
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Metastasis is responsible for the vast majority of cancer associated deaths. The
formation of metastasis is directly preceded by the formation of a hospitable microen-
vironment supportive of metastasis known as the pre-metastatic niche. The study of
the pre-metastatic niche has been significantly hampered by the stochasticity of its
formation in natural organs. Implantable biomaterials have emerged as a model for
the pre-metastatic niche and are capable of recruiting tumor cells in vivo. Bioma-
terial scaffolds can serve as a site for modulation of the microenvironment in order
to probe the pre-metastatic niche and observe the impact on metastasis. Lentivirus
can be delivered from PCL scaffolds in vivo and achieve long-term transgene ex-
pression (>30 days). Immune cells were the primary targets of lentiviral transgene
expression in vivo. Macrophages, neutrophils and B cells were preferentially trans-
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duced by lentivirus, while monocytes, CD4/CD8 T cells, and Natural Killer cells
were less likely to express the transgene. IL10 delivery resulted in a significant de-
crease in tumor cell recruitment to scaffolds in vivo. Delivery of immunomodulatory
CXCL12 lentivirus enhanced CD45+ immune cell recruitment to scaffolds while de-
livery of IL10 reduced immune cell recruitment. Multiple linear regression was em-
ployed across all immunomodulated microenvironments to identify key populations
of immune cells responsible for tumor cell recruitment and found overall CD45+ im-
mune and CD8+ T cell percentages to be significantly associated with reduced tumor
cell recruitment, while CD11b+Gr1+ neutrophils and CD4+ T cell percentages were
significantly associated with enhanced tumor cell recruitment. Conditioned media
from immunomodulated scaffolds identified effects on tumor cell phenotype in vitro
such as reduced proliferation from CXCL12 delivered microenvironments, enhanced
proliferation from IL10 microenvironments, enhanced scratch closure in CCL2 mi-
croenvironments, and reduced closure in IL10 microenvironments. Altogether these
findings support the idea that biomaterial scaffolds that recruit metastatic tumor
cells in vivo are a robust platform to probe events in pre-metastatic niche formation,
tumor cell recruitment and metastasis.
4.3 Introduction
Metastasis is the single greatest contributor to cancer associated deaths [149].
One of the many challenges in treating metastasis is a lack of biological understand-
ing regarding the formation of metastasis permissive microenvironments known as
the pre-metastatic niche. The seed and soil hypothesis postulated by Stephen Paget
in 1889 hypothesized that something about the soil of organs that are targets for
metastasis is primed to support the seed of the metastatic tumor cell [6]. This phe-
nomenon was confirmed in a landmark study by Rosandra Kaplan and colleagues in
2005 and termed the pre-metastatic niche [8]. Since 2005, many more review articles
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have been published on the pre-metastatic niche than primary literature which high-
lights the intense interest in this area but difficulty in its study. The steps directly
preceding metastasis formation are particularly difficult to probe for a number of
reasons. First, the pre-metastatic niche occurs in stochastic locations within a target
organ and the altered locations make up a very small percentage of the organ itself
[7, 51, 150]. Second, genetic alterations to probe the pre-metastatic niche often have
to be done on an organism wide scale through genetically engineered mouse models
and often have off-target effects on primary tumor development. Biomaterials that
recruit metastatic cancer cells in vivo are an emerging technology to address both of
these problems [30, 31, 34, 42, 151, 152]. First, they provide a defined site in vivo to
which tumor cells are recruited, allowing for a concentrating effect of the factors and
cell types associated with the pre-metastatic niche and metastasis. Second, they are
readily modifiable on a local scale, such that the properties of the site may be altered
without any off-target effects on the host at large. As a result, biomaterial scaffolds
that model the pre-metastatic niche in vivo represent a transformative approach to
understand the development of the pre-metastatic niche, the recruitment of tumor
cells, and the contribution of individual factors to each of these processes [151].
Many factors associated with the pre-metastatic niche and metastasis have mul-
tifaceted effects on immune and tumor cells that make discerning their role in the
local microenvironment of the pre-metastatic niche difficult. For example, CXCL12
or SDF-1 is known to be a chemoattractant for breast cancer cells [153] however, it
also has broad effects on the immune system [154], fibroblasts [155] , and endothelial
cells [156]. While many studies have investigated the role of such immunomodula-
tory factors on metastasis through knock-out genetically engineered mouse models
[157], these factors have not been investigated on a purely local scale. Similarly, IL10
[158, 159] and CCL2 [15, 128] have both been implicated in metastasis, but their role
on a local scale has not been elucidated.
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In this study, we hypothesized that recruitment of tumor cells to the scaffold was
driven by immune cells, and investigated modulation of the immune microenviron-
ment as a means to influence tumor cell recruitment and to dissect the contribution
of specific immune cell populations.
4.4 Results
4.4.1 Lentiviral delivery from scaffolds achieves sustained transgene ex-
pression in immune cells in the in vivo biomaterial microenviron-
ment
The ability of poly(ε-caprolactone) (PCL) scaffolds to deliver lentivirus from the
epididymal fat pad was assessed via delivery of firefly luciferase (FLUC) lentivirus and
measured by bioluminescence imaging over 42 days following implantation (Figure
4.1A). Expression peaked at day 7 following implantation (6.36E6 +/- 1.98E6 pho-
tons/sec for FLUC loaded scaffolds and 1.81E4 +/-3.68E3 photons/sec for blank scaf-
folds) and was significantly higher than blank scaffolds at all time points investigated
(p<0.05 via two-tailed Students T test). Next, we investigated what proportion of
cells recruited to the scaffold was transduced by lentivirus. To this end, we delivered
GFP lentivirus from PCL scaffolds and assessed the percentage of GFP+ cells by flow
cytometry at day 7 following implantation. The percentage of GFP+ cells in scaffolds
with GFP encoding lentivirus delivered was significantly higher than in blank scaffolds
(2.54+/-0.81% for GFP and 1.7+/-0.08% for blank scaffolds, p<0.05 via two-sided
t-test, Figure 4.1B). In this same experiment we also evaluated the relative distri-
bution of immune cells within transduced and non-transduced cells by comparing the
percentage of all cells for each immune population to the percentage of GFP+ cells
for a given population for both innate (Figure 4.1C) and adaptive immune cell pop-
ulations (Figure 4.1D). GFP+ cells that were transduced with lentivirus were more
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likely to be CD45+ (35.52+/-15.48% CD45+ for all cells and 58.6+/-6.75% CD45+
for GFP+ cells), CD11b+F4/80+ (macrophages, 5.26+/-1.79% CD11b+F4/80+ of
CD45+ for all cells and 16.46+/-3.84% CD11b+F4/80+ of CD45+ for GFP+ cells),
CD11b+Gr1+ (neutrophils, 4.51+/-0.57% CD11b+Gr1+ of CD45+ for all cells and
16.5+/-2.64% CD11b+Gr1+ of CD45+ for GFP+ cells), CD19+ (B cells, 2.44+/-
0.39% CD19+ of CD45+ for all cells and 10.8+/-1.26% CD19+ of CD45+ for GFP+
cells) and less likely to be Ly6C+F4/80- (monocytes, 36+/-6.73% Ly6C+F4/80- for
all cells and 27.8+/-3.38% Ly6C+F4/80- for GFP+ cells), CD4+ (helper T cells,
1.34+/-0.23% CD4+ of CD45+ for all cells and 0.17+/-0.11 %CD4+ of CD45+ for
GFP+ cells), CD8+ (cytotoxic T cells, 7.02+/-1.54 % CD8+ of CD45+ for all cells
and 2.17+/-0.47% CD8+ of CD45+ for GFP+ cells), and CD49b+ (Natural Killer
cells, 0.96+/-0.24% CD49b+ of CD45+ for all cells and 0.046+/-0.04 for GFP+ cells).
4.4.2 Lentiviral delivery of immunomodulatory factors successfully mod-
ulates the scaffold immune microenvironment in vivo and alters
tumor cell recruitment
Following sustained transgene expression and identification of cells types trans-
duced, we next investigated the effect of lentiviral delivery of immunomodulatory
cytokines including CCL2 (MCP-1), CXCL12 (SDF-1), and IL-10 from PCL scaf-
folds in tumor-bearing mice. We first investigated the alterations in immune cell
recruitment to the scaffold in each condition (Figure 4.2A) and found CXCL12 de-
livery significantly enhanced the percentage of CD45+ cells of total cells compared
to FLUC control (35.9+/-5.9% CD45+ cells of total for CXCL12 and 31.4+/-3.2%
of CD45+ cells of total for FLUC), while the delivery of IL10 significantly reduced
the percentage of CD45+ cells of total compared to FLUC control (27.4+/-4.1% of
CD45+ cells of total for IL10 and 31.4+/-3.2% of CD45+ cells of total for FLUC).
We next investigated the effect of immunomodulatory cytokine delivery on tumor
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Figure 4.1: Lentiviral delivery from scaffolds implanted in epididymal fat
pad achieves sustained transgene expression in immune cells.
(A) Scaffolds implanted into epididymal fat pad and loaded with FLuc
lentivirus demonstrate sustained transgene expression over 42 days, with
expression peaking at day 7 and significantly higher (p<0.05) than Blank
scaffolds at all time points investigated. (B) Scaffolds implanted into epi-
didymal fat pad and loaded with eGFP lentivirus demonstrate a signifi-
cantly higher percentage of GFP+ cells (*p<0.05) at day 7 following im-
plantation. Flow cytometry evaluation of cells transduced by lentivirus for
surface markers demonstrate populations more or less likely to be trans-
duced by lentivirus including (C) innate immune cell populations CD45+,
CD11b+F480+, CD11b+Gr1+, Ly6C+F480- cells and (D) adaptive im-
mune cell populations including CD45+, CD19+, CD4+, CD8+, CD49b+
cells. (*p<0.05 via two-sided t-test)
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cell recruitment to implanted scaffolds (Figure 4.2B) and found IL10 significantly
reduced the percentage of tdTomato+ 4T1 metastatic tumor cells spontaneously ar-
riving at the scaffold relative to all other conditions (0.06+/-.03% tdTomato+ of to-
tal cells for IL10, 0.13+/-04% tdTomato+ for FLUC, 0.09+/-0.02% tdTomato+ for
CCL2, and 0.11+/-04% tdTomato+ for CXCL12). Following evaluation of a change
in both overall immune cell recruitment and tumor cell recruitment, we next sought
to understand if the relative distribution of immune cells changes with delivery of
immunomodulatory factors (Figure 4.2C). To this end we evaluated the presence of
innate immune cell populations: CD11b+F480+ macrophages, CD11b+Gr1+ neu-
trophils, CD11b+Gr1+Ly6C- myeloid derived suppressor cells, CD11c+F480- den-
dritic cells, Ly6C+F480- monocytes, and adaptive immune cell populations: CD4+
T cells, CD8+ T cells, CD19+ B cells, and CD49b+ NK cells by flow cytometry.
We found a few small, but statistically significant differences between immunomod-
ulatory conditions including a significant increase in CD11b+F480+ macrophages in
CXCL12 (5.22+/-1.6%) relative to CCL2 (2.7+/-0.86%) and IL10 (3.26+/-0.65%), a
significant decrease in CD11b+Gr1+Ly6C- myeloid derived suppressor cells in CCL2
(6.86+/-2.9%) relative to CXCL12 (15.7+/-9.4%) and IL10 (11.9+/-4.8%) conditions,
a significant increase in CD11c+F480- dendritic cells in FLUC (22.0+/-2.6%) rela-
tive to CCL2 (17.1+/-2.2%) and IL10 (14.9+/-2.7%) and in CXCL12 (20.6+/-5.5%)
relative to IL10 (14.9+/-2.7%), a significant increase in Ly6C+F480- monocytes in
CCL2 (16.0+/-3.6%) relative to IL10 (12.1+/-3.4%), a significant increase in CD8+
T cells in CCL2 (9.8+/-2.3%) and IL10 (10.3+/-3.4%) relative to FLUC (6.97+/-
1.7%) and CXCL12 (6.91+/-2.4%), and a significant increase in CD19+ B cells in
CCL2 (2.70+/-1.3%) relative to FLUC (1.60+/-0.3%) , CXCL12 (1.43+/-0.7%), and
IL10 (1.50+/-0.4%).
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Figure 4.2: Lentiviral delivery of immunomodulatory factors from scaffolds
results in modulation of the scaffold immune microenvironment.
Delivery of immunomodulatory lentivirus alters (A) the percentage of
CD45+ cells of singlets (B) the percentage of CD45-tdTomato+ 4T1
tumor cells, and (C) innate immune cell populations CD11b+F480+
macrophages, CD11b+Gr1+ neutrophils, CD11b+Gr1+Ly6C- myeloid
derived suppressor cells, CD11c+F480- dendritic cells, Ly6C+F480-
monocytes and adaptive CD4+ T cells, CD8+ T cells, CD19+ B cells,
and CD49b+ NK cells as evaluated by flow cytometry. Letter indicates
significance p<0.05 where a is significantly altered from FLuc, b from
CCL2, c from CXCL12, and d from IL10.
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4.4.3 Modulation of the scaffold immune microenvironment provides in-
sights into immune cell populations critical to tumor cell recruit-
ment in vivo
Following the finding that delivery of immunomodulatory lentivirus from bioma-
terial scaffolds alters immune cell recruitment subsequent tumor cell recruitment in
vivo we next sought to use the immune marker and tumor cell marker flow cytome-
try data to investigate the role of individual immune cell populations in tumor cell
recruitment. First, unsupervised hierarchical clustering was performed on the flow
cytometry data to identify how different the immune microenvironments are when
the all of the immune populations are taken into account (Figure 4.3A). We found
that in general, samples of the same condition clustered together somewhat but there
was significant variability in the data that could not be explained simply by the
delivery of one cytokine. For example, two major clusters were identified with the
first encompassing all FLUC and IL10 samples, all but one CXCL12 sample, and
3/6 IL10 samples. The second cluster contained one CXCL12 sample and one CCL2
sample and upon visual inspection it appears that the strongest indicators of this
first level of clustering were due to higher than average content of CD19+ B cells
and CD11b+Gr1+ neutrophils. Upon further subdividing the first cluster containing
all FLUC, IL10, and most CXCL12 samples this cluster can be further subdivided
into 3 clusters. The first of these three clusters contains 2/6 FLUC samples and 3/6
CXCL12 samples which appear to be clustering primarily on higher than average
CD45+ and CD11b+Gr1+Ly6C- myeloid derived suppressor cell content. The sec-
ond of these clusters contains 2/6 CXCL12 samples, 4/6 FLUC samples, 2/6 CCL2
samples, and 1/6 IL10 sample and appear to be similar primarily due to relatively
high CD45-tdTomato+ tumor cell content and CD45+ cell content. The final cluster
contains 5/6 IL10 samples, 2/6 CCL2, and 2/6 CXCL12 and the primary character-
istic of this cluster appears to be relatively high CD8+ T cell content accompanied
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by relatively high Ly6C+F480- monocyte content.
Since correlations between cell types were not obvious by unsupervised hier-
archical clustering, we next performed correlation analysis to look at the correla-
tion between each cell population in the scaffold microenvironments (Figure 4.3B,
Supplemental Figure 4.7). Interestingly, we found CD11b+Gr1+ neutrophils,
CD11c+F480- dendritic cells, Ly6C+F480- monocytes, CD4+ T cells, and CD19+ B
cells to positively associated with tumor cell recruitment (r>0) while overall CD45+,
CD11b+F480+ macrophages, CD11b+Gr1+Ly6C- putative myeloid derived suppres-
sor cells, CD8+ T cells, and CD49b+ Natural Killer cells were all negatively correlated
with tumor cell recruitment (r<0). Additionally, some immune cell populations were
strongly positively correlated with each other including CD11b+Gr1+ neutrophils
and CD19+ B cells (r=0.75), CD11b+F480+ macrophages and CD11b+Gr1+Ly6C-
myeloid derived suppressor cells (r=0.672), and CD11b+Gr1+ neutrophils and Ly6C+F480-
monocytes (r=0.67); while others had strong negative correlations including CD11b+Gr1+Ly6C-
myeloid derived suppressor cells and Ly6C+F480- monocytes (r=-0.72). To inves-
tigate the key players in tumor cell recruitment further, we performed stepwise
multiple linear regression analysis to create a model that explains the variability
in the recruitment of tumor cells to the immunomodulated scaffold microenviron-
ments (Table 4.1) with the percentage of tumor cells of total cells as the output
and the percentage of each population (CD45+ total immune cells, CD11b+F480+
macrophages, CD11b+Gr1+ neutrophils, CD11b+Gr1+Ly6C- myeloid derived sup-
pressor cells, CD11c+F480- dendritic cells, Ly6C+F480- monocytes, CD4+ T cells,
CD8+ T cells, CD19+ B cells, and CD49b+ NK cells) as continuous predictors. This
analysis method created a model with the equation Tumor-Cells = 0.0794 - 0.004651
CD45 + 0.00438 Neutrophil + 0.0756 CD4 - 0.00298 CD8 and a model R2 = 69.69%,
adjusted R2 = 64.42%, and p-value <0.001 for the model. The positive coefficients for
CD11b+Gr1+ neutrophils and CD4+ T cells indicate that these positively contribute
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Predictor Term P-value Coefficient Coefficient S.E.
Constant 0.118 0.0794 0.0489
%CD45+Live of singlets <0.001 -0.004651 0.000973
%CD11b+Gr1+ of CD45+Live Cells 0.001 0.00438 0.00120
%CD4+ of CD45+Live Cells 0.001 0.0756 0.0206
%CD8+ of CD45+Live Cells 0.039 -0.00298 0.00137
Table 4.1: Multiple Linear Regression for immunomodulated scaffolds iden-
tifies key immune cell populations role in tumor cell recruitment.
Regression Equation: Tumor-Cells = 0.0794 - 0.004651 CD45 + 0.00438 +
0.0756 CD4 - 0.00298 CD8. Model R2 = 69.69%, Adjusted R2 = 64.42%,
p<0.001 for model.
to tumor cell recruitment, while total CD45+ cells and CD8+ T cells negatively con-
tribute to tumor cell recruitment; similar to what we saw by simple linear correlations
(Figure 4.3B).
4.4.4 Modulation of the scaffold immune microenvironment exhibits dif-
ferential effects on tumor cell phenotype in vitro
Finally, we evaluated the effect of immunomodulated microenvironments on tu-
mor cells in vitro. We did this by implanting FLUC control scaffolds in the right
epididymal fat pad and a virus of interest (CCL2, CXCL12, IL10) in the left epi-
didymal fat pad of the same mouse. Using this method, the FLUC scaffold in each
mouse serves as an internal control. Seven days following implantation, we explanted
scaffolds, placed them in sterile RPMI-1640, minced the scaffold, and allowed the
cells to condition the media for 48 hours. This conditioned media was then used
for various assays with tumor cells including proliferation (Figure 4.4A), scratch
assay (Figure 4.4B), and mammosphere formation assay (Figure 4.4C). In prolif-
eration assays CXCL12 suppressed tumor cell proliferation relative to FLUC controls
(84,440+/-41,000 cells/well for FLUC and 54,400+/-15,000 cells/well for CXCL12)
from the same set of mice while IL10 enhanced proliferation relative to FLUC con-
trols (17,700+/-9,000 cells/well for FLUC and 35,900+/-24,000 cells/well for IL10)
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Figure 4.3: Lentiviral delivery of immunomodulatory factors from scaffolds
results in modulation of the scaffold immune microenvironment.
(A) Unsupervised hierarchical clustering of immune populations in scaf-
folds with Fluc, mCCL2, mCXCL12, or mIL-10 delivered. (B) Correlation
analysis of immune cell populations and tumor cell recruitment showing
heatmap of Pearson correlation coefficient values for each immune cell
population and tumor cells identified as CD45-tdTom+
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from the same mice (Figure 4.4A). In scratch assays CCL2 significantly enhanced
the number of wells with partial closure relative to FLUC (11% partial in FLUC and
89% partial closure in CCL2), while IL10 significantly enhanced no closure (0% of
scratches with no closure in FLUC and 42% of scratches in IL10 with no closure,
Figure 4.4B). In mammosphere assays no significant differences in mammosphere
formation ability were observed as a result of different immunomodulated conditioned
medias, however a reduction in mammosphere formation ability was observed across
all scaffold conditioned media samples relative to the RPMI-1640 unconditioned me-
dia (CTRL, Figure 4.4C).
4.5 Discussion
Metastasis is responsible for 90% of cancer related deaths [149]. Enhancing un-
derstanding of the key events for tumor cell recruitment and development of the
pre-metastatic niche has the potential to significantly impact treatment of metas-
tasis. The pre-metastatic niche has been particularly difficult to study given the
stochastic, focal nature of development in pre-metastatic organs. In this study we
validate the use of biomaterial scaffolds as a platform to engineer the pre-metastatic
niche and observe the impact on immune cell recruitment and subsequent tumor cell
recruitment. The standard platform for altering the properties of a pre-metastatic
site and observing the impact on metastasis has been genetically engineered mouse
models. However, these have a significant disadvantage as there are usually off-target
effects other than the tissue of interest as well as the cost to develop these models is
very high. Biomaterial scaffolds have been used to recruit tumor cells in models of
breast [30, 31, 34, 42, 152], prostate [27], ovarian [29], melanoma [26] and leukemic
[36] cancers. The recruitment of tumor cells to a site that is readily modifiable makes
an ideal platform for probing the pre-metastatic and metastatic niche, however to
this point only single factors have been identified for their ability to enhance tumor
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Figure 4.4: Scaffold immunomodulatory effect on tumor cell phenotype. 4T1
tumor cells were grown in vitro and treated with conditioned media gen-
erated from scaffolds loaded with FLUC, CCL2, CXCL12, or IL10 in
(A) proliferation assays where the number of cells per well was assessed
by measuring tdTomato fluorescence via plate reader, (B) scratch assay
where the number of scratches achieving complete, partial, or no closure
was evaluated using light microscopy, and (C) mammosphere assay where
tumor cells were plated in a mammosphere assay in ultra low attachment
plates and allowed to grow as spheres in the presence of conditioned me-
dias and proliferation of spheres assessed by measuring tdTomato fluores-
cence via plate reader.
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cell recruitment[31, 34, 42] but no alterations have been found that reduce tumor cell
recruitment relative to control, nor has the interplay between the immune microen-
vironment present in a scaffold and the subsequent recruitment of tumor cells been
fully investigated.
To date, this study is the first to look at a range of inflammatory and anti-
inflammatory factors to probe their effect on the immune microenvironment of the
foreign body response, as well as their effect on tumor cell recruitment. While, we
did see modulation of total immune cell content by flow cytometry, the changes of
relative immune cell populations were smaller than expected. This may be a result of
transducing only 2% of resident cells, even though detectable increases in the delivered
factor were observed Supplemental, Figure 4.6. Even with relatively small changes
in individual immune cell populations we found a decrease in tumor cell recruitment
to IL10 loaded scaffolds. This finding is the first in which tumor cell recruitment
has been negatively impacted simply by modulating the immune microenvironment
of the scaffold.
While we did not observe large changes in individual immune cell populations
present in the scaffold, we were able to use the sum total of the immune microenvi-
ronment as evaluated by surface marker flow cytometry to observe how delivery of
various factors biased the whole immune environment. This multifaceted approach
allowed us to investigate immune cell populations that are positively and negatively
correlated with tumor cell recruitment. Interestingly, we found CD11b+Gr1+ neu-
trophils, CD11c+F480- dendritic cells, Ly6C+F480- monocytes, CD4+ T cells, and
CD19+ B cells to positively associated with tumor cell recruitment, while overall
CD45+, CD11b+F480+ macrophages, CD11b+Gr1+Ly6C- putative myeloid derived
suppressor cells, CD8+ T cells, and CD49b+ Natural Killer cells were all negatively
correlated with tumor cell recruitment. Neutrophils, monocytes, and CD4+ T cells
were not surprising for their positive association with tumor cell recruitment as these
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have been previously reported [150]. Similarly, the negative association of CD8+
T cells and CD49b+ Natural Killer cells is to be expected as these are well known
negative-regulators of tumor cells at metastatic or pre-metastatic sites [150, 151].
However, the positive association of dendritic cells and B cells with metastasis has not
been previously reported. Additionally, we were surprised to find CD11b+Gr1+Ly6C-
putative myeloid derived suppressor cells were negatively associated with tumor cell
recruitment in this context. It is possible that this cell population may be heteroge-
neous [160] and contain neutrophils as well as granulocytic MDSCs that may explain
their negative impact on tumor cell recruitment [46]. These findings were then further
investigated by creation of a multiple linear regression model with stepwise validation
of terms to find the populations that were significantly associated with tumor cell re-
cruitment. Similar to simple correlation analysis and as would be expected based
on the literature, we found CD45+ and CD8+ T cells [161] to be negatively associ-
ated with recruitment and neutrophils [162] and CD4+ T cells [163] to be positively
associated with tumor recruitment. This analysis indicates that tumor cell recruit-
ment to a biomaterial scaffold in vivo can be described reasonably well by knowing
the relative proportions of CD45+ immune cells, CD8+ T cells, CD4+ T cells, and
CD11b+Gr1+ neutrophils. This finding is significant as it indicates that for a given
patient, the relative distribution of immune cells could be tracked as a surrogate for
tumor cell recruitment to the implant.
Finally, we investigated the role of the immunomodulated microenvironments on
tumor cell phenotype in vitro. These experiments were performed with whole scaf-
fold conditioned media and 4T1 mouse breast adenocarcinoma cells in vitro due to
the relative difficulty of ascertaining the effect of a microenvironment on recruited
tumor cells in vivo [151]. This approach also allowed for more controlled understand-
ing of the effect of modulated microenvironments on tumor cell phenotype relative
to direct analysis of recruited tumor cells which could be biased by recruitment of
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different subpopulations of tumor cells to different microenvironments. Interestingly,
we found CXCL12 modulated microenvironments significantly reduced proliferation
relative to the FLUC control in the same mouse. This is consistent with other reports
demonstrating that enhanced CXCL12 expression by the primary tumor inhibits tu-
mor growth and metastasis through regulation of anti-tumor immunity [164]. This
finding in the context of the various literatures surrounding CXCL12 role in breast
cancer metastasis highlights ability of this platform to understand metastasis on a lo-
cal scale instead of a primary tumor driven [164] or GEMM model [153]. Additionally,
we found IL10 modulated microenvironments significantly enhanced proliferation rel-
ative to FLUC controls in the same set of mice. As a potent anti-inflammatory factor,
IL10 is known to enhance metastasis through suppression of various immune surveil-
lance mechanisms [159, 165] but in other cases has been found to reduce metastasis
[158]. By using conditioned media from the modulated microenvironment, we re-
move all cell-contact dependent mechanisms and rely only on secreted factors. These
results indicate that biasing the scaffold microenvironment toward a more immune
suppressive role has dual effects on tumor cells: it reduces tumor cell recruitment
to the scaffold but enhances proliferation. Additionally, we find by scratch assay
that IL10 modulated microenvironments reduce migration of tumor cells in a scratch
assay. This is consistent with the finding of reduced tumor cell recruitment to the
scaffold. These findings highlight the ability of this platform to begin to tease out
the role of various cytokines in metastasis on a local scale, rather than through global
modulation of tumor cells or immune cells.
Lentiviral gene delivery from biomaterial scaffolds has been performed in the past
with poly(lactide-co-glycolide) (PLG) scaffolds [31, 66, 166]. In this work we chose
to use PCL scaffolds, as we have achieved higher levels of tumor cell recruitment in
PCL relative to PLG [30] and thus hypothesized that we would have better resolution
for identifying effects of immunomodulation on tumor cell recruitment. We achieved
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long-term sustained transgene expression from scaffolds loaded with lentivirus and
implanted into the epididymal fat pad, similar to previous work [66]. We found
slightly different cell populations stably expressing the lentivirus transgene relative to
previously reported work [66]. This may be a result of mouse strain differences (balb/c
versus CD1) or biomaterial differences (PCL versus PLG). As the cells transduced
with the lentivirus were more likely to be immune cells than non-immune cells, this
represents an ideal platform for modulating the immune microenvironment.
In this study, we demonstrate the utility of lentiviral delivery from biomaterial
scaffolds to alter immune cell populations and tumor cell recruitment in vivo. Appli-
cation of this technology toward dissecting the role of various immune cell populations
and secreted factors in metastasis provides an engineering platform to molecularly dis-
sect metastatic processes, identify key pathways for intervention, ultimately providing
new targets for the prevention and treatment of metastasis.
4.6 Materials and Methods
4.6.1 Lentivirus production
Lentiviral production was performed as previously described 24. Briefly, DNA
encoding for eGFP, firefly luciferase, murine IL10, CCL2, or CXCL12 in a self-
inactivating lentiviral vector cassette was purchased from Vector Builder. Lentivirus
was produced in HEK-293FT cells grown in DMEM with 10% FBS. Lentiviral packag-
ing vectors were co-transfected with the lentiviral vector into HEK293FT cells using
Lipofectamine 2000 (Life Technologies). After 48 h, the supernatant was collected and
cell debris removed via centrifugation. Lentiviral particles were then concentrated us-
ing PEG-it (System Biosciences) and re-suspended in sterile dPBS with 1M sucrose to
aid in viral stability. Lentiviral titer was determined using qPCR Lentivirus Titer Kit
(Applied Biological Materials). Typical titers ranged from 1e9 to 5e9 particles/mL.
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4.6.2 Scaffold fabrication and implantation
Microsphere preparation. PCL microspheres were prepared as previously de-
scribed11. Briefly, microspheres were prepared by emulsification of a 6% (w/w)
solution of PCL (Lactel Absorbable Polymers; Inherent viscosity 0.65-0.85 dL/g)
in dichloromethane in a 10% (w/v) poly(vinyl alcohol) solution followed by homog-
enization at 10,000 rpm for 1 minute. The solution was then stirred for 3 hours to
evaporate dichloromethane solvent. Microspheres were then collected by centrifuga-
tion at 2000 x g for 10 minutes and washed at least five times in deionized water.
Finally, microspheres were lyophilized for 48 hours.
Scaffold fabrication. Microporous PCL scaffolds were prepared by mixing PCL
microspheres and sodium chloride crystals (250-425 μm in diameter) at a 1:30 (w/w)
ratio. This salt and polymer microsphere mixture was then pressed in a steel die for
45 seconds at 1500 PSI. Polymer/salt disks were then heated at 60C for 5 minutes
per side to melt polymer microparticles around salt crystals to form a continuous
structure. Salt crystals were subsequently removed by immersion in water for 1.5
hours. Scaffolds were then sanitized for animal studies using 70% ethanol, rinsed
with sterile water, and dried on a sterile surface.
Scaffold lentivirus loading. 2e7 viral particles (in 20 μL dPBS with 1M sucrose)
were added to the scaffold using a micropipette, allowed to dry for 2 minutes and
then immediately implanted into the mouse.
Scaffold implantation. Scaffolds were implanted into the epididymal fat pads of
8-week-old female balb/c mice (Jackson Laboratory) as previously described 10. For
the implantation procedure, animals were anesthetized via isoflurane (2%, inhaled),
prepared with Carprofen analgesia (5 mg/kg, subcutaneous injection), the belly was
shaved and prepped using a Betadine swab followed by an ethanol swab and this
procedure was repeated 3 times. A fenestrated sterile field was draped over the
surgical area and a 1 cm incision was made in the skin parallel to the top of the hip.
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Next, a 1 cm incision was made in the peritoneal wall and the epididymal fat pads
were gently pulled out of the peritoneal cavity and placed on sterile gauze. Scaffolds
were placed on the fat pad and the fat pad was manipulated to enclose the scaffold
in fat. Each fat pad was gently re-inserted into the peritoneal cavity taking care to
keep the scaffold enclosed in the fat tissue. The peritoneal wall was closed with 5-0
vicryl resorbable sutures (Ethicon). The skin was then closed using sterile wound
clips (Reflex 9 mm, Roboz Surgical Instrument Co).
4.6.3 Tumor Inoculation
Animal studies were performed in accordance with institutional guidelines and
protocols approved by the University of Michigan Institutional Animal Care and Use
Committee (IACUC). Tumor inoculations were performed by injection of 2e6 4T1-
tdTomato-luc2 (Perkin Elmer) cells in 50 μL PBS (Life Technologies) into the fourth
right mammary fat pads of 10-week-old female Balb/c mice (Jackson Laboratory).
Cell lines were confirmed to be pathogen free and authenticated by short tandem
repeat DNA analysis and compared to the ATCC STR profile database (DDC Medi-
cal).
4.6.4 In vivo bioluminescence imaging
Luciferase expression was monitored longitudinally using an IVIS imaging system
(Caliper). Mice were anesthetized with isoflurane and administered an intraperitoneal
injection of d-luciferin (Caliper) at a dose of 150 mg/kg. Animals were then placed
in the imaging chamber and images were acquired every 5 min for a total of 30 min
or until the peak signal was found for each mouse. Signal intensity is reported as
integrated light flux (photons/sec) as calculated by Living Image Software (Caliper).
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4.6.5 Statistical Analysis
All results are presented as mean +/- standard error of mean (SEM). Statisti-
cal comparisons of parameters between groups were made using Students t-test for
unpaired samples. A p value of <0.05 was considered statistically significant. Unsu-
pervised hierarchical clustering was performed in MATLAB release 2018a.
4.6.6 Flow Cytometry
Scaffolds were minced, digested using Liberase TL (Roche) and strained through a
70 μm filter to produce a single cell suspension. Cells were pelleted via centrifugation
at 500 x g for 5 min. Following isolation of a single cell suspension, cells were blocked
using anti-CD16/32 (Biolegend) and stained with anti-mouse CD45 AF700 (Biole-
gend), CD11b V500, F4/80 PECy7, Gr1 PacBlue, Ly6C FITC, and CD11c APC for
innate panel. For adaptive panel samples were stained with anti-mouse CD45 AF700,
CD4 V500, CD8 FITC, CD19 PacBlue, and CD49b PECy7. Samples were run on
MoFlo Astrios Flow Cytometer (Beckman Coulter) and data processed using FlowJo
(TreeStar Inc.).
4.6.7 Conditioned Media Assays
Generation of conditioned media. Scaffolds were isolated, separated from epididy-
mal fat pad and placed in 600 μL sterile RPMI 1640 media with non-essential amino
acids, HEPES buffer, and without phenol red. Scaffolds were then minced using a
microfeather scalpel and incubated at 37C and 5% CO2 for 48 hours. Following con-
ditioning of media, supernatant was collected into microcentrifuge tubes (MCT) and
centrifuged at 2000xg for 5 min at 4C. Supernatant was then transferred to a new
MCT and stored at -80C until use.
Conditioned Media Assays. 4T1-tdTomato-luc2 cells were thawed and allowed
to grow to confluency before passaging for proliferation, scratch and mammosphere
85
assays. All assays were performed in 96 well plates with 50 μL of conditioned media
and 50 μL of serum-free or serum-containing RPMI 1640 as appropriate for the assay.
For all conditioned media assays each condition was compared to a F-Luc control in
the same mouse (F-Luc loaded and implanted into right fat pad and virus of interest
loaded and implanted into left fat pad). RPMI 1640 with non-essential amino acids,
HEPES buffer and without phenol red, was used as a control for all assays.
Proliferation Assays. Cells were plated at 50,000 cells/well and the number of
cells was monitored once a day for four days using a plate reader with excitation at
554 and emission at 581 reading from the bottom of the plate. Scratch Assays. Cells
were plated at 100,000 cells/well and allowed to attach for 12 hours. After 12 hours,
a p200 pipette tip was used to create a scratch in the center of each well spanning the
length of the well. The plate was gently shaken to remove any loosely attached cells.
Next the media was replaced the 50 μL of the appropriate conditioned media and
50 μL of RPMI-1640 with 10% fetal bovine serum. Wells were imaged using a light
microscope immediately after scratch formation and imaged every 3 hours following
scratch formation to monitor scratch closure. At 12 hours following scratch formation
each well was imaged and evaluated for full, partial or no closure of the scratch.
Mammosphere Assays. Cells were plated at 10,000 cells/well in an ultra-low at-
tachment 96 well plate with 50 μL of mammosphere media and 50 μL of the appro-
priate conditioned media. Mammosphere formation was monitored with imaging via
light microscope for 5 days and evaluation of whole well tdTomato fluorescence using
a plate reader as with the proliferation assay above.
4.7 Supplemental Figures
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Figure 4.5: Delivery of UBC-mIL10 lentivirus demonstrates significantly
higher protein levels of mIL-10 as evaluated by ELISA relative to
scaffolds that receive no lentivirus.
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Figure 4.6: Single linear regression of cell populations identified as signifi-
cantly explaining variability in tumor cell recruitment including
(A) %CD45+Live cells of singlets (B) %CD11b+Gr1+ (Neutrophils) of
CD45+Live cells (C) %CD4+ T cells of CD45+Live cells and (D) %CD8+
T cells of CD45+Live cells. Single regression line and 95% confidence in-
terval are reported for each single linear regression.
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CHAPTER V
Biomaterial Scaffolds Recruit an Aggressive
Population of Metastatic Tumor Cells in Vivo
5.1 Authors
Grace G Bushnell, Tejaswini P Hardas, Scott Ronquist, Rachel M Hartfield, Yin-
ing Zhang, Robert S Oakes, Haiming Chen, Indika Rajapakse, Max S Wicha, Jacque-
line S Jeruss, Lonnie D Shea
5.2 Abstract
For most cancers, metastasis is the point at which clinical treatment shifts from
curative intent to extending survival. Biomaterial implants act as a synthetic pre-
metastatic niche recruit metastatic cancer cells and provide a survival advantage, and
their use as a diagnostic platform requires assessing their relevance to disease pro-
gression. Here, we show that scaffold captured tumor cells (SCAF) are 30 times more
metastatic to the lung than primary tumor cells (PT), similar to cells derived from
lung micrometastases (LUNG). SCAF cells were more aggressive in vitro, demon-
strated higher levels of migration, invasion, and mammosphere formation, and had a
greater proportion of cancer stem cells than PT. SCAF were highly enriched for gene
sets associated with metastasis and had associated genome structural changes includ-
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ing globally enhanced entropy. Collectively, our findings demonstrate that SCAF cells
are distinct from PT, more closely resembling LUNG, indicating tumor cells retrieved
from scaffolds are reflective of cells at metastatic sites.
5.3 Significance
The use of biomaterial scaffolds as a diagnostic requires assessing relevance of re-
cruited cells to disease progression. Scaffold-recruited tumor cells are highly metastatic;
resembling those found in the lung and were investigated for metastasis-associated
genome structure changes. Scaffold-captured cells may serve as diagnostic towards
developing a molecular staging of metastasis.
5.4 Introduction
In most types of cancer, the formation of distant metastases is the point at which
the disease is no longer considered curable. Tumor cell colonization of distal sites oc-
curs through a sequence of events, initiated by generation of pre-metastatic niches by
cells originating in the bone marrow [8, 150, 167]. A small subset of tumor cells that
have successfully invaded the tumor vasculature then home to these pre-conditioned
locations [168] and are often more aggressive [5], resistant to therapy [169], and can-
cer stem cell like [170]. This suggests that neither the primary tumor nor CTCs
are representative of cells with metastatic potential. At present, methods to detect
metastasis involve radiologic imaging, which are capable of detecting metastatic foci
7-10 mm in size [171]. Imaging is typically performed for evaluation of clinical symp-
toms indicating compromised tissue function, and thus foci of this size are usually
associated with late stage disease.
Most early detection strategies currently developed focus on the use of blood as
a liquid biopsy. The umbrella term liquid biopsies includes circulating tumor cell
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(CTC), circulating tumor DNA (ctDNA), and exosome detection in the blood: all
of which are emerging as platforms to stage patients beyond the presence, size, and
molecular characteristics of the primary tumor [172]. However, while each of these
is associated with metastatic risk the interplay between the presence and relative
number of each of these markers and presence of metastatic disease is tenuous. Bio-
material scaffolds that capture metastatic tumor cells [151] extend beyond the power
of the liquid biopsy to capture immune cells associated with the metastatic niche and
metastatic tumor cells themselves [30, 31, 34, 42, 152]. These technologies have been
successful in mouse models of breast [30, 31, 34, 42, 152], ovarian [29], prostate [27],
melanoma [26], and hematologic cancers [36] and have captured tumor cells, reduced
metastatic burden [30, 31], and improved survival [30].
A crucial piece of scaffolds as a detection platform and alternative to liquid biopsy
is understanding the phenotype of tumor cells recruited to biomaterial scaffolds in vivo
testing the hypothesis that these cells are truly metastatic and similar to tumor cells
that have colonized an organ. As poly(ε-caprolactone) (PCL) scaffold implantation
in combination with surgical resection results in a survival advantage relative to mock
surgery [30], we expect that the scaffold may be capturing an aggressive population
of metastatic tumor cells. Identifying the phenotype of scaffold-captured tumor cells
within the continuum of tumor cell phenotypes will inform the use of scaffolds as
surrogates for metastatic sites, facilitating the development of therapeutic strategies
targeting metastatic disease.
In this report, we derived cell lines from the primary tumor MDA-MB-231BR
breast cancer xenografts, as well as matched lung micro-metastasis, and biomaterial
scaffold captured-tumor cells. In vitro and in vivo assays were utilized to characterize
phenotypic differences between these cell lines. Finally, we performed RNAseq and Hi-
C to elucidate transcriptional and chromatin configuration differences that generate
these phenotypic characteristics. These studies support the utility of scaffold-captured
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cells as a metastasis surrogate to reveal molecular mechanisms and identify potential
therapeutic targets for metastatic cancer.
5.5 Results
5.5.1 Tumor cell lines were derived from scaffold, primary tumor, and
metastatic sites in vitro
We generated cell lines from various tumor cell locations in vivo including cells
derived from subcutaneously implanted scaffolds and compared them to cell lines
derived from primary tumors or lung metastases derived from the same set of mice.
Based on previous reports, the earliest metastatic cells should be captured in the scaf-
fold [30, 31], with metastases arriving in the lung at subsequent times. This difference
in time of arrival may underlie some variations in these metastatic cell populations.
Using a mouse cell depletion kit and magnetic activated cell sorting, we isolated hu-
man MDA-MB-231BR human breast cancer cells from each location. Approximately
10,000 cells were plated for PT-derived cells, whereas approximately 100 and 500 cells
were isolated for scaffold and lung derived cells respectively. Representative images
of each are shown (Figure 5.1). While PT cells attached and spread day 1 (Figure
5.1A), scaffold and lung-derived cells took much longer to attach and begin growing,
likely due to plating density (Figure 5.1B). By day 12 of culture, scaffold-captured
cells had attached and formed approximately 15 individual colonies and lung-derived
cells had formed hundreds of colonies, whereas primary tumor formed confluent cul-
tures without visible colonies (Figure 5.1C). Cells were passaged and cultured to
develop stable cell lines, hereafter referred to as SCAF (scaffold-captured), LUNG
(lung micro-metastasis derived) and PT (primary tumor-derived) cell lines.
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Figure 5.1: Micro-porous scaffolds implanted in NSG mice recruit 231BR
cells in vivo. Tumor cells can be isolated by MACS mouse cell depletion
and tdTomato+ primary tumor (PT), scaffold (SCAF), and lung (LUNG)
derived tumor cells are evident initially at day 0 (A), PT cells begin to
attach at day 1 but SCAF and LUNG cells remain in suspension (B), and
by day 12 SCAF cells attached and grew out to form approximately 15
colonies of cells, LUNG cells grew out from approximately 500 cells and
PT from approximately 1e5 cells (C). Scale bars represent 25, 50, 100 or
400 um as labeled.
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Figure 5.2: SCAF cell line is highly metastatic in vivo compared to the
PT cell line and similar to LUNG cell line. (A) Representative
bioluminescence images for lungs of mice inoculated with SCAF (n=11
mice), PT (n=5 mice), or LUNG (n=6 mice) cells. Tumor burden as
measured by flow cytometry for tdTomato+ cells normalized to average
tumor burden for PT cell line for scaffolds (B) and lungs (C). Error bars,
SEM. *p<0.05 by two tailed t-test.
5.5.2 Scaffold-captured cells are highly metastatic in vivo
We investigated the metastatic capacity of these cell lines in vivo. Cell lines were
orthotopically inoculated into NSG mice and allowed to grow for 21 days. Tumor and
spleen mass were similar for all lines (data not shown). Representative bioluminescent
images of the lungs indicate metastasis, with differential metastatic capacity for each
(Figure 5.2A). Metastasis was quantified by the presence of tdTomato+ cells in
tissue homogenates by flow cytometry. Metastatic tumor burden was significantly
higher in implanted scaffolds (Figure 5.2B) (2.4 +/- 1.4 times higher) and lungs
(Figure 5.2C) (27.3 +/- 22.5 times higher) for SCAF tumor-bearing mice relative
to PT tumor-bearing mice (p<0.05 via t-test). Metastatic tumor burden was not
significantly different between LUNG and PT or LUNG and SCAF in implanted
scaffolds (Figure 5.2B) (1.9 +/- 1.2 times higher than PT) or lungs (Figure 5.2C)
(18.1 +/- 22.3 times higher than PT). Collectively, these studies demonstrate that
SCAF are more metastatic than PT and more comparable to LUNG.
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5.5.3 Scaffold-captured cells display distinct phenotypic behavior in vitro
As scaffold-captured cells were highly metastatic in vivo, we next investigated the
lines in vitro to identify mechanisms of enhanced metastasis. Assays were performed
to analyze migration and invasion as well as cancer stem cell characteristics. Using a
standard scratch assay, migration into a defect was quantified. Representative images
demonstrate migrating tumor cells at 0 and 12 hours following the scratch (Figure
5.3A). PT and LUNG samples demonstrate failure to generate closure (7/12) or
partial closure (5/12), and show no samples with full closure (Figure 5.3B). For the
SCAF cell line, a statistically significant increase was observed in both partial (9/12)
and total (2/12) closure and a significant decrease in no closure (1/12) was observed
relative to PT and LUNG (p<0.05 via Fishers Exact Test).
The invasion characteristics were measured using a transwell invasion assay. Rep-
resentative images are provided (Figure 5.3C). PT and LUNG invaded at a rate of
44 +/- 17 and 51.3 +/- 18.1 cells/image respectively (Figure 5.3D). Consistent with
the scratch assay, a significant increase in the number of SCAF cells were observed,
with 109 +/- 44 cells/image respectively. The results demonstrate that SCAF cells
have a higher capacity for invasion and migration than either PT or LUNG.
We next investigated expression of cancer stem cell markers in each cell population.
Using flow cytometry, we evaluated the expression of EpCAM, CD44 and CD24. Rep-
resentative plots are provided, showing relative levels of EpCAM+ and CD44+CD24-
cells in cell lines (Figure 5.4A). PT cells had 6.2 +/- 0.2% EpCAM+CD44+CD24-
(CSC+) cells. A significantly increased proportion of CSC+ cells (7.3 +/- 0.2%) was
observed for SCAF (Figure 5.4B). LUNG had a significantly decreased percentage
of CSC+ cells relative to both PT and SCAF (5.3 +/- 0.4%) (Figure 5.4B).
The stem cell characteristics were also investigated via mammosphere assay, which
measures self-renewal in suspension. Representative images are provided (Figure
5.4C), demonstrating mammosphere formation for SCAF, PT, and LUNG cell lines.
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Figure 5.3: SCAF cell line is more migratory and invasive than PT cell line
and similar to metastatic cell lines. SCAF and PT cells were an-
alyzed in parallel for migration and invasion ability to close a scratch
in 12h. SCAF cells close a scratch faster than PT and LUNG cells with
representative images (scale bar 100 m) (A) and as quantified by the num-
ber of scratched with no closure, partial closure, or complete closure (B)
(*p<0.05 relative to PT and LUNG via two tailed t-test, n=12 distinct
samples per condition). SCAF cells were found to be more invasive as
determined by transwell invasion assay than PT and LUNG cells with
representative images (scale bar 400 μm) (C) and quantified as the num-
ber of invading cells in each 5x field of view (n=6 distinct samples per
condition) (D).
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PT generated 4.3 +/- 1.5 spheres/well of a 24 well culture dish, which was comparable
to the LUNG, which was 3.9 +/- 1.9 spheres/well (Figure 5.4D). SCAF had signif-
icantly increased mammosphere formation capability with 9.4 +/- 3.1 spheres/well
(p<0.05 relative to PT, and LUNG). Additionally, mammospheres in the SCAF line
were much larger than PT or LUNG, however we cannot rule out that this was a
result of aggregation of individual spheres thus only sphere number was quantified.
Collectively, these results demonstrate that the scaffold sequesters a population of
cells that have increased capacity for migration and invasion, and increased propor-
tion of cancer stem cells, both of which could contribute to the survival advantage
provided by the scaffold.
5.5.4 Scaffold-captured cell transcriptome is more similar to Lung derived
than PT derived cells
We next utilized RNAseq to characterize transcriptomic differences between the
cell lines that might account for their phenotypic properties. We identified 14,232
genes with measured expression, 2901 of which were differentially expressed (Benjamini-
Hochberg corrected p<0.05 and log fold change >0.6) between SCAF and PT cells
and 14,572 genes with measured expression, 2,398 genes of which were differentially
expressed between SCAF and LUNG cells. A small subset of the most differen-
tially expressed genes (Supplemental, Figure 5.9A) was confirmed using qRT-
PCR (Supplemental, Figure 5.9B). Of this set of genes, the vast majority (19/20)
were found to be more similarly expressed between SCAF and LUNG compared to
SCAF and PT. The PAM50 gene set [173] was interrogated, and the majority of
genes (35/50) were more similarly expressed in SCAF and LUNG when compared to
SCAF and PT. These genes included Myc, MDM2, ESR1, ERBB2, EGFR, CCNB1,
CXCR1, IL8, IL6R, IL6ST. Using unsupervised hierarchical clustering with all sam-
ples and genes, SCAF cells clustered separately from all PT samples and all but one
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Figure 5.4: Scaffold-captured tumor cell line shows higher proportion of
cancer stem cell like cells. (A) Representative flow plots for SCAF,
PT, and LUNG cell lines. (B) Percentage of EpCAM+CD44+CD24- can-
cer stem cells (n=3 distinct samples per condition). (C) Representative
images of mammospheres from SCAF, PT, and LUNG cell lines. (D)
Number of mammospheres per well for each cell line. (n=12 distinct
samples per condition). Error bars represent s.e.m. *p<0.01 relative to
PT, and LUNG lines via two tailed t-test.
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LUNG sample (Figure 5.5A). Using gene set enrichment analysis (GSEA), TNFα
via NFκB signaling and epithelial-to-mesenchymal transition (EMT) were positively
enriched and glycolysis was depleted in SCAF (false discovery rate q-value <0.25 and
p<0.05) relative to PT (Figure 5.5B). EMT was also enriched in SCAF relative
to LUNG (Figure 5.5C) along with E2F Targets, Myc Targets, and G2M Check-
point. Similarly, Estrogen Response and Myogenesis were depleted in SCAF relative
to both PT and LUNG and Peroxisome and IL-6, JAK/STAT3 signaling were de-
pleted in SCAF relative to LUNG (Figure 5.5C). No pathways were enriched in
PT relative to LUNG by GSEA, however TNFα via NFκB signaling was enriched
in LUNG relative to PT (NES 1.969 with FDR q-value <0.001). Collectively, this
analysis of gene expression indicates that the SCAF phenotype aligns more closely to
LUNG than to PT.
5.5.5 Scaffold-captured cells have a distinct chromatin structure resulting
in functional changes consistent with enhanced aggressiveness and
metastatic ability
We subsequently compared SCAF and PT cell lines by Hi-C [174] to investigate
chromatin structure and genome organization differences that may give rise to differ-
ential gene expression and resultant functional behavior including metastatic pheno-
type. Hi-C data was collected from SCAF and PT lines and analyzed in conjunction
with RNAseq results at three scales: 1 Mb, 100 kb, and gene/pathway level binning
(Supplemental, Figure 5.10). Overall, the Hi-C matrices appear similar with the
same translocations and copy number changes visible within the Toeplitz normalized
matrices at 1 Mb binning (Figure 5.6A). With filtering to the 95th percentile of
each matrix, translocations are visible as blocks of strong trans interchromosomal
interactions and unbalanced and balanced translocations have an L or X appearance
respectively and were found to be matched between SCAF and PT (Supplemental,
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Figure 5.5: Scaffold-captured tumor cell line shows distinct transcriptome
from PT and similar to LUNG by RNAseq demonstrating 2901
differentially expressed (DE) genes relative to PT (of 14232 with measured
expression) and 2398 DE genes relative to LUNG (of 14572 with measured
expression). (A) Heat map with unsupervised hierarchical clustering of
all genes with measured expression for SCAF (S1-S6, n=6), PT (P1-P3,
n=3), and LUNG (L1-L3, n=3) demonstrating SCAF cells have a distinct
transcriptome relative to LUNG and PT but cluster more closely with
LUNG than PT. (B) Gene set enrichment analysis (GSEA) enrichment
plots for pathways altered in SCAF transcriptome relative to PT (C)
Gene set enrichment analysis for Hallmark pathways positively enriched
in SCAF vs PT and SCAF vs LUNG (red) and negatively enriched in
SCAF vs PT and SCAF vs LUNG (blue) (false discovery rate q-value
<0.25 and p-value <0.05)
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Figure 5.11A). Copy number changes can also be visualized by looking at the sum
of Hi-C contacts at 100 Mb binning for each chromosome and these were also found
to be concordant between SCAF and PT (Supplemental, Figure 5.11B). Addi-
tionally, the copy number normalization method published by Seaman et al.[175] was
utilized to investigate differential breakpoints. No differential breakpoints were found
between SCAF and PT samples. Normalized 1 Mb Hi-C contact matrices were first
investigated for large-scale structural differences by summing the counts for each 1
Mb bin in one dimension. Bins with a value more than 4 standard deviations above
the mean were identified as altered in structure and starred in red (Figure 5.6B)
with all having higher contact density in SCAF compared to PT. These altered bins
were then investigated for changes in gene expression (Figure 5.6C), which showed
that the increased genomic interaction measured by Hi-C was accompanied by an
increase in expression in SCAF relative to PT for the majority of bins. For bins
with altered gene expression the average number of genes per bin that were differ-
entially expressed with a log2 fold change >0.6 was significantly increased relative
to randomly selected bins of the same number of genes (p<0.05). Next, eigenvalue
decomposition (Figure 5.6D) and calculation of entropy difference between sam-
ples was performed on 100 kb binned matrices for each chromosome (Figure 5.6E)
demonstrating enhanced entropy in SCAF relative to PT for the majority of chromo-
somes. Additionally, the Fiedler vector (the eigenvector associated with the second
smallest eigenvalue of the Laplacian matrix [176]) was calculated for each 100 kb
binned matrix for each chromosome and plotted with the Hi-C contact matrix and
RNAseq at the same binning. Structural differences from PT to SCAF were found in
the Fiedler vector for chromosomes 11 (Figure 5.7A), 18 and 21 (not shown).
Next, Hi-C contact matrices were generated at the gene level for the whole genome
(Figure 5.7B, top) and individual chromosomes 18 and 21 identified as altered in
structure at 1 Mb and 100 kb (Figure 5.7B). Finally, changes in centrality were
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Figure 5.6: SCAF tumor cells show distinct genome structure identified by
Hi-C. (A) Hi-C contact matrices for SCAF and PT cells at 1 Mb binning.
(B) Contact density difference (SCAF-PT) for each 1 Mb bin calculated
by summing the counts for each bin in one dimension. Bins with a value
more than 4 standard deviations above the mean were identified as altered
in structure and starred in red. (C) Log2 fold change in gene expression
for SCAF/PT plotted for each of the altered bins identified in B. For
identified bins with higher counts for SCAF, most have a corresponding
higher gene expression. (D) Eigenvalue decomposition of 100 kb Hi-C
matrices for each chromosome showing subtle differences in the eigenval-
ues for both samples. (E) Entropy difference for SCAF - PT calculated
for each chromosome at 100 kb resolution.
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calculated for each gene (Hi-C) and combined with gene expression (RNAseq) in
principal component analysis (PCA) to reduce the dimension of the data while main-
taining meaningful variability. Projections of each bin onto the first two PCs are
shown (Figure 5.7C). To quantify which genes have the greatest change, the distance
in the PC space from PT to SCAF samples was calculated. Genes whose distance
from PT to SCAF changed more than 4 standard deviations from the mean whole
genome distance were identified as altered in structure/function. KEGG pathways
were then selected based on RNAseq (Figure 5.5C) to investigate enrichment of
structure/function changes within subsets of genes (Table S3). By centrality analy-
sis the KEGG MAPK, ErbB, HIF-1α, FoxO, mTOR, PI3-Akt, AMPK, VEGF, Focal
Adhesion, TNFα, Leukocyte Transendothelial Migration, Cancer, and Breast Can-
cer pathways were significantly altered from PT to SCAF (p<0.05) (Figure 5.7C).
Similarly, distances greater than 4 standard deviations above the mean could be ob-
served for specific genes within pathways including COL6A1, FN1, and CTNNB1 for
the Focal Adhesion pathway (Figure 5.7C). Finally, based on GSEA implicating
NFκB as a key regulatory pathway, genes with NFκB binding sites were investigated
for changes in structure/function. By centrality analysis, genes with NFκB binding
sites were significantly altered in structure and function. Altered genes more than 4
standard deviations above the mean were identified including HSP90AB1, COL7A1,
EIF5A, and BRD2 among others (Figure 5.7C). Taken together, these results indi-
cate we can identify genome structure organizational differences that are associated
with development of a metastatic phenotype.
5.6 Discussion
In this study metastatic tumor cells derived from those captured by microporous
PCL scaffolds in vivo were investigated for their phenotype relative to tumor cells
from the primary tumor, and metastatic lung lesions. This work was motivated by
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Figure 5.7: SCAF cells demonstrate differential structure and function re-
lationships from PT cells. Structure (Hi-C matrix and corresponding
Fielder Vector) and function (RNAseq) investigated at the 100kB level
for Chromosome 11 (A). Structure relationships for the whole genome
(top) for SCAF and PT and differences in gene level contacts for chro-
mosome 18 and 21 visualized as the SCAF matrix PT matrix (bottom)
(B). Gene level centrality analysis for the whole genome comparing struc-
ture/function for SCAF and PT pairs for each gene connected by dashed
black line (C). KEGG pathways investigated for difference in centrality
distance from SCAF to PT for genes in a given pathway, red stars indi-
cate pathways that are significantly different from the mean genome-wide
centrality distance by two tailed t-test. Centrality distance for SCAF PT
calculated for KEGG Focal Adhesion Pathway and for genes with NFκB
binding sites. Red stars indicate genes that are more than four standard
deviations above the genome-wide mean centrality distance.
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the idea that scaffold-captured cells may be more easily sampled, while accessing
organ-derived metastatic cells would necessitate an invasive biopsy with potential for
high morbidity and false negative results dependent upon the extent of disease pro-
gression. Our work and that of others have demonstrated that scaffolds recapitulate
multiple elements of the pre-metastatic niche in vivo along with the capacity to cap-
ture metastatic cells within a biomaterial implant [151]. Analyzing these cells along
the continuum of cancer cell phenotypes provides a foundation for using a scaffold
biopsy to impact patient care, such as for the development of personalized therapies
[177]. We developed stable cell lines from metastatic locations in order to have suf-
ficient numbers of cells for in depth in vitro behavioral, functional, and molecular
assays and in vivo metastasis assays. Notably, the scaffold-derived tumor cells were
highly metastatic in vivo, demonstrated substantial invasiveness in vitro, and molec-
ular analysis indicated these cells were similar to cells derived from metastatic lung
lesions.
SCAF and LUNG were more highly metastatic than PT in vivo, supporting the
notion that cells captured by the scaffold represent a population with the ability to
successfully metastasize and colonize a tissue. Interestingly, the SCAF line showed
comparable ability to metastasize to both scaffold and lung tissues, which differs from
literature that has reported cell proclivity to metastasize to the location of origin
[64, 178, 179]. The concordant metastatic tropism to lung for both SCAF and LUNG
suggests that the metastatic traits of SCAF are not site specific yet are indicative of
overarching traits required for metastasis. Consistent with increased aggressiveness
in vivo, scaffold-captured cells were more migratory, invasive, and stem-like in vitro
than cells from the primary tumor. These results provide the first evidence that tumor
cells derived from biomaterial scaffolds are a functionally aggressive and metastatic
population of cells, with the capacity to spread to distal sites and compromise organ
function.
105
Unsupervised hierarchical clustering of RNAseq data identified that SCAF clus-
tered more closely with LUNG than with PT. Additionally, upon investigation of the
top differentially expressed genes between SCAF and PT, 19/20 of these genes showed
greater homology between SCAF and LUNG when compared with SCAF and PT.
Similarly, for the PAM50 gene set 35/50 genes had more similar expression between
SCAF and LUNG than for SCAF and PT. Collectively, these results indicate that
scaffold and lung-derived cells, both originating from metastatic sites, show greater
homology compared to scaffold-captured cells and those derived from the primary
tumor.
Further investigation of the tumor cell phenotypes by GSEA identified pathways
significantly enriched/depleted in SCAF cells relative to PT and LUNG. Hallmark
pathways [180] enriched in SCAF relative to PT included TNFα signaling via NFκB,
Epithelial to Mesenchymal Transition (EMT), Angiogenesis, and Complement. TNFα
signaling through NFκB has been shown to enhance stemness of breast cancer cells
[134], angiogenesis and complement are indicators of metastasis and survival in pa-
tients [181, 182], and EMT is closely linked to metastasis and stemness [183, 184].
Interestingly, EMT is enriched in SCAF relative to both PT and LUNG. This ob-
servation, in combination with the ideas that (i) the earliest metastatic tumor cells
colonized the scaffold prior to the lung [31], (ii) SCAF are more homogeneous than
LUNG, as demonstrated by hierarchical clustering, (iii) IL-6 JAK/Stat3 signaling was
enriched in LUNG relative to SCAF which may enhance metastasis in vivo through
paracrine communication with myeloid derived suppressor cells but may not influence
phenotype in vitro [185] and (iv) SCAF cells are more stem-like and demonstrate
higher entropy/plasticity may explain why the SCAF line was more migratory and
invasive than the LUNG line in vitro. Hallmark pathways enriched in SCAF relative
to LUNG also included E2F targets [186], Myc targets [187], and G2M checkpoint
[187]: all important axes in breast cancer. Peroxisome and IL-6 JAK/Stat3 signaling
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were enriched in LUNG relative to SCAF and have been implicated in therapeutic
resistance [188] and stemness [185]. Importantly, TNFα signaling through NFκB was
enriched in both SCAF and LUNG relative to PT, indicating this may be the cru-
cial pathway for gaining enhanced metastatic ability for these cells. These results
suggest that LUNG and SCAF may evolve toward similar phenotypes through the
same dominant transcriptional program (TNFα via NFκB) but with different acces-
sory programs facilitating site-specific adaptations (i.e. SCAF with EMT and LUNG
with IL-6 JAK/Stat3 signaling) [185], which is consistent with other observations of
metastatic lines [85]. This supports the use of scaffold as a sampling location and also
suggests that both metastatic locations are derived from a similar pool of cells yet
may experience differential evolutionary pressure and adaptation at different distal
sites. The scaffold has the capacity to provide a sampling site that would be clinically
easy to access relative to an organ biopsy and contains a source of cells with clear
phenotypic and molecular similarities to the pathologic metastatic site.
The underlying genome/chromatin organization role in the development of metastatic
phenotype from PT to SCAF was identified with Hi-C. Using a multi-scale approach,
we found structural changes linked to functional outcomes at all points. Critically,
for all except chromosome 4, entropy for SCAF was higher than PT, indicating a
more dysregulated network consistent with the concept of increased aggressiveness
and phenotypic flexibility that are hallmarks of stemness and metastasis [189–191].
We chose to analyze SCAF as a surrogate for other metastatic sites due to the in
vivo and transcriptomic similarity of these cells to the LUNG. Importantly, no copy
number changes or additional translocations were observed, indicating the karyotype
from PT to SCAF was conserved. Even at 1 Mb binning analysis of whole genome
contact density we found structural differences between SCAF and PT indicating
areas of chromosomes 11, 18, and 21 with a higher density of intrachromosomal
contacts for SCAF. Interestingly, there were no locations identified where PT had
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higher contact density. Investigating these altered bins further, we found the vast
majority had higher expression in SCAF indicating increased connectivity resulted in
enhanced gene expression. Similarly, we observed subtle changes in both eigenvalue
decomposition and Von Neumann entropy for each chromosome. At 100 kb we found
chromosomes 11, 18 and 21 identified by contact density at 1 Mb to have differ-
ences in Fiedler vector consistent with a change in structure from SCAF to PT. We
also investigated the centrality of each chromosome at the gene level (structure) and
gene expression (function) for the whole genome and identified significantly altered
pathways in structure/function. Implicated genes in these pathways include many
genes associated with metastasis and stemness including COL6A1, FN1, ITGA3,
IL11, IL6ST, IL8, and TGFβR2. In particular, IL8 has been implicated in enhanced
stemness, aggressiveness [192, 193], and resistance to therapy [194]. Finally, based on
GSEA of RNAseq data implicating TNFα via NFκB signaling as the common tran-
scriptional program associated with metastatic phenotype in both SCAF and LUNG
cells, we investigated structure/ function relationships for genes with NFκB binding
sites. We found this gene set to be significantly altered from PT to SCAF in struc-
ture/function. This further supports NFκB as one of the major drivers of phenotypic
change from non-metastatic to metastatic phenotype [195–197]. Our data are among
the first to connect genome/chromatin structure alterations to changes in functional
gene expression driving metastatic phenotype.
5.7 Outlook
Our results provide primary evidence that biomaterial scaffold-captured tumor
cells are a functionally aggressive and metastatic population capable of distal organ
colonization. Taken together, this work demonstrates scaffold recruited tumor cells
are similar to other metastatic sites, but also represent a population of highly ag-
gressive, stem-like cells whose capture may hold promise for reducing breast cancer
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mortality. Additionally, these results support the possibility that metastatic pheno-
type can be gained through changes in genome structure impacting functional gene
expression rather than mutational alterations. Heritable alterations in tumor cell
phenotype and plasticity thus may be equally as important as mutational changes
for development of metastatic ability. The scaffold platform technology provides a
unique opportunity to analyze the earliest metastatic cells, enabling the analysis of
tumor cells that have left the primary tumor and colonized a distal site. This plat-
form provides an unprecedented opportunity for analysis and development of tools
for personalized medicine.
5.8 Methods
5.8.1 Scaffold fabrication and implantation
Microsphere preparation. PCL microspheres were prepared by emulsification of
a 6% (w/w) solution of PCL (Lactel Absorbable Polymers; Inherent viscosity 0.65-
0.85 dL/g) in dichloromethane in a 10% (w/v) poly(vinyl alcohol) solution followed
by homogenization at 10,000 rpm for 1 minute. The solution was then stirred for
3 hours to evaporate dichloromethane solvent. Microspheres were then collected by
centrifugation at 2000 x g for 10 minutes and washed at least five times in deionized
water. Finally, microspheres were lyophilized for 48 hours.
Scaffold fabrication. Microporous PCL scaffolds were prepared by mixing PCL
microspheres and sodium chloride crystals (250-425 μm in diameter) at a 1:30 (w/w)
ratio. This salt and polymer microsphere mixture was then pressed in a steel die for
45 seconds at 1500 PSI. Polymer/salt disks were then heated at 60C for 5 minutes
per side to melt polymer microparticles around salt crystals to form a continuous
structure. Salt crystals were subsequently removed by immersion in water for 1.5
hours. Scaffolds were then disinfected for animal studies using 70% ethanol, rinsed
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with sterile water, and dried on a sterile surface.
Scaffold Implantation. All animal studies were performed in accordance with
institutional guidelines and protocols (PRO00007801) approved by the University of
Michigan Institutional Animal Care and Use Committee. Scaffolds were implanted
into the dorsal subcutaneous space of 8-week-old female NOD/SCID-IL2Rγ-/- (NSG)
mice (Jackson Laboratory) immediately above the shoulder blades and as physically
distant from the fourth-right mammary fat pad as possible. For the implantation
procedure, animals were anesthetized via isoflurane (2%, inhaled), prepared with
Carprofen analgesia (5 mg/kg, subcutaneous injection), the upper back was shaved
and prepped using a Betadine swab followed by an ethanol swab and this procedure
was repeated 3 times. A fenestrated sterile field was draped over the surgical area and
a 1 cm incision was made in the upper back. Following incision, subcutaneous pockets
were created perpendicular to the incision, into which sanitized scaffolds were inserted
(2 scaffolds/mouse). The skin was then closed using sterile wound clips (Reflex 7 mm,
Roboz Surgical Instrument Co).
5.8.2 Tumor inoculation
Tumor inoculations were performed by injection of 2e6 MDA-MB-231BR-tdTomato-
luc2 (parental line, Northwestern University Developmental Therapeutics Core) or
231BR-SCAF,-PT, or -LUNG derived cell lines in 50 μL PBS (Life Technologies)
into the fourth right mammary fat pads of 10-week-old female NSG mice (Jackson
Laboratory). Cell lines were confirmed to be pathogen- and mycoplasma-free and au-
thenticated by short tandem repeat DNA analysis and compared to the ATCC STR
profile database (DDC Medical).
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5.8.3 Magnetic Mouse Cell Depletion and Culture
Mice were euthanized four weeks following tumor inoculation and scaffolds and
organs were retrieved and washed in Hanks Balanced Salt Solution (HBSS, Life Tech-
nologies). Samples were minced using microscissors in Liberase TL or TM (0.38
mg/mL, Roche) and incubated at 37C for 20 minutes. Following incubation with
liberase, the enzyme was neutralized via addition of 0.5M EDTA (Life Technologies)
and digested tissues were strained through a 70 μm filter in FACS buffer [PBS (Life
Technologies) with 0.5% Bovine Serum Albumin (Sigma Aldrich) and 2 mM EDTA
(Life Technologies)]. Cells were counted using a Countess Automated Cell Counter
(Invitrogen) and magnetically sorted using a Mouse Cell Depletion Kit (Miltenyi) ac-
cording to manufacturer instructions. Human cell fractions were cultured in DMEM
D6429 (Sigma Aldrich) with 10% FBS and 1% penicillin/streptomycin until growth
of tumor cell colonies was evident. Following the first passage of cells, culture was
continued without antibiotics. Care was taken to minimize passage number of tumor
cells, for all experiments the passage number was less than ten.
5.8.4 Flow cytometry to identify tdTomato+ tumor cells
For quantification of in vivo metastatic ability of 231BR-SCAF, -PT, and LUNG
derived cell lines, mice were euthanized three weeks after tumor inoculation and re-
trieved scaffolds and lungs were washed in HBSS (Life Technologies) and processed
with liberase as described for Magnetic Mouse Cell Depletion above. Following isola-
tion of a single cell suspension, tdTomato+ tumor cells were quantified using a MoFlo
Astrios Flow Cytometer (Beckman Coulter). The detection sensitivity for cancer cells
via flow cytometry was 0.002% (i.e. 5 cancer cells in 250,000 total cells) [31]. Gat-




Scratch assays were performed as described by Justus et al [198]. Briefly, cells
were seeded in 24 well plates and allowed to grow to form a confluent monolayer. A
sterile 200 μL pipette tip was used to create a wound in the monolayer. The surface
was washed with PBS (Life Technologies) to remove any detached cells and replaced
with media. Images were taken immediately after wounding, 5h and 10-12h after
wounding. Results were quantified by identification of the proportion of scratches
that had no closure at endpoint (no cells touching from either side of wound), partial
closure (at least 2 cells from either side of wound in direct contact), or complete
closure (no evidence of wound remains). Assays were repeated 3 times.
5.8.6 Transwell invasion assays
Transwell assays were performed as described by Justus et al. [198]. Briefly, Ma-
trigel invasion chambers (BD Biosciences) were rehydrated for 30 min at 37C using
500 μL serum-free media. 750 μL of chemoattractant media (serum-containing) was
placed in the receiver well plate. Cells were harvested using TryplE (Life Technolo-
gies), counted and suspended at 50,000 cells/mL in serum-free media. Rehydrated
invasion chambers were transferred to receiver well plate containing chemoattractant
and 500 μL of cell suspension was added to each insert. Care was taken to prevent
trapped air between the insert and chemoattractant media. Assays were incubated
for 24h at 37C and subsequently stained and fixed using crystal violet in ethanol.
Invaded cells were imaged directly on the membrane using a Nikon Eclipse inverted
microscope and imaged at 10X. Four images per well were captured and cell num-
bers were quantified in ImageJ using automatic particle counting with constant image
thresholds. Assays were repeated three times.
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5.8.7 Cancer stem cell marker flow cytometry and mammosphere assay
Proportion of cancer stem cell like tumor cells in each cell line was determined
by quantification of EpCAM+CD44+CD24- cell population by flow cytometry. Tu-
mor cells were harvested using TryplE (Life Technologies), counted and suspended at
1e7 cells/mL. Cells were evenly split between control and test conditions and stained
with anti-human BV421 EpCAM (clone EBA-1, BD Biosciences), PerCP-Cy5.5 CD44
(clone G44-26, BD Biosciences), and PE/Cy7 CD24 (clone ML5, Biolegend). Samples
were run on MoFlo Astrios Flow Cytometer (Beckman Coulter) and data processed
using FlowJo (TreeStar Inc.). Gating strategy is provided in Supplemental, Figure
5.12B. Cancer stem cell marker flow cytometry was repeated three times. Mammo-
sphere assays were performed as described by Tarasewicz et al. [199]
5.8.8 RNAseq sample preparation, library construction, and sequencing
Cells were harvested using TryplE (Life Technologies), counted and suspended
at 5e6 cells/mL. RNA was isolated using High Pure RNA Isolation Kit (Roche)
according to manufacturer instructions. Isolated RNA concentrations were quantified
using NanoDrop 2000 (Thermo Fisher) and resuspended at 80 ng/μL. RNA samples
were kept at -80C until further use. RNA quality was assessed using an Agilent 2100
Bioanalyzer. The DNA Sequencing Core at University of Michigan performed library
construction and sequencing using the Hiseq-4000 platform using single-end 50-base
sequence reads with a multiplex of 6 per sequencing lane.
5.8.9 Transcriptome analysis
Transcriptome analysis was performed as previously described [175]. For RNAseq
data processing the raw reads were checked with FastQC to identify potential qual-
ity issues in the raw data. Next, Tophat and Bowtie were used to align the reads
to a human reference transcriptome (HG19). Alignment settings were kept on de-
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fault except for -b2-very-sensitive, -no-coverage-search and -no-novel-juncs in order
to limit the search to known transcripts only. FastQC was then performed again on
the mapped reads. Cuﬄinks/Cuffdiff were then utilized to quantify expression and
perform differential expression analysis using parameter settings multi-read-correct
and upper-quartile-norm. CummeRbund was then used to format the cuﬄinks out-
put. Benjamini-Hochberg procedure was used in CummeRbund for multiple testing
method correction. Gene level analysis was performed using fragments per kilobase
per million reads (FPKM) values outputted by Cuﬄinks and log2 fold change with
pseudocounts. Bin level gene expression vectors were calculated using raw counts
outputted by cuﬄinks and adding up the counts for all the genes in each bin then
normalizing by million reads to convert them to FPM. Gene Set Enrichment analysis
[200, 201]was performed with GSEA v3.0 software.
5.8.10 Hi-C sample preparation, library construction, and sequencing
Hi-C library construction was performed as described by Chen et al [202]. Briefly
2e6 cells for each condition were crosslinked with 1% formaldehyde (Fisher Scientific)
in serum-free media for 10 min at room temperature and subsequently quenched with
glycine (Sigma Aldrich) to a final concentration of 0.125 M. Crosslinked cells were
flash frozen in liquid nitrogen and stored at -80C until the construction of libararies.
Crosslinked cells were thawed on ice and resuspended in 1 mL lysis buffer (10 mM
Tris-HCl, 10 mM NaCL, 0.2% Igpel (Signma Aldrich) and incubated for 15 min. Cells
were next homogenized on ice and the lysate was transferred to a 1.7 mL tube. Cells
were collected by centrifugation (5 min at 2000xg) and washed twice in NEB buffer.
HindIII digestion was then performed in NEB buffer at 37C overnight. Following
digestion, restriction overhang ends were filled and labeled with biotin. Samples were
then ligated at 16C for 4 h in a reaction containing 1x ligation buffer, 1% Triton
X-100 (Sigma Aldrich), 1 mg/mL bovine serum albumin (Fisher Scientific), 10 mM
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ATP (Sigma Aldrich) and 50 u T4 DNA ligase (Life Technologies). Proteinase K (0.5
mg, Life Technologies) was then added and incubated for 4 h at 65C. After this incu-
bation an additional 0.5 mg proteinase K was added to each tube and the incubation
was continued overnight at 65C. DNA was then extracted using phenol:chloroform
(1:1) and desalted using AMICON ultra centrifugal filter unit (Millipore) with 1x
TE buffer. Biotin was then removed from un-ligated ends, DNA purified with signle
phenol extraction and precipitated by addition of ethanol. DNA was resuspended in
water and fragmentation was performed using a sonicator (Covaris). Fragments of
200-400 bp were recovered with Agencourt AMPure XP (Beckman Coulter) utiliz-
ing manufacturer protocols. DNA fragment ends were repaired and purified with a
MinElute column, and A-tailing was performed. Streptavidin pull-down of biotiny-
lated Hi-C DNA was performed. Illumina adapter ligation was then performed and
then DNA was amplified by 15 PCR cycles for Illumina HiSeq Sequencing. A standard
quality control protocol was performed prior to sequencing and all libraries passed.
Samples were pooled and sequence in a single lane of a flow cell on HiSeq 4000 to
generate paired-end sequence reads at 100 bases per end read.
5.8.11 Nucleome analysis
Generation of Hi-C Matrices: A standard pipeline was used to process Hi-C se-
quence data using the University of Michigan Bioinformatics Core facilities. Raw
sequence reads were processed with FastQC for data quality control and paired-end
reads were mapped to the HG19 reference human genome using Bowtie2. HOMER
was used to develop the contact matrix at 100 kb and 1 Mb resolution. Analysis of
Hi-C Matrices: Hi-C matrices were normalized, plotted, and analyzed in conjunction
with RNAseq data for cell lines using the 4D Nucleome Analysis Toolbox (4D-NAT)
described by Seaman et al [175].
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5.8.12 Whole Exome Sequencing
Sequencing : SCAF, PT, and LUNG cell lines were cultured and passaged as
described above. Roughly 2e6 cells were isolated and genomic DNA was isolated with
Qiagen DNEasy kit according to manufacturer instructions. Samples were submitted
to the UMich DNA sequencing core and the core performed quality control, exome
capture using the Nimblegen Human Exome Capture kit, and paired-end sequencing
at 150 bases per end read using the Illumina HiSeq-4000 platform with 100x coverage
for each cell line.
Analysis : Genestack platform was used for analysis of whole exome sequencing
data. Quality control was performed using FastQC algorithm Adaptors and contami-
nants were trimmed according to methods published by Aronesty et al [203] and then
sequences were mapped onto the human reference genome HG19. Quality control of
the mapped reads was again performed using the FastQC algorithm. Variant calling
and effect prediction was then performed using SAMtools and SnpEff algorithms re-
spectively and variants were selected to only include those resulting in missense or
nonsense mutations with a quality >60. Gene ontology analysis of mutant genes was
then performed using the Gene Ontology Consortium software (Consortium 2004).
5.9 Supplementary Figures
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Figure 5.8: Whole exome sequencing demonstrates similar numbers of mu-
tations for all samples. Venn diagram showing intragenic missense or
nonsense mutations relative to human hg19 (GRCh37) reference genome
with quality greater than 60 for each line and those that are shared among
cell lines.
Figure 5.9: RNAseq supplemental information. (A) Heat map of top differen-
tially expressed genes between SCAF, PT, and LUNG cells, TPM nor-
malized to SCAF across two RNAseq experiments. (B) Gene expression
of selected genes by qRT-PCR, delta-delta-cT relative to PT. Heatmaps
normalized across row for each gene for each data set.
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Table 5.1: Intragenic missense or nonsense mutations with quality greater
than 60 for each cell line (SCAF, PT, LUNG) and those shared between















































Table 5.2: Gene Ontology Terms Significantly Altered in Genes with Muta-
tions in SCAF, PT and LUNG cell lines
Figure 5.10: Schematic of Hi-C and RNAseq data analysis scales
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Figure 5.11: Hi-C does not reveal additional copy number variations,
translocations, or breakpoint mutations between SCAF and
PT cell line. (A) Hi-C contact matrix at 1 Mb binning with filtering
to 95th percentile to show translocations with a butterfly appearance
marked with arrows in both SCAF and PT and the overlay. (B) Sum
of Hi-C counts for each cell line (SCAF in red, PT in blue) for each
chromosome 1-22 demonstrating concordance of translocations and copy
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Table 5.3: KEGG Pathways Investigated for Structure/Function Relation-
ships
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Figure 5.12: Gating strategies for flow cytometric experiments. (A) Gating
strategy for analysis of tumor cells in tissues for in vivo metastasis as-
say showing identification of cells, singlets gated by side scatter, singlets
gated by forward scatter, PE+ (tdTomato+) single positive cells, and
finally PE+APC- (tdTomato+ events that are not autofluorescent in the
dump channel APC). (B) Gating strategy for analysis of cancer stem cell
surface markers showing identification of cells, singlets gated by side scat-
ter, singlets gated by forward scatter, EpCAM+ cells gated as BV421+,
and CD44+CD24- cells gated as PerCP-Cy5.5+PECy7-. All gates were
set according to appropriate positive and negative controls and antibod-
ies were tittered to develop assays. Each arrow indicates a nested gate
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6.2 Abstract
The formation of distant metastasis represents the shift from a curable disease to
non-curable for most patients. Currently, no clinical method is available to identify
metastasis before it has affected the function of a vital organ. We have developed
a biomaterial implant that recruits immune cells associated with the pre-metastatic
niche and metastasis and thus recruits tumor cells in vivo. This platform has demon-
strated promise in orthotopic mouse models of breast cancer, yet to this point has not
been tested in spontaneous models of tumorigenesis and metastasis which are more
representative of the progression of human disease. Here we show scaffolds recruit
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tumor cells in the PyMT model of spontaneous breast cancer and the KPCY model
of spontaneous pancreatic cancer. In addition to the recruitment of tumor cells, scaf-
fold implantation also facilitated a two order of magnitude improvement in sensitivity
of detection relative to blood in the KPCY model and also reduced metastatic tu-
mor burden in the liver. Scaffolds also demonstrated tumor-progression dependent
immunomodulation in both models, with the changes in immune cell populations di-
verging from breast cancer to pancreatic cancer. Finally, the scaffold platform also
identified differential changes in immune cell crucial to recruitment of metastatic tu-
mor cells in both models including total immune cells in PyMT and dendritic cells
and macrophages in KPCY models. Collectively, our findings demonstrate the util-
ity of scaffolds for the recruitment of tumor cells and reflection of tumor-dependent
immunomodulation in spontaneous models of tumorigenesis and metastasis.
6.3 Introduction
Metastasis is responsible for 90% of cancer-related deaths [149]. The spread of
tumor cells from the location of origin to secondary sites is deadly for two reasons.
First, metastasis is often not detected until the function of an organ has been com-
promised. Second, when chemotherapeutic agents are deployed at this high state of
tumor burden, resistance to these therapies often develops. Methods for the early
detection of metastasis are a crucial need in order to intervene earlier at a time when
tumor burden is low and provide a better opportunity for eradication of the disease.
An emerging technology for early detection of metastasis is biomaterial scaffolds
that recruit metastatic tumor cells in vivo. Degradable microporous materials in-
cluding poly(lactide-co-glycolide) and poly(ε-caprolactone) have been employed to
recruit immune cells associated with the pre-metastatic niche and metastasis which
in turn recruit tumor cells in orthotopic syngeneic mouse [30] and xenogeneic hu-
man [31] models of breast cancer. Similar materials have also been employed for the
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recruitment of leukemic [36], prostate [27], ovarian [29], and melanoma [26] models
of cancer. The utility of simple biomaterials to recruit tumor cells in a diverse ar-
ray of orthotopic and subcutaneous models of metastasis indicates there are common
features of the foreign body response to an implanted material and various material
modifications that may be performed to enhance metastasis to an ectopic implanted
site. However, to date the ability of biomaterial scaffolds to recruit tumor cells has
not been investigated in any spontaneous models of tumorigenesis and metastasis.
Spontaneous models of tumorigenesis recapitulate key features of cancer disease
progression as it occurs in humans far better than orthotopic or subcutaneous models
[204, 205]. For example, in subcutaneous models of metastasis, tumor cells do not
reside in the normal microenvironment of the organ of origin, but instead form a
tumor with the help of Matrigel under the skin. This model does not represent the
selective pressures that exist in the normal tumor microenvironment for a given type
of cancer [206], with the exception of melanoma. In orthotopic models of metasta-
sis, tumor cells are injected into the organ or tissue or origin but already have the
ability to metastasize and thus do not replicate the processes in humans where not
all tumor cells present in the primary tumor are capable of invasion, dissemination,
and metastatic colonization [149, 207]. In spontaneous model of tumorigenesis the
minimum number of genetic insults is provided in a tissue specific manner in order
to cause tumorigenesis in this tissue. This serves in stark contrast to models where
a tumor cell line that has been passaged many times in vitro is injected into a tis-
sue. Tumor cell lines have many more mutations and genetic aberrations relative to
human tumors, are adapted to in vitro culture conditions, and often represent very
late stages of disease [208, 209]. While there are relatively few models of spontaneous
tumorigenesis that also spontaneously metastasize, these provide a better platform
for a more translational model of human tumor development and metastasis.
Though biomaterial scaffolds recruit tumor cells in mouse models of breast cancer
125
[30, 31, 34, 42, 152], to date no studies have investigated tumor cell recruitment to an
engineered site in pancreatic cancer. Pancreatic ductal adenocarcinoma has the worst
prognosis of any cancer with a 5-year survival rate of 3% [210]. Low survival is not
only due to the aggressive nature of the primary tumor and impact on a vital organ,
unlike breast or prostate cancer, but due to the very high likelihood of metastasis in
these patients. Pancreatic cancer is often not diagnosed until metastasis has already
occurred [210]. While there is a critical need to develop technologies to identify
metastasis at its earliest stages for all cancers, it is clear that these technologies
could have substantial impact on the diagnosis and progression of pancreatic cancer.
This platform also allows investigation of the ability of biomaterial scaffolds to recruit
tumor cells in cancers that metastasize to different organs (i.e. breast most commonly
to the lung and pancreatic most commonly to the liver).
In this report we use the spontaneous MMTV-PyMT model of breast cancer and
the spontaneous KPCY model of pancreatic cancer to investigate the ability of bio-
material scaffolds to recruit tumor cells and identify tumor dependent immunomod-
ulation.
6.4 Results
6.4.1 Scaffolds recruit tumor cells in a spontaneous model of breast can-
cer
The ability of scaffolds to recruit tumor cells in a spontaneous model of breast can-
cer was initially assessed by implanting scaffolds subcutaneously into RFP+PyMT+
or RFP+ mice at 6 weeks of age prior to palpable tumor formation. Once tumors
reached endpoint size (approximately 13-14 weeks of age) mice were euthanized and
scaffolds, lungs, and primary tumors were explanted for flow cytometric analysis of
RFP+ tumor cells. In order to account for varied RFP background in different tissues
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present even in the RFP+ tumor-free control mice, each tissue was normalized to the
tumor-free RFP+ control tissue. The highest fold change in RFP+ cells from tumor
free was observed for the primary tumor tissue as expected (6.907 +/- 6.886 fold
change from tumor free). Interestingly, the scaffolds had a higher fold change than
lungs (1.712+/-0.8835 for scaffolds and 1.445+/-0.5179 for lungs), though not statis-
tically significant, indicating similar metastatic tumor burden in scaffolds and lungs
(Figure 6.1A). We next investigated the impact of scaffold implantation on disease
progression relative to a mock surgery. We found scaffold implantation trended to-
ward reduced primary tumor burden (2.304 +/- 1.36 g for scaffold implanted mice and
4.320 +/- 1.501 g for mock surgery mice) though this was not statistically significant
(Figure 6.1B). We also found the same trend in spleen weight with PyMT- tumor
free mice having the lowest spleen weight (145.3 +/- 36.50 mg), PyMT+ tumor bear-
ing mice implanted with scaffolds had a slightly higher spleen weight (188.3 +/- 68.30
mg), and PyMT+ tumor bearing mice receiving a mock surgery having the highest
spleen weight (246.3 +/- 73.55 mg) though these differences were not statistically
significant (Figure 6.1C). Finally, we investigated the impact of scaffold implanta-
tion on metastasis and found similar levels of liver and lung tumor burden for both
scaffold implanted and mock surgery mice (Liver burden 1.138 +/- 0.2269 for scaf-
fold implanted and 1.433 +/- 0.5163 fold change from tumor free for mock surgery
and Lung burden 1.104 +/- 0.2275 for scaffold implanted and 1.215 +/- 0.08842
for mock surgery, Figure 6.1D). Thus we conclude in this model scaffolds recruit
spontaneously metastasizing tumor cells but do not significantly impact primary or
metastatic tumor burden and disease progression.
127
Figure 6.1: Microporous scaffolds recruit tumor cells in the MMTV-PyMT
model of transgenic, spontaneous breast cancer tumorigenesis
and metastasis and do not significantly influence disease pro-
gression or metastasis. (A) Flow cytometry evaluation of fold change
of RFP+ tumor cells in scaffolds, lungs, and primary tumor in PyMT+
mice relative to WT mice. (B) Primary tumor mass for scaffold implanted
mice relative to mice receiving mock surgery. (C) Spleen mass for wild-
type mice implanted with scaffolds, PyMT+ mice implanted with scaf-
folds, and PyMT+ mice receiving mock surgery. (D) Metastatic tumor
burden in the liver and lungs of mice receiving either scaffold implantation
or mock surgery.
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6.4.2 Scaffolds can be used to monitor the dynamic immune system
changes in spontaneous breast cancer development
The dynamic immune response to the scaffold was next evaluated in the context of
disease progression by evaluating the changes in immune cell populations in the lung,
primary tumor, scaffold, and spleen via multicolor flow cytometry for surface markers
associated with immune cells including CD45+ total immune cells, CD11b+Gr1+
neutrophils, CD11c+F4/80- dendritic cells, CD11b+F4/80+ macrophages, Ly6C+
F4/80- monocytes, CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD49b+ natural
killer cells (Figure 6.2). Each tissue is normalized to the RFP+ tumor free control in
order to better view the change associated with tumor development in each tissue. We
found a significant reduction in CD45+ immune cells in the primary tumor (0.138
+/- 0.08269 fold change from tumor free) and a significant increase in the lungs
(2.121 +/- 1.587 fold change from tumor free, Figure 6.2A).We found a significant
increase in CD11b+Gr1+ neutrophils in all tissues evaluated with a fold change of
4.314 +/- 2.915 for lung, 74.71 +/- 68.58 for primary tumor, 1.838 +/- 1.079 for
scaffolds, and 6.463 +/- 5.139 for spleens (Figure 6.2B). CD11c+F4/80- dendritic
cells were found to be significantly elevated in tumor bearing mice primary tumor
(14.49 +/- 12.46 fold change) and scaffolds (1.372 +/- 0.8327 fold change, Figure
6.2C). CD11b+F4/80+ macrophages were found to be significantly increased in the
primary tumor (57.76 +/- 44.74) and significantly decreased in the scaffold relative
to tumor bearing mice (0.7255 +/- 0.2384 fold change, Figure 6.2D). Ly6C+F4/80-
monocytes were found to be significantly altered in all tumor bearing tissues with a
fold change of 1.346 +/- 0.2655 for lung, 0.5971 +/- 0.4341 for primary tumor, 2.032
+/- 0.8675 for scaffold, 1.712 +/- 0.7720 for spleen (Figure 6.2E). CD4+ T cells
were found to be significantly reduced in tumor bearing lung (0.7182 +/- 0.0960 fold
change) and primary tumor (0.4509 +/- 0.4446 fold change, Figure 6.2F). CD8+
T cells were also found to be significantly reduced in the tumor bearing lung (0.9567
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+/- 0.5193 fold change) and primary tumor (0.3129 +/- 0.2804 fold change, Figure
6.2G). CD19+ B cells were significantly reduced in the lung with a fold change of
0.610 +/- 0.2940 relative to tumor free (Figure 6.2H). CD49b+ natural killer cells
were not significantly altered from tumor free due to high variability in this population
of immune cells (Figure 6.2I).
Following the identification of many immune cell populations in the scaffold being
significantly altered with tumor progression (CD11b+Gr1+, CD11c+F480-, CD11b+
F480+, Ly6C+F480-) we next investigated the dynamics of immunomodulation with
tumor progression by implanting multiple scaffolds in tumor free and tumor bear-
ing mice at 5 weeks of age. Each week until the mice reached endpoint tumor size
(11 weeks of age) scaffolds were explanted from the mice and a new set implanted
as a survival surgery. Analysis of scaffolds explanted at each time point allowed
us to track the changes of each cell population over time with disease progression
(Figure 6.3). The majority of populations investigated varied over time but did
not appear to follow a trend with disease progression including CD45+ total immune
cells (Figure 6.3A), CD11b+Ly6C+ monocytes (Figure 6.3C), CD11b+F4/80+
macrophages (Figure 6.3D), CD11c+F4/80- dendritic cells (Figure 6.3E), CD4+
T cells (Figure 6.3F), CD8+ T cells (Figure 6.3G), and CD49b+ natural killer
cells (Figure 6.3I). However, some populations clearly tracked with tumor pro-
gression including CD11b+Gr1+ neutrophils steadily increasing with tumor progres-
sion (Figure 6.3B) and CD19+ B cells decreasing with tumor progression (Figure
6.3H). We also evaluated the presence of tumor cells at each of these time points and
found this population to be relatively stable over time (Figure 6.3J).
Following the determination of immune dynamics at the scaffold longitudinally in
the same cohort of mice, we next sought to understand how these dynamics compare
to the changes in immune cell populations occurring in the spleen, lung, and primary
tumor with disease progression. To this end we isolated tissues at various ages close
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Figure 6.2: Breast tumor-dependent immunomodulation occurs at the scaf-
fold site and is similar to modulation observed in the spleens
of PyMT+ mice. Flow cytometric evaluation of surface markers for
immune cells and reported as fold change in % of each population from
tumor free (WT, PyMT- mice) relative to tumor bearing (PyMT+ mice)
for lung, primary tumor (PT), scaffold, and spleen for (A) CD45+ (B)
CD11b+Gr1+ (C) CD11c+F480- (D) CD11b+F480+ (E) Ly6C+F480-
(F) CD4+ (G) CD8+ (H) CD19+ and (I) CD49b+ immune cells.
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Figure 6.3: Breast tumor-dependent immunomodulation and tumor cell re-
cruitment to the scaffold can be monitored longitudinally in a
single cohort of mice. Flow cytometric evaluation of surface markers
for immune cells and reported as fold change in % of each population
from tumor free (WT, PyMT- mice) relative to tumor bearing (PyMT+
mice) for scaffolds for (A) CD45+ (B) CD11b+Gr1+ (C) CD11c+F480-
(D) CD11b+F480+ (E) Ly6C+F480- (F) CD4+ (G) CD8+ (H) CD19+
and (I) CD49b+ immune cells and (J) PE+FITC- Tumor cells to observe
dynamics of immune cell populations over time with tumor progression.
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to tumor-size endpoint (12-14 weeks of age) and investigated changes in immune cell
populations in each tissue with time (Figure 6.4). Linear regression analysis was
performed on each tissue over time and those with significant linear relationships were
assessed. We found the scaffold demonstrates a significant positive linear relationship
with time for CD45+ (Figure 6.4A) and CD11b+Gr1+ cells (Figure 6.4B) with a
trend similar to that of the lung. Significant negative linear relationships were found
in the scaffold for CD11c+F4/80- dendritic cells (Figure 6.4C) and CD4+ T cells
(Figure 6.4F). The trends observed over time in general agree between the scaffold,
spleen, and lung with the only exception being CD8+ T cells (Figure 6.4G).
6.4.3 Scaffolds enrich tumor cells relative to blood and reduce metastatic
tumor burden in spontaneous pancreatic cancer
The ability of scaffolds to recruit tumor cells in a spontaneous model of pancreatic
cancer was next assessed by implanting scaffolds subcutaneously into KPCY or CY
mice at 8 weeks of age prior to tumor formation. We first assessed a very early
timepoint in tumor progression and isolated scaffolds, blood, liver, and pancreas at
12 weeks of age (Figure 6.5). We first evaluated metastasis to the scaffold implant
by quantifying the number of YFP+ cells in each scaffold. We found 309 +/- 304
YFP+ pancreatic cells per scaffold and found that the number of tumor cells per
scaffold appeared to be associated with the stage of the tumor (Figure 6.5A) with
scaffolds from a mouse with PanIN1 and PanIN2 lesions having an average of 699
YFP+ cells/scaffold relative to mice with ADM and PanIN1 lesions demonstrating
an average of 114 YFP+ cells/scaffold. We next investigated whether the number of
YFP+ cells found in the scaffold could be explained by the concentration of these cells
in the blood and found a two order of magnitude enrichment of YFP+ cells in scaffolds
relative to blood (Figure 6.5B). We next investigated if scaffold implantation relative
to mock surgery altered the progression of disease by quantifying YFP+ cells in the
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Figure 6.4: Breast tumor-dependent immunomodulation demonstrates sim-
ilar dynamics in spleen, scaffold, and lung with tumor pro-
gression. Changes in immune cell populations were evaluated at var-
ious stages in tumor progression within scaffolds spleen, lung, and pri-
mary tumor via flow cytometry for (A) CD45+ (B) CD11b+Gr1+
(C) CD11c+F480- (D) CD11b+F480+ (E) Ly6C+F480- (F) CD4+ (G)
CD8+ (H) CD19+ and (I) CD49b+ immune cells. Linear regression anal-
ysis was performed for each tissue with cell populations having a signifi-
cant (p<0.05 for linear regression) linear relationship with age and thus
tumor progression reported in the matching color for the tissue.
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Figure 6.5: Scaffolds recruit tumor cells in KPCY model of pancreatic can-
cer, enrich tumor cell concentration relative to blood, and re-
duce metastatic tumor burden in the liver relative to mock
surgery. (A) Scaffolds capture tumor cells corresponding to tumor
histopathological grade as evaluated by quantification of YFP+ cells via
flow cytometry relative to the total number of cells per scaffold. (B)
Scaffolds significantly enrich tumor cells relative to blood as evaluated
via flow cytometry for percentage of YFP+ cells in scaffolds relative to
blood. (C) Scaffolds trend toward reduced metastatic tumor burden in
blood and (D) significantly reduce (p<0.05) tumor burden in the liver
relative to a mock surgery.
blood (Figure 6.5C) and liver (Figure 6.5D). We found no statistical difference
between the number of YFP+ cells in the blood of mock mice relative to scaffold
implanted mice, however we did find a statistically significant reduction in YFP+
cells present in the liver of mice that receive scaffolds relative to a mock surgery
(0.030 +/- 0.005 % YFP+ for mock surgery mice and 0.017 +/- .004 % YFP+ for
scaffold implanted mice).
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6.4.4 Scaffolds can be used to monitor the dynamic immune system
changes as a result of spontaneous pancreatic cancer
As in the PyMT model, we next evaluated the dynamic immune response to the
scaffold in the context of disease progression by evaluating the changes in immune
cell populations in the liver, pancreas, scaffold, and spleen (Figure 6.6). We found
significant increase in the proportion of CD45+ cells present in pancreas (7.861 +/-
2.668 fold change from tumor-free CY) and a significant decrease in CD45+ cells in the
spleen (0.7513 +/- .1227 fold change from tumor free, Figure 6.6A). We also found
a significant increase in CD11b+Gr1+ neutrophils in scaffolds (1.370 +/- 0.5013)
and spleens (4.355 +/- 3.429) of tumor bearing mice relative to tumor free (Figure
6.6B). We observed a significant increase in CD11c+F4/80- dendritic cells in the
pancreas (Figure 6.6C, 4.605 +/- 3.609), a significant decrease in CD11b+F4/80+
macrophages in the liver (Figure 6.6D, 0.6274 +/- 0.2325), a significant increase in
Ly6C+F4/80- monocytes in the spleen (Figure 6.6E, 1.185 +/- 0.8896), and finally
a significant decrease in CD4+ T cells in the liver (Figure 6.6F, 0.4941 +/- 0.3145).
For all cell types, scaffolds and spleens tended to demonstrate the same trend from
tumor-free CY mice.
We next sought to investigate the ability of scaffolds to dynamically indicate
disease progression. To this end, we used CD45+ cells present in the pancreas as a
surrogate for age, as this was significantly linearly associated with age (p=0.0031)
and gave better discrimination between mice that we the same age but at different
stages of tumor progression (Figure 6.7A). We then used the burden of CD45+
cells in the pancreas as a surrogate for disease progression and performed linear
regressions of each cell type present in each tissue against this independent variable.
We found YFP+CD45- cells also increased linearly with age in scaffolds, though
this was not significant (Figure 6.7B). We found CD11b+Gr1+ did not vary with
disease progression in this model (Figure 6.7C), though they were elevated relative
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Figure 6.6: Pancreatic tumor-dependent immunomodulation occurs at the
scaffold site and is similar to modulation observed in the spleens
of KPCY mice. Flow cytometric evaluation of surface markers for im-
mune cells and reported as fold change in % of each population from tumor
free (CY mice) relative to tumor bearing (KPCY mice) for lung, pancreas,
scaffold, and spleen for (A) CD45+ (B) CD11b+Gr1+ (C) CD11c+F480-
(D) CD11b+F480+ (E) Ly6C+F480- (F) CD4+ (G) CD8+ (H) CD19+
and (I) CD49b+ immune cells.
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to tumor free at all timepoints investigated. However, F4/80+ macrophages (Figure
6.7D), Ly6C+ monocytes (Figure 6.7E), CD4+ T cells (Figure 6.7F), CD8+ T
cells (Figure 6.7G), CD19+ B cells (Figure 6.7H), and CD49b+ natural killer
cells (Figure 6.7I) all had a significant linear relationship with disease progression.
Interestingly innate immune cell populations including macrophages and monocytes
decreased with disease progression while adaptive cell populations including CD4+
and CD8+ T cells, B cells, and natural killer cells all increased at the scaffold with
disease progression. Additionally, the scaffold and the spleen demonstrated similar
slopes with linear regression with the exception of CD19+ B cells (Figure 6.7H).
6.4.5 Scaffold immune signatures can distinguish between breast and
pancreatic cancer conditioning and identify key immune players
associated with tumor cell recruitment
Finally, we investigated whether immune signatures from scaffolds could distin-
guish between breast and pancreatic cancer dependent immunomodulation. To this
end we first performed unsupervised hierarchical clustering for each scaffold sam-
ple immune populations (CD45+ total immune cells, CD11b+Gr1+ neutrophils,
CD11b+F480+ macrophages, CD11c+F480- dendritic cells, CD11b+Ly6C+ mono-
cytes, CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD49b+ natural killer
cells, Figure 6.8A). Using this approach most RFP+PyMT+ samples cluster on
the left and most KPCY cluster on the right. However, 5 KPCY samples cluster on
the left with the PyMT samples. Interestingly, these all appear to have high levels
of Ly6C+F4/80- monocytes relative to other samples. KPCY samples on the right
cluster appear to be differentiated primarily by their high levels of adaptive cell pop-
ulations relative to other samples, including CD49b+ natural killer cells, CD19+ B
cells, and CD4+ and CD8+ T cells. As hierarchical clustering was unable to separate
PyMT from KPCY clearly, we next performed principal component analysis (PCA)
138
Figure 6.7: Pancreatic tumor-dependent immunomodulation demonstrates
dynamic response with tumor progression. Changes in immune cell
populations were evaluated at various stages in tumor progression within
scaffolds spleen and pancreas via flow cytometry. First, the progression of
CD45+ cell burden in the pancreas was confirmed by its significant linear
relationship with age in (A). Then the % change in CD45+ cell burden
was used as a surrogate for tumor progression and dependent variable
against (B) YFP+CD45- tumor cells, (C) CD11b+Gr1+, (D) F480+,
(E) Ly6C+, (F) CD4+, (G) CD8+, (H) CD19+, and (I) CD49b+ cells.
Linear regression analysis was performed for each tissue, only scaffolds
were found to have significant linear relationships with tumor progression
and R2 and p-value of the linear regression for scaffolds are reported on
each plot.
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Figure 6.8: Scaffold immune signature can distinguish breast tumor bear-
ing mice (RFP+PyMT+) from pancreatic tumor bearing mice
(KPCY). (A) Unsupervised hierarchical clustering of scaffold im-
mune signatures from flow cytometry from CY, KPCY, RFP+, and
RFP+PyMT+ mice. (B) These scaffold immune signatures from flow
cytometry data were fed into principal component analysis and demon-
strate separation of RFP+PyMT+ scaffolds from KPCY scaffolds.
and plotted the scores in the first two principal components for each sample (Figure
6.8B). PCA more successfully discriminated samples based on the multivariate na-
ture of the immune signature as demonstrated by most KPCY samples diverging to
the upper left quadrant while PyMT samples diverge to the bottom right quadrant.
Next, we investigated the role of immune cell populations and their association
with tumor cell recruitment in both the PyMT breast cancer model (Figure 6.9A)
and the KPCY pancreatic cancer model (Figure 6.9B). To this end we first per-
formed correlation analysis of immune cell populations and tumor cell recruitment
showing a heatmap of the Pearson correlation coefficient for each immune cell popula-
tion and tumor cells. A number of positive correlations were found between immune
cell populations for PyMT including CD4+ and Ly6C+ cells (0.6667), CD8+ and
CD49b+ cells (0.712), and total CD45+ and CD4+ (0.6066) and CD45+. Nega-
tive correlations were also found between populations including F480+ and Ly6C+
(-0.5535), F480+ and CD19+ cells (-0.5426), and CD4+ and CD8+ T cells (-0.5039).
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Next, stepwise multiple linear regression analysis was performed to build a model
that explains the contribution of immune cells to tumor cell recruitment. For PyMT
scaffolds, this approach found that the total number of CD45+ cells was positively as-
sociated with recruitment (coefficient 3.089 +/- 0.937 and p = 0.004), CD8+ cells are
negatively associated with recruitment (coefficient -0.563 +/- 0.280 and p = 0.058),
and CD49b+ cells are positively associated with recruitment (coefficient 0.596 +/-
0.208 and p = 0.010). The model R2 however, was relatively low 46.72%, indicating
that there is variability in tumor cell recruitment that cannot be explained by the
immune cell composition of the scaffold. Applying the same approach to KPCY we
found a number of positive associations between immune cell populations including
CD45+ and F480+ cells (0.6351), CD45+ and CD49b+ cells (0.6338), CD11b+Gr1+
and Ly6C+ cells (0.5378), F480+ and CD19+ cells (0.5095), F480+ and CD49b+ cells
(0.6127), and CD4+ and CD49b+ cells (0.5691). Additionally, some negative associ-
ations between immune cell types were identified including F480+ and Ly6C+ cells
(-0.8029), Ly6C+ and CD4+ cells (-0.6081), and Ly6C+ and CD19+ cells (-0.5895).
Next, stepwise multiple linear regression analysis identified populations significantly
contributing to a model of tumor cell recruitment. This approach identified CD11c+
dendritic cells to be positively associated with recruitment (coefficient 2.674 +/- 0.885
and p = 0.012), F480+ macrophages to be positively associated with recruitment (co-
efficient 1.336 +/- 0.176 and p <0.001), CD8+ T cells to be negatively associated
with recruitment (coefficient - 0.1264 +/- 0.0776 and p = 0.132), and CD49b+ nat-
ural killer cells to be positively associated with recruitment (coefficient 0.6260 +/-
0.0917 and p <0.001).
6.5 Discussion
In this study poly(ε-caprolactone) biomaterial scaffolds were investigated for their
ability to recruit tumor cells in two spontaneous models of tumorigenesis and metas-
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Figure 6.9: Scaffold immune signatures can identify key immune players
in tumor cell recruitment to biomaterial scaffolds in models of
breast and pancreatic cancer. Correlation analysis of immune cell
populations and tumor cell recruitment showing heatmap of Pearson cor-
relation coefficient values for each immune cell population and tumor
cells and stepwise multiple linear regression of these immune signatures
with tumor cells as a response and changes in immune cell populations
as predictors identifying terms significantly contributing to tumor cell re-
cruitment in (A) PyMT breast cancer model and (B) KPCY pancreatic
cancer model.
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tasis for breast and pancreatic cancer. This work was motivated by the idea that
implanted biomaterials have been found to recruit tumor cells in many diverse ortho-
topic models of metastasis, however their function in spontaneous models of metas-
tasis has never been reported. The ability of scaffolds to recruit tumor cells in these
models is crucial for an indication that this technology may be applicable in human
patients, as orthotopic models of metastasis do not represent the timeline or cascade
of events that must occur in a human patient for a tumor to develop and metastasis
to occur.
Indeed, we found biomaterial scaffolds recruit tumor cells in spontaneous breast
cancer and pancreatic cancer. In the PyMT model of breast cancer we found that
at endpoint tumor size (12-14 weeks of age) scaffolds on average had more tumor
cells than the lungs, the primary site of metastasis in this model. Additionally, by
longitudinal analysis of the same cohort of mice, we found tumor cells were detectable
as early as 5 weeks of age in these mice, indicating we recruit early metastatic tu-
mor cells similar to the finding of disseminated tumor cells in the bone marrow in
these models [211]. Interestingly, we observed dynamics of RFP+PyMT+ tumor cells
within the scaffold in the same cohort of mice, with tumor cells being significantly
elevated at 5 weeks of age, demonstrating a reduction in number from 6-8 weeks of
age, and returning to significantly elevated levels from 10-11 weeks of age. These
dynamics somewhat mirror the elevation of CD8+ T cells and CD49b+ natural killer
cells at these timepoints and thus may be a result of enhanced adaptive immunity
clearing early metastatic cells at these timepoints [212]. We also observed early dis-
semination of tumor cells in the KPCY model of pancreatic cancer. At stages prior
to full pancreatic ductal adenocarcinoma, we observed YFP+ pancreatic cells in the
scaffold, blood, and liver of KPCY mice, similar to findings reported in the litera-
ture [213]. Importantly, we found the scaffold enriched these YFP+ cells two order
of magnitude relative to the blood. This indicates that tumor cells are not simply
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non-specifically collected within the scaffold as a result of their presence in the blood,
but also demonstrates that the scaffold platform provides a significant advantage over
the detection of circulating tumor cells [214, 215].
Interestingly, we found in a trend toward reduced primary tumor burden in the
PyMT model, however this was not statistically significant. Additionally, this did not
seem to translate into a reduction in metastatic tumor burden in scaffold implanted
mice relative to mock surgery mice. However, in the KPCY model we found a scaffold
implantation provided a significant reduction in YFP+ cells in the liver of scaffold
implanted mice relative to those receiving a mock surgery. This was accompanied by
a trend towards reduced numbers of circulating YFP+ cells in the blood of scaffold
implanted mice relative to mock mice, however this was not statistically significant.
These differences between models in ability to impact metastatic burden may be
attributed to the high level of variability between individual mice obscuring some
effects in the PyMT model relative to the KPCY model.
Importantly, we found the scaffold demonstrated tumor-progression dependent
immunomodulation in both models of breast and pancreatic cancer. In both cases,
the alterations in the scaffold immune microenvironment most closely followed the
immune changes observed in the spleen. This finding is similar to our findings in
orthotopic models of breast cancer [30, 31] and likely represents changes in the sys-
temic availability of immune cells in the blood, and thus a change in the immune cells
responding to the biomaterial as part of the foreign body response. In the PyMT
model we found an increase in CD11b+Gr1+ neutrophils, CD11c+F480+ dendritic
cells, Ly6C+F480- monocytes, and a decrease in CD11b+F480+ macrophages in tu-
mor bearing mice relative to tumor free. In the KPCY model we found a similar
increase in CD11b+Gr1+ neutrophils in tumor bearing mice relative to tumor free.
Interestingly, the dynamics of immune cell populations with tumor progression were
quite different between the two models. In the PyMT model we found an increase
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in CD45+ cells and neutrophils and a decrease in dendritic cells and CD4+ T cells.
In the KPCY model we found a decrease in macrophages and monocytes and an in-
crease in CD4+ and CD8+ T cells, CD19+ B cells and CD49b+ natural killer cells
with tumor progression. These trends observed in the scaffold track with the changes
observed in the spleen with tumor progression for all cell types with the exception
of CD8+ T cells in the PyMT model and CD19+ B cells in the KPCY model. This
highlights the ability of the scaffold to largely reflect systemic immune changes, but
also reflect changes occurring in the primary tumor and metastatic sites as the in-
crease in CD8+ T cells in PyMT is concordant with the trend in the primary tumor.
After observing different trends with primary tumor progression in both models we
next asked if the immune signature within the scaffold alone was enough to distin-
guish between mice bearing breast and pancreatic cancer. Unsupervised hierarchical
clustering identified some separation between PyMT and KPCY samples. However,
principal component analysis was better able to identify divergence of immune cell
populations between PyMT and KPCY. This finding highlights the ability of a bio-
material scaffold to not only recruit tumor cells but serve as a sentinel for different
mechanisms of immunomodulation.
We also sought to understand if the scaffold could provide insights into positive
and negative regulators of tumor cell recruitment in two very different models of
metastasis. To this end we performed multiple linear regression of immune cell pop-
ulations as predictors and tumor cell recruitment as the independent variable. In
the PyMT model we found CD45+, CD8+, and CD49b+ cells to be significantly
associated with recruitment of tumor cells with CD45+ cells and CD49b+ cells as
positive regulators of recruitment and CD8+ cells as negative regulators of tumor cell
recruitment. Similarly, in the KPCY model we found CD8+ cells to be negatively
associated with recruitment and CD49b+ cells to be positively associated with recruit-
ment. However, in contrast with the PyMT model, CD45+ cells were not associated
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with recruitment while CD11c+ and F480+ cells were both positively associated with
tumor cell recruitment. Interestingly, the model of tumor cell recruitment for KPCY
had a much higher adjusted-R2 (94.10% relative to 38.72% for PyMT) indicating
there may be other cell populations or microenvironmental factors contributing to
tumor cell recruitment in the PyMT model that cannot be explained simply by the
changes in immune cell populations within the scaffold. The finding that CD49b+
cells are positively associated with tumor cell recruitment to the scaffold is surprising
as natural killer cells are capable of controlling metastasis by eliminating metastatic
tumor cells [216–218]. However, it is possible that a greater population of natural
killer cells is associated with a larger pool of metastatic tumor cells in response to an
attempt to eliminate these cells. It is also possible that an increase in natural killer
cells may be associated with NK cell exhaustion and thus reduced tumor cell killing
[219].
For the first time, these results report the recruitment of tumor cells in sponta-
neous models of tumorigenesis and metastasis and the first evidence that this platform
recruits metastatic pancreatic tumor cells. Additionally, this work supports the use of
biomaterial scaffolds for monitoring the dynamic immune response as a result of pri-
mary tumor development and metastasis. Importantly, we also show the first evidence
that the immune response to biomaterial scaffolds differs in the context of different
cancer models. The scaffold platform technology represents a unique opportunity to
recruit tumor cells and reflect tumor dependent immunomodulation in diverse models
of metastasis. Thus this platform provides unprecedented opportunity for the early
detection of metastasis.
146
6.6 Materials and Methods
6.6.1 Transgenic animal models
Animal studies were performed in accordance with institutional guidelines and
protocols approved by the University of Michigan Institutional Animal Care and Use
Committee (IACUC). MMTV-PyMT-RFP (PyMT+RFP+) mice and their respective
tumor free control MMTV-RFP (RFP+) as well as KPCY mice (Pdx1-Cre KrasG12D
p53fl/+ RosaYFP) and CY (Pdx1-Cre RosaYFP) mice were bred in house. Scaffold
implantation was performed between 5-8 weeks of age in these mice, prior to tumor
formation. For both models, mice were monitored a minimum of three times a week
for the duration of experiments for evidence of tumor-related morbidity. Mice were
sacrificed when tumors reached endpoint size as defined by the animal use protocol
(PRO00007801) or exhibited limited physical activity.
6.6.2 Scaffold fabrication and implantation
Microsphere preparation. PCL microspheres were prepared as previously described
(ref). Briefly, microspheres were prepared by emulsification of a 6% (w/w) solu-
tion of PCL (Lactel Absorbable Polymers; Inherent viscosity 0.65-0.85 dL/g) in
dichloromethane in a 10% (w/v) poly(vinyl alcohol) solution followed by homoge-
nization at 10,000 rpm for 1 minute. The solution was then stirred for 3 hours to
evaporate dichloromethane solvent. Microspheres were then collected by centrifuga-
tion at 2000 x g for 10 minutes and washed at least five times in deionized water.
Finally, microspheres were lyophilized for 48 hours.
Scaffold fabrication. Microporous PCL scaffolds were prepared by mixing PCL
microspheres and sodium chloride crystals (250-425 m in diameter) at a 1:30 (w/w)
ratio. This salt and polymer microsphere mixture was then pressed in a steel die for
45 seconds at 1500 PSI. Polymer/salt disks were then heated at 60C for 5 minutes
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per side to melt polymer microparticles around salt crystals to form a continuous
structure. Salt crystals were subsequently removed by immersion in water for 1.5
hours. Scaffolds were then sanitized for animal studies using 70% ethanol, rinsed
with sterile water, and dried on a sterile surface.
Scaffold implantation. Scaffolds were implanted into the subcutaneous space of 8-
week-old female NOD/SCID-IL2Rγ-/- (NSG) or balb/c mice as previously described
(ref). For the implantation procedure, animals were anesthetized via isoflurane (2%,
inhaled), prepared with Carprofen analgesia (5 mg/kg, subcutaneous injection), the
upper back was shaved and prepped using a Betadine swab followed by an ethanol
swab and this procedure was repeated 3 times. A fenestrated sterile field was draped
over the surgical area and a 1 cm incision was made in the upper back. Following
incision, subcutaneous pockets were created perpendicular to the incision, into which
sanitized scaffolds were inserted (2 scaffolds/mouse). The skin was then closed using
sterile wound clips (Reflex 7 mm, Roboz Surgical Instrument Co).
Longitudinal scaffold explant and reimplantation. For longitudinal tracking of
one cohort of mice over time, 2 scaffolds were explanted from each mouse once a
week. Mice were anesthetized as described above and shaved directly over the scaffold
implant site. The surgical site was prepared as described and a 5-10 mm incision was
made between the two implanted scaffolds. Both scaffolds were explanted and a fresh
pair of scaffolds was implanted into the same location. The incision was closed with
4-0 vicryl resorbable sutures (Ethicon).
6.6.3 Statistical and Computational Analysis
Statistical Analysis. All statistical tests were performed in Prism version 6.0.1. All
graphs are reported as mean with standard error of the mean unless otherwise stated.
Linear regressions were performed in Prism. All statistical tests were performed as
a two sided T test with unequal variances unless otherwise stated after checking for
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normality of data distribution.
Hierarchical clustering and principal component analysis. Unsupervised hierarchi-
cal clustering was performed in MATLAB 2018a with normalization across rows and
clustering across columns. Principal component analysis was performed in MATLAB
2018a.
Multiple Linear Regression Analysis. Stepwise multiple linear regression analysis
was performed in Minitab version 18 with alpha = 0.15 to add or remove terms.
6.6.4 Flow Cytometry
Scaffolds were minced, digested using Liberase TL (Roche) and strained through
a 70 m filter to produce a single cell suspension. Cells were pelleted via centrifuga-
tion at 500 x g for 5 min. Following isolation of a single cell suspension, cells were
blocked using anti-CD16/32 (Biolegend) and stained with anti-mouse CD45 AF700
(Biolegend), CD11b V500, F4/80 PECy7, Gr1 PacBlue, Ly6C FITC for PyMT and
Ly6C PE for KPCY, and CD11c APC for innate panel. For adaptive panel sam-
ples were stained with anti-mouse CD45 AF700, CD4 V500, CD8 FITC for PyMT
and CD8 PE for KPCY, CD19 PacBlue, and CD49b PECy7. Samples were run on




Non-invasive ultrasound imaging for early
detection
7.1 Authors
Grace G Bushnell*, Xiaowei Hong*, Shreyas S Rao, Rachel M Hartfield, Yining
Zhang, Robert S Oakes, Jacqueline S Jeruss, Cheri X Deng, Lonnie D Shea *these
authors contributed equally to this work
7.2 Abstract
For most cancers, the formation of distant metastasis is the point at which clinical
treatment shifts from curative intent to palliative care. We have developed a bioma-
terial implant that acts as a synthetic pre-metastatic niche and recruits metastatic
cancer cells in xenogeneic human and syngeneic mouse models of breast cancer. Here,
we investigate ultrasound as a non-invasive strategy for detecting metastasis to the
synthetic scaffold.. Spectral ultrasound imaging (SUSI), which detects parameters
related to the composition and structure of tissues, identified changes at the earliest
time point that tumor cells were recruited to scaffolds. SUSI demonstrated changes
in spectral parameters with tumor status in orthotopic models of both human and
mouse breast cancer cells in mice. The associated changes were reflected in the cellu-
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lar composition of the scaffold microenvironment, and not the acellular composition.
This included an increase in the number of CD31+CD45- endothelial cells in tumor
bearing mice (1237 +/- 252 cells for control and 1909 +/- 385 cells for tumor bearing
scaffolds). Finally, the changes in SUSI parameters was used to develop a classifica-
tion model to stratify tumor free and tumor bearing status from scaffold parameters.
Combination of a linear discriminant analysis model and a bagged decision trees
model resulted in an area under the curve of 0.92 for prediction. Ultrasound is widely
used in the clinic and the potential for early non-invasive detection of metastasis could
facilitate clinical translation of the scaffolds for monitoring metastatic disease.
7.3 Introduction
Metastasis is responsible for 90% of cancer related deaths [116]. This transition
to stage IV disease has a devastating prognosis for many reasons. First, metastasis is
not often detected until whole organ systems have been compromised. Currently, a
definitive diagnosis of metastasis relies on the use of PET, CT, or MRI to locate and
visualize a metastatic lesion, typically >7-8mm in diameter [171]. Second, widespread
metastatic disease is often more resistant to therapy, more aggressive, and overall
much harder to treat. Early detection of metastatic disease or a risk of metastasis
has significant potential to reduce cancer mortality associated with metastasis by
allowing interventions when the burden of disease is low.
Early detection strategies have primarily focused on the use of blood as a liquid
biopsy. Liquid biopsies including circulating tumor cell (CTC), circulating tumor
DNA (ctDNA), and exosome detection in the blood are emerging as a technology to
stage patients beyond the presence, size, and molecular characteristics of the primary
tumor [172]. However, the connection between the presence and relative number
of each of these markers and metastasis is still unclear. For example, while a high
number of circulating tumor cells (5 CTCs in 7.5 mL blood) correlates with poor
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prognosis [220], studies in animal models have shown that 99.99% of CTCs do not
have the ability to metastasize [168] and thus understanding when to intervene in a
patient that has a high number of CTCs is still elusive. Biomaterial scaffolds that
capture metastatic tumor cells [151] extend beyond liquid biopsy to capture immune
cells associated with the metastatic niche and metastatic tumor cells themselves [30,
31, 34, 42, 152]. These technologies have been successful in mouse models of breast
[30, 31, 34, 42, 152], ovarian [29], prostate [27, 81], melanoma [26] and hematologic
cancers [36] and have captured tumor cells, reduced metastatic burden [30, 31], and
improved survival [30].
A crucial piece of this detection platform is non-invasive monitoring of the implant
for metastasis. Inverse spectroscopic optical coherence tomography (ISOCT) has been
implemented in this system in order to detect the presence of tumor cells at the earliest
stages of metastatic cell dissemination, prior to detection of tumor cells in vital organs
[30, 31]. However, optical imaging techniques are highly specialized and not currently
available in the clinic. Additionally, while the resolution of optical techniques is high,
the penetration depth is low [112, 148] such that this technology is unlikely to be
successful in non-invasive imaging through human skin.
Ultrasound imaging is the most commonly used imaging modality in radiology
due to its noninvasive and nondestructive nature and optimal balance of resolution
and penetration depth for many clinical applications. Spectral ultrasound imaging
(SUSI), an imaging modality extended from the conventional grayscale B-mode ultra-
sound imaging, utilizes the raw radiofrequency data (RF) of ultrasound backscattered
signals to extract quantitative measures of tissue properties. Power spectra of the RF
signals can be computed and calibrated such that all system effects are removed and
linear regression of the calibrated spectra over the bandwidth of imaging provides
quantitative parameters for a given tissue including slope, midband fit (MBF), av-
erage acoustic scatter diameter, and acoustic concentration. Spectral characteristics
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have been previously used to characterize atherosclerotic plaque composition [221],
changes in tissue properties for the prostate [222], pancreas, and lymph node [223],
and non-invasively monitor the development of tissue-engineered constructs in vitro
[224–227].
In this study, we demonstrate the use of SUSI for determination of tissue character-
istics that correspond with spontaneous metastatic tumor cell arrival to a biomaterial
scaffold in vivo. We investigated the parameter alterations that occur from healthy
to tumor bearing mice within biomaterial scaffolds for models of orthotopic human
and mouse breast cancer metastasis. We also developed a classification algorithm
to classify healthy and tumor bearing mice according to SUSI parameter measure-
ment in scaffolds. Finally, we evaluated the biological components of the scaffold that
changed with tumor inoculation in order to identify those components that chang-
ing SUSI parameters used to stratify tumor bearing from healthy samples. The use
of SUSI in combination with scaffolds that capture metastatic tumor cells has the
potential to create a non-invasive platform for identifying metastatic disease at its
earliest stages, allowing for intervention while disease burden is low and profoundly
impacting cancer mortality as a result of metastasis.
7.4 Results
7.4.1 SUSI detects changes in mouse-tumor bearing mice relative to tu-
mor free at late stages of metastatic disease
The ability of SUSI to distinguish between late stage tumor bearing mice and
healthy controls was initially assessed by explanting scaffolds from healthy and 4T1
breast tumor bearing mice at day 14 following inoculation and imaging ex vivo. Day
14 post tumor inoculation represents a timepoint at which tumor cells are present both
in the scaffold and in the lung and liver as micrometastases [30]. Grayscale images
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(Figure 7.1A) with 3D reconstruction (left panel) and section (right panel) for tumor
free and tumor bearing conditions show no obvious changes in implant structure at the
macroscopic scale. Assessment of SUSI parameters demonstrated clear distinctions
between tumor free and tumor bearing mice at this relatively late stage (Figure
7.1B) including significantly lower slope for tumor bearing scaffolds (control: 0.103
+/- 0.076 and tumor bearing: 0.0583 +/- 0.078 dB/MHz). Additionally, acoustic
scatter diameter (ASD: 20.82 +/- 1.88 μm for control and 21.90 +/- 1.83 μm for tumor
bearing) and average acoustic concentration (AAC: 42.77 +/- 3.02 dB[mm-3] for
control and 44.41 +/- 3.17 dB[mm-3] for tumor bearing) were both higher for tumor
bearing relative to tumor free. For each parameter the number of pixels outside of the
sample 95% confidence interval were also assessed for their alteration between control
and tumor bearing scaffolds (Figure 7.1C). This approach gave more consistent
differences between tumor bearing and control scaffolds with all parameters assessed
having statistically significant alterations from control to tumor bearing scaffolds.
Interestingly, for all parameters the number of pixels outside of the 95% confidence
interval was lower in tumor bearing mice, including grayscale (23017 +/- 8772 pixels
for control and 20210 +/- 6859 pixels for tumor bearing scaffolds) and mid-band fit
(426 +/- 197 pixels for control and 369 +/- 142 pixels for tumor bearing scaffolds)
which were not significantly different by measurement of the raw parameter value
itself (Figure 7.1B).
7.4.2 SUSI detects changes in mouse and human-tumor bearing mice
relative to tumor free at early stages of metastatic disease
Following the finding that SUSI was capable of detecting tissue changes in scaffolds
from tumor bearing mice at late time points relative to control, we next investigated
the ability of SUSI to identify changes at early stages of metastasis. We chose day 5
following inoculation of breast adenocarcinoma cells as this time point is associated
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Figure 7.1: SUSI detects changes in mouse-tumor bearing mice relative to
tumor-free at late stages of metastatic disease. (A) Grayscale
images of scaffolds from tumor free and tumor bearing mice. (B) Raw
parameter values generated by SUSI analysis of control and tumor bearing
scaffolds including grayscale, mid-band fit, slope, ASD, and AAC. (C)
Confidence interval analysis of parameters showing the number of pixels
lower than the lower bound of the 95% confidence interval of the sample
for that given parameter per frame. Error bars s.e.m. *p<0.05 via two-
sided t-test
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with occasional tumor cells in the scaffold yet not metastasis to vital organs [30, 31].
Again, instead of looking at the raw parameters from SUSI we assessed the number
of pixels outside of each samples 95% confidence interval. Like late-stage tumors we
found that there were not any visible macroscopic alterations in implant architecture
in three dimensional reconstructions or gray scale slices for scaffolds in mice bearing
either human (231-BR) or mouse (4T1) tumors at day 5 compared to their tumor free
controls (Figure 7.2A, C). Also similar to late stage disease, we found the number
of pixels outside of the sample 95% confidence interval to be significantly lower in
scaffolds from tumor bearing mice relative to control for both human and mouse
breast tumors (Figure 7.2B, D). The number of pixels was significantly altered for
all parameters for the comparison of scaffolds from mice bearing day 5 human 231-BR
tumors relative to control. For mice bearing mouse 4T1 tumors, all parameters except
for AAC (624 +/- 234 pixels for control and 561 +/- 207 pixels for tumor bearing)
were significantly altered between control and tumor bearing scaffolds.
7.4.3 SUSI detects changes in cellular composition and extracellular ma-
trix with tumor progression and metastasis
Following identification of the ability for SUSI to detect changes in tumor bearing
relative to control scaffolds in both human and mouse breast cancer at early and late
stages of disease, we next sought to identify the biological changes being detected by
SUSI in the scaffolds. We first investigated changes in extracellular matrix (ECM)
associated genes as these are both likely to be observed by SUSI [224–227] and are also
altered in the pre-metastatic niche [8, 42, 150] We investigated expression of Col1a1,
Col4a1, Fn1, Lox, and Mmp2 and found no significant differences in gene expression
between control and 4T1 tumor bearing scaffolds at day 7 post inoculation (Figure
7.3A). As no differences were observed in gene expression of ECM associated genes
we next investigated changes in cell populations within the scaffolds. Previous work
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Figure 7.2: SUSI detects changes in mouse and human-tumor bearing mice
relative to tumor-free at early stages of metastatic disease. (A)
Grayscale images of scaffolds taken from control and 231-BR tumor bear-
ing mice at day 5 post-inoculation. (B) Number of pixels lower than
the 95% confidence interval for each sample and each parameter show-
ing grayscale, mid-band fit, slope, ASD, and AAC for control and day 5
231-BR tumor bearing scaffolds. (C) Grayscale images of scaffolds taken
from control and 4T1 tumor bearing mice at day 5 post-inoculation. (D)
Number of pixels lower than the 95% confidence interval for each sam-
ple and each parameter showing grayscale, mid-band fit, slope, ASD, and
AAC for control and day 5 4T1 tumor bearing scaffolds. Error bars s.e.m.
*p<0.05 via two-sided t-test
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with scaffolds in tumor bearing mice has identified major changes in immune cell
populations as a result of tumor development and metastatic progression [30, 31, 34,
42, 152], however other stromal populations had not been investigated. As a result,
we performed flow cytometry to identify numbers of CD31+ endothelial cells present
in each scaffold (Figure 7.3B). A significantly increased number of CD31+CD45-
endothelial cells were present in the scaffolds of day 5 4T1 tumor bearing mice relative
to control scaffolds (1237 +/- 252 cells for control and 1909 +/- 385 cells for tumor
bearing scaffolds). We next sought to determine if our findings of alterations in SUSI
properties would be recapitulated in both decellularized scaffolds (Figure 7.3C) and
by isolating the cells from scaffolds and imaging these in a collagen gel (Figure 7.3D).
While no statistically significant differences between control and day 5 4T1 tumor
bearing scaffolds were observed with either decellularized scaffolds or investigating
scaffold-derived cells in collagen gel, scaffold-derived cells better mirror the changes
we saw in whole scaffolds. In decellularized scaffolds the number of pixels outside of
the 95% confidence interval decreased for grayscale, ASD, and AAC for tumor bearing
relative to control. However, the number of pixels for MBF and slope increased for
tumor bearing relative to control. For scaffold-derived cells, the number of pixels
outside of the 95% confidence interval decreased for all parameters in tumor bearing
relative to control, consistent with the whole scaffold. Scaffold-derived cells in a
collagen gel also reflect the trends observed with spleen-derived cells in a collagen gel
where we found a statistically lower number of pixels outside of the 95% confidence
interval for all parameters (Figure 7.3E). Previous work has identified immune cell
populations are altered similarly with tumor inoculation in both implanted scaffolds
and spleens [30, 31] and these results are concordant with that finding. Representative
grayscale images of scaffold-derived and spleen-derived cells in collagen gels as well
as decellularized scaffolds can be found in Supplemental, Figure 7.5 and SUSI
parameters for the blank scaffold can be found in Supplemental, Figure 7.6.
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Figure 7.3: SUSI detects changes in cellular composition and extracellular
matrix with tumor progression and metastasis. (A) qRT-PCR data
showing normalized gene expression for ECM associated genes including
Col1a1, Col4a1, Fn1, Lox, and Mmp2 for scaffolds from control and day 15
4T1 tumor bearing mice. (B) Flow cytometric analysis of CD31+CD45-
endothelial cells in scaffolds from control and day 15 4T1 tumor bearing
mice. (C) SUSI analysis of decellularized scaffolds taken from control
and day 5 4T1 tumor bearing mice showing fold change from control of
number of pixels under 95% confidence interval for each sample for each
parameter including grayscale, mid-band fit (MBF), ASD, and AAC. (D)
SUSI analysis of scaffold-derived cells in a collagen gel taken from control
and day 5 4T1 tumor bearing mice showing fold change from control of
number of pixels under 95% confidence interval for each sample and each
parameter including grayscale, MBF, ASD, and AAC. (E) SUSI analysis
of spleen-derived cells in a collagen gel taken from control and day 5
4T1 tumor bearing mice showing fold change from control of number of
pixels under 95% confidence interval for each sample and each parameter
including grayscale, MBF, ASD, and AAC. Error bars s.e.m. *p<0.05 via
two-sided t-test
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7.4.4 SUSI parameters are able to classify tumor free and tumor bearing
mice with good sensitivity and specificity
We next built classification models to discriminate between tumor bearing and
control mice based on a consistent decrease in the number of pixels outside of the 95%
confidence interval observed in tumor bearing scaffolds. A schematic of the method
used to develop classification models is provided (Figure 7.4A) and a schematic of
experimental timeline is provided (Supplemental, Figure 7.7). A heatmap with
unsupervised hierarchical clustering across samples is shown for the number of pixels
outside of the 95% confidence interval for each parameter and each sample in the
test cohort (Figure 7.4B). Using unsupervised hierarchical clustering most tumor
free control samples (TF) cluster on the left and most tumor bearing samples (TB)
cluster on the right of the heatmap. However, the number of trees generated in the
clustering indicates the samples are heterogeneous in each classification and that a
simple cutoff value for each parameter cannot suffice to predict tumor status. Thus,
linear discriminant and bagged decision trees models were created to classify the test
cohort based on the training cohort. Each model gave each sample a score from
0 to 1 based on the likelihood of being tumor free (0) or tumor bearing (1) and
these scores are plotted in Figure 7.4C, demonstrating good separation in scores of
tumor free and tumor bearing scaffolds. A receiver operating characteristics (ROC)
curve was created for the classification of both models individually and the linear
addition of both models, with any score greater than 1 classified as tumor bearing
(Figure 7.4D). The area under the curve was calculated for each and the combined
score was found to outperform the individual models (Combined AUC: 0.92, Linear
Discriminant Analysis AUC: 0.88, and Bagged Decision Trees AUC: 0.87)
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Figure 7.4: SUSI parameters are able to classify tumor free and tumor bear-
ing mice with good sensitivity and specificity. (A) Schematic of
method used to classify samples as tumor free or tumor bearing. A train-
ing cohort of n=6 tumor free and n=8 tumor bearing mice was used to
build both a linear discriminant model and a bagged decision trees model.
The test cohort was then fed into the model and the classification pre-
dicted. (B) Heatmap with unsupervised hierarchical clustering of test
cohort data normalized across each parameter. (C) Classification of test
cohort data and score given by each algorithm indicating prediction of
either tumor free status (score of 0) or tumor bearing status (score of 1).
(D) Receiver Operating Characteristic curve for tumor status classifica-
tion showing the classification accuracy for the combined score including




Metastasis is responsible for 90% of cancer-related deaths in part, because no
clinical strategies currently detect metastasis prior to the compromise of organ func-
tion. In this work, we validate the use of SUSI on implanted scaffolds for the early
detection of metastasis at time points where no tumor cells are found in vital organs
[30, 31] but are found in implanted scaffolds in two animal models of breast cancer
metastasis.
Inverse spectroscopic imaging (ISOCT) has also been used to detect ultrastruc-
tural tissue changes associated with metastasis in these models [30, 31], however
ISOCT is greatly limited by a low penetration depth and expense of imaging plat-
forms. Traditional ultrasound imaging alone is often used in the clinic for evaluation
of primary breast cancer [228] indicating bedside ultrasound is a safe, non-invasive,
and highly cost-effective technology that fits well with current practice. Importantly,
SUSI represents a significant improvement beyond traditional grayscale techniques,
as these are unable to detect changes associated with metastasis, and is able to
monitor objective and quantitative parameters that are intrinsic to the properties of
tissues. In this study, while we recorded the absolute value of the SUSI including
grayscale, mid-band fit, slope, ASD, and AAC, we found that for all parameters the
number of pixels outside of the 95% confidence interval for each sample better sep-
arated tumor bearing and tumor free scaffolds. For all parameters the number of
pixels outside of the sample 95% confidence interval was found to be lower in tumor
bearing scaffolds indicating not only small but significant differences in SUSI param-
eters and tissue properties, but also a fundamental change in tissue heterogeneity.
The ability to use these parameters and change in implant infiltrate homogeneity (by
the number of pixels outside the 95% confidence interval for each sample) provides
promising translation for human samples as longitudinal monitoring is operator and
system independent and is dependent upon the heterogeneity of a tissue rather than
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the absolute value of a tissue parameter. This finding was similar in both syngeneic
(mouse 4T1) and xenogeneic (human 231-BR) mouse models of spontaneous metas-
tasis. This result was expected as we observe similar changes in tumor cell arrival
and immune/stroma alteration with the development of the pre-metastatic niche and
transition to metastasis in implanted scaffolds [30, 31]. We have also successfully
detected changes associated with metastasis in both models using ISOCT [30, 31].
Additionally, the observed changes in SUSI do appear to have some progression as-
sociated with early compared to relatively late stage metastasis. For 4T1-inoculated
mice all parameters are significantly altered between tumor free and tumor bearing
at day 15 whereas at day 5 only 4/5 parameters were significantly altered.
The observed alterations in SUSI parameters were hypothesized to be associated
with changes in ECM as this has been robustly measured using SUSI [229] and is
associated with the pre-metastatic niche [10, 51, 150] and metastasis to implanted
biomaterial scaffolds [42], however we did not find significant alterations in ECM
associated genes by qRT-PCR and decellularized scaffolds did not recapitulate the
change from tumor free to tumor bearing scaffolds (2/5 parameters were significantly
different between decellularized and whole scaffolds, while no parameters (0/5) were
significantly altered from the imaged scaffold cells to whole scaffolds). Thus, we looked
at cellular alterations and found a significant increase in endothelial cells, which are
also associated with metastasis and the pre-metastatic niche [8, 60]. We have also
already discovered a number of other significant changes in immune cells at this time
point [30, 31], which may also be part of the cellular changes SUSI detects between
tumor free and tumor bearing scaffolds.
Classification models built on the input of SUSI data were able to classify tu-
mor bearing and tumor free mice with good sensitivity and specificity. As a result,
we believe that SUSI of implanted biomaterial scaffolds represents a promising tool
to enable the non-invasive early detection of metastasis. The scaffold may be non-
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invasively monitored using SUSI, which is both operator and system independent,
to identify changes indicative of metastasis risk and then the scaffold explanted and
analyzed via histology, RT-qPCR, or other techniques to validate the arrival and
presence of immune cells (myeloid derived suppressor cells etc. [30, 31]) and gene
signatures (unpublished data, Oakes et al.) associated with metastasis as well as
directly quantifying the arrival of tumor cells. Early detection may enable the initia-
tion of early chemotherapeutic treatment among high-risk patients while the burden
of disease is low before whole organ systems are compromised. Specifically, we fore-
see this scaffold platform and imaging technologies being used in patients who have
received a diagnosis of invasive breast cancer, completed chemotherapy and surgery,
and are deemed cancer-free but may experience metastatic recurrence. Non-invasive
monitoring of a scaffold implant is complementary and potentially advantageous over
liquid biopsy approaches as the scaffold identifies risk of metastasis based on presence
of metastatic niche forming cells and tumor cells that have successfully metastasized
to a tissue and are similar to the metastatic lung (unpublished data, Bushnell et al.).
7.6 Outlook
In this study, we demonstrate the utility of SUSI to detect changes associated with
metastasis to biomaterial scaffolds in both syngeneic mouse and xenogeneic human
models of spontaneous metastasis before tumor cells are detectable in vital organs.
SUSI imaging of biomaterial scaffolds represents an important technological advance-
ment in the early and non-invasive detection of metastasis, providing a platform for
detection leading to early intervention and reducing mortality from cancer metastasis.
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7.7 Materials and Methods
7.7.1 Scaffold fabrication and implantation
Microsphere preparation. PCL microspheres were prepared as previously de-
scribed [30]. Briefly, microspheres were prepared by emulsification of a 6% (w/w)
solution of PCL (Lactel Absorbable Polymers; Inherent viscosity 0.65-0.85 dL/g) in
dichloromethane in a 10% (w/v) poly(vinyl alcohol) solution followed by homoge-
nization at 10,000 rpm for 1 minute. The solution was then stirred for 3 hours to
evaporate dichloromethane solvent. Microspheres were then collected by centrifuga-
tion at 2000 x g for 10 minutes and washed at least five times in deionized water.
Finally, microspheres were lyophilized for 48 hours.
Scaffold fabrication. Microporous PCL scaffolds were prepared by mixing PCL
microspheres and sodium chloride crystals (250-425 μm in diameter) at a 1:30 (w/w)
ratio. This salt and polymer microsphere mixture was then pressed in a steel die for
45 seconds at 1500 PSI. Polymer/salt disks were then heated at 60C for 5 minutes
per side to melt polymer microparticles around salt crystals to form a continuous
structure. Salt crystals were subsequently removed by immersion in water for 1.5
hours. Scaffolds were then sanitized for animal studies using 70% ethanol, rinsed
with sterile water, and dried on a sterile surface.
Scaffold implantation. Scaffolds were implanted into the subcutaneous space of
8-week-old female NOD/SCID-IL2R-/- (NSG) or balb/c mice as previously described
[30]. For the implantation procedure, animals were anesthetized via isoflurane (2%,
inhaled), prepared with Carprofen analgesia (5 mg/kg, subcutaneous injection), the
upper back was shaved and prepped using a Betadine swab followed by an ethanol
swab and this procedure was repeated 3 times. A fenestrated sterile field was draped
over the surgical area and a 1 cm incision was made in the upper back. Following
incision, subcutaneous pockets were created perpendicular to the incision, into which
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sanitized scaffolds were inserted (2 scaffolds/mouse). The skin was then closed using
sterile wound clips (Reflex 7 mm, Roboz Surgical Instrument Co).
7.7.2 Tumor Inoculation
Animal studies were performed in accordance with institutional guidelines and
protocols approved by the University of Michigan Institutional Animal Care and Use
Committee (IACUC). Tumor inoculations were performed by injection of 2e6 MDA-
MB-231BR-tdTomato-luc2 (Northwestern University Developmental Therapeutics Core)
or 4T1-tdTomato-luc2 (Perkin Elmer) cells in 50 μL PBS (Life Technologies) into the
fourth right mammary fat pads of 10-week-old female NSG mice or Balb/c mice re-
spectively (Jackson Laboratory). Cell lines were confirmed to be pathogen free and
authenticated by short tandem repeat DNA analysis and compared to the ATCC
STR profile database (DDC Medical).
7.7.3 Ultrasound Imaging
The Vevo 770 system (Visualsonics, Toronto, Canada) with a 55 MHz center fre-
quency single element transducer (Vevo 708 scan head) were used to image scaffolds
ex vivo or in situ. Scaffolds were imaged with B-mode, 3D scan mode, and radiofre-
quency mode to acquire data for SUSI analysis.
7.7.4 Spectral Ultrasound Imaging (SUSI) Analysis
Grayscale. Raw backscattered RF data was Hilbert transformed to obtain the
complex analytical signal p(y,z). Grayscale values were determined as the mean
absolute value of the signal over the selected region as:
GS(y, z) = log10[p(y, z)]
Spectral parameters. The power spectra of each RF scan line was calculated by
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taking the Fast Fourier Transform of the segment of signals gated by a hamming
window with 0.2 μs sliding with a 0.1 μs offset. For calibration and removal of system-
dependent factors the power spectrum was divided by the spectrum of a perfect
reflector (oil-water interface). Slope (m) and mid-band fit (MBF) were determined
using linear regression to the calibrated power spectrum within a -9 dB bandwidth.
Acoustic scatter diameter (a), the effective size of acoustic scatters in a tissue, was
assessed using slope (m), the geometry index (n), the center frequency of the imaging
transducer (fc), and bandwidth of the transducer (b):
a = 2 ∗
√







Acoustic concentration (CQ2) was calculated by using MBF, scatter diameter (a),



















Average scatter diameter (ASD) and average acoustic concentration were calcu-
lated as the average value of the scatter size (a) and acoustic concentration (CQ2)
respectively in the chosen region. AAC values are given in decibel scale. For each
parameter 95% confidence intervals were calculated for each sample and the number




Regions in at least 10 frames from each scaffold were identified and quantified by
GS value and spectral parameters. All results are presented as mean +/- standard
error of mean (SEM). Statistical comparisons of parameters between groups were
made using Students t-test for unpaired samples. A p value of ¡0.05 was considered
statistically significant.
7.7.6 RT-qPCR Analysis
Scaffolds were explanted from tumor-free and tumor bearing mice, flash frozen
in isopentane, and stored until use. Total RNA was isolated from explanted scaf-
folds via homogenization in TRIzol (Thermo Fisher, Waltham, MA). Samples were
centrifuged at 10,000 x g to remove non-soluble particles. Total RNA was iso-
lated using Direct-zolTM RNA Miniprep Plus kit (Zymo Research Corp, Irvine,
CA). RNA concentration and purity were assessed by light absorbance via Nan-
oDrop 2000c (Thermo Fisher). cDNA was generated from RNA via reverse tran-
scription using SuperScriptTM VILOTM cDNA synthesis kit (Thermo Fisher). Taq-
man probes were purchased from Thermo Fisher including Mm00495386m1 (Lox),
Mm00439498m1(Mmp2), Mm00801666g1 (Col1a1), Mm01210125m1 (Col4a1), Mm-
01256744m1 (Fn1) and reference genes Gapdh, Tbp, Ywhaz, Hmbs, Ubc. RT-qPCR
was performed on CFX ConnectTM Real-Time PCR Detection System (Bio-Rad Inc,
Hercules, CA) with CFX Manager Software.
7.7.7 Decellularization of scaffolds
Scaffolds were decellularized using the method described by Aguado et al. [42]. In
brief, scaffolds were explanted from tumor-free and tumor bearing mice and washed
in dPBS, then treated with sequential 30 min washes in 1%, 2% and 3% Triton X-
100 (Sigma Aldrich), followed by an overnight incubation in 0.1% sodium dodecyl
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sulfate (SDS) with shaking at 4’C. This treatment was repeated the following day
until scaffolds were completely decellularized.
7.7.8 Preparation of cell suspensions for SUSI
Single cell suspensions were prepared as described above for flow cytometry. Fol-
lowing preparation of a single cell suspension cells were added to 4 mg/mL collagen
I, 5x DMEM solution, Fetal Bovine Serum, and 0.1N NaOH at a ratio of 1:5:2:1:1
resulting in a collagen gel with a final concentration of approx 500,000 cells/mL, 1x
DMEM, 2 mg/mL collagen I, 10% FBS, and 0.01N NaOH. Gels were plated in a 24
well plate and allowed to crosslink for 30 min at 37’C prior to imaging.
7.8 Supplemental Figures
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Figure 7.5: SUSI detects changes in tumor bearing spleens relative to con-
trol. (A) Representative grayscale images of cells from control or day 5
4T1 tumor bearing scaffolds embedded in a collagen gel. (B) Representa-
tive grayscale images of decellularized scaffolds from control or day 5 4T1
tumor bearing mice. (C) Representative grayscale images of cells from
control or day 5 4T1 tumor bearing spleens embedded in a collagen gel.
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Figure 7.6: SUSI parameters for blank scaffold. (A) representative B-
mode image of a blank scaffold. (B) SUSI analysis results includ-
ing grayscale, mid-band fit (MBF), ASD, and AAC of blank scaffolds.
(C) SUSI analysis results of pixels under 95% confidence interval for each
sample and each parameter including grayscale, MBF, ASD, and AAC of
blank scaffolds
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Figure 7.7: Schematic of experimental timeline for SUSI experiments.
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CHAPTER VIII
Conclusions and Future Directions
8.1 Summary of Findings
Taken together, the work presented in this dissertation describes developing a
biomaterial implant for the early detection of metastasis, therapeutic benefit, and
as a tool to study metastasis. By recruiting tumor cells to a defined site in vivo
metastasis can be detected non-invasively using both optical and ultrasound tech-
niques. Furthermore, the diversion of immune cells associated with metastasis as well
as tumor cells themselves to the implant significantly enhanced survival in a mouse
model of therapeutic tumor resection. The phenotype of tumor cells recruited to
the implant was elucidated and compared to tumor cells derived from the primary
tumor and lung metastasis. Scaffold-recruited tumor cells were found to be a highly
aggressive population of metastatic tumor cells with many phenotypic and functional
similarities to tumor cells found in the lung. Additionally, immunomodulation at the
scaffold site was used to study the effect of cytokine delivery on immune and tumor
cell recruitment in vivo and identified key immune populations associated with tumor
cell recruitment across a range of different immune microenvironments. The scaffold
platform was also evaluated in two transgenic models of tumorigenesis and metastasis
including one breast cancer model and one pancreatic cancer model. Implants were
found to recruit tumor cells and demonstrate tumor-progression dependent immune
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dynamics, providing further evidence for their translatability to human patients. The
research described in this dissertation continues the previous work done in this area
and advances the promise for the utility of this platform in a clinical setting.
8.2 Significance and Impact
The work presented in this dissertation addresses a crucial gap in the current
treatment of cancer. Metastasis is not detected until late stages of the disease, when
many billions of tumor cells have colonized a vital organ. This research furthers the
development of a platform to enable the detection of metastasis at its earliest stages,
when intervention and treatment may have a greater impact on patient survival. The
strategy of using a biomaterial platform to detect metastatic tumor cells is in con-
trast to liquid biopsy detection of CTCs by capturing tumor cells that are capable of
metastasis, unlike an estimated 99.99% of circulating tumor cells. In Chapter 3 we
develop an implant that is stable for months in vivo and yet is able to recruit tumor
cells long after implantation. We also demonstrate in a mouse model of tumor resec-
tion, scaffold implantation enhances survival relative to mock surgery. These findings
both increase translatability of the scaffold platform to patients as the scaffold would
be stable for months as well as indicate the scaffold may have use as a therapy as well
as detection platform. In Chapter 4 we investigated immunomodulation at the scaf-
fold implant as a way to elucidate novel contributors to metastatic progression and
recruitment to the implant that had not previously been identified. This approach
may be further applied to many other factors associated with metastasis and the pre-
metastatic niche as a more controlled system for identifying the local contributions
of individual factors to metastasis. Additionally, this approach may also be used to
enhance tumor cell recruitment to the implant, potentially enhancing the signal to
noise ratio in the clinical setting. In Chapter 5 we discuss the phenotype of tumor
cells recruited to biomaterial implants and investigate whether these tumor cells are a
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population capable of metastasis. Indeed, we find tumor cells recruited to the implant
represent an aggressive population of metastatic tumor cells whose diversion may be
partially responsible for the therapeutic and survival benefits found in Chapter 3.
In Chapter 6, we test the function of biomaterial implants in transgenic models of
tumorigenesis and metastasis that are more clinically translatable than orthotopic
models. Scaffolds recruited spontaneously metastasizing breast and pancreatic tumor
cells in these models and demonstrated tumor-progression-dependent immunomod-
ulation. The finding of tumor cell recruitment in pancreatic cancer is particularly
significant as it is the cancer with the lowest survival rate as a result of its rapid
progression to metastasis. Finally, in Chapter 7 we describe the use of non-invasive
ultrasound imaging for the detection of metastasis at the scaffold implant. Ultrasound
is a more translatable platform for non-invasive imaging in humans relative to optical
techniques previously used and thus represents and important finding for translation
of the scaffold as a detection platform for metastasis. Collectively this work highlights
the opportunities for translation of this device as a tool to detect metastasis early and
potentially reduce metastatic tumor burden as well as a platform to study metastasis.
8.3 Future Directions
The following section proposes future studies that will enhance the significance
and impact of the work presented in this dissertation.
8.3.1 Single cell analysis of tumor and immune cells recruited to bioma-
terial scaffolds
Single cell analysis is a burgeoning technique in biomedical research [230] and has
the ability to gain information about individual cell types in a tissue, their transcrip-
tome, and the heterogeneity of these populations. Single cell transcriptome analysis
of tumor cells recruited to biomaterial scaffolds was an original aim of this disser-
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tation, however collection of a sufficient number of metastatic tumor cells using a
variety of techniques including fluorescence-activated cell sorting (FACS), magnetic-
activated cell sorting (MACS), and circulating tumor cell capture devices including
EpCAM+ dendrimer coated surfaces [231], Labyrinth microfluidic cell sorting device
[232], flexible microspring array device [233], and Hydro-seq (unpublished data, Yu-
Chih Chen). Ultimately, as these approaches were not successful, the cell lines from
various metastatic locations were created in order to have sufficient number of tu-
mor cells for analysis including phenotypic and functional analyses that could not
have been performed with directly isolated tumor cells. While techniques for single
cell analysis were relatively exhaustive there were a few areas that were not inves-
tigated due to their ease of availability including laser-capture microdissection [234]
and Seq-Well [235]. It is likely that a combinatorial approach used to purify tumor
cells from the scaffold and remove polymer debris with a microfluidic method will
achieve greater success.
Single cell analysis of the immune and stromal infiltrate in biomaterial scaffolds
is another key area for future work. While this dissertation and the work before it
have performed exhaustive flow cytometric characterization of immune cell surface
markers and the dynamics of these populations with scaffold implantation and tumor
development, surface marker analysis does not provide any clues into the various
phenotypes possible for each of these cell types and their role within the paracrine
signaling to develop, maintain, and progress the pre-metastatic and metastatic niche.
This is an area of immediate interest and exploration for the future.
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8.3.2 Understanding the alterations within the scaffold microenviron-
ment that are required for tumor cell recruitment in different cancer
types
One original aim of this dissertation was to develop a model for tumor cell re-
cruitment as a function of the various immune cell populations present. As we see
variability in both tumor cell recruitment and immune cell populations present at
the scaffold this provides a natural avenue to investigate the interplay between these
populations. Indeed, this analysis was performed in both Chapter 4 and Chapter 6
in order to elucidate the role of various immune cell populations in tumor cell recruit-
ment in three different models of metastasis including orthotopic and spontaneous
breast cancer and spontaneous pancreatic cancer. While models were developed for
each, simply associating the presence of various immune cell populations does not
provide information or insight into the phenotype of these cells, what they are secret-
ing and how they are interacting with tumor cells either directly or indirectly. This
dissertation provides key cell populations for further investigation including CD4 and
CD8+ T cells, whose role at the pre-metastatic niche has yet to be fully elucidated
and have not been implicated in tumor cell recruitment to biomaterial scaffolds to
date (Chapter 2), neutrophils which have dual roles in metastasis promotion and
suppression [236], dendritic cells whose direct role in metastasis is not yet well estab-
lished [47, 142, 237], and natural killer cells which are primarily shown to eliminate
metastatic tumor cells [238] but in these studies demonstrated an increase with in-
creased tumor cell presence. These populations may be further elucidated for their
roles via single cell sequencing as described above, adoptive transfer of labeled cells
[239] and observation of trafficking to the scaffold, and/or validation in a broader
range of immunomodulated microenvironments. Further investigation into this area
not only facilitates a greater understanding of the mechanisms of biomaterial scaffold
function in various models, but also provides crucial insights into common mecha-
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nisms of metastasis across various tumor types and crucial correlates for translation
to patients.
8.3.3 Improved understanding of immune cell trafficking and education
within the scaffold microenvironment
The work presented in this dissertation provides evidence that the foreign body
response is dynamic and sensitive to systemic immunomodulation that occurs during
cancer progression. However, it is still unknown at what time scales this turnover and
trafficking of immune cells as part of the foreign body response occur on. Further-
more it is unknown whether immune cells are educated by the foreign body response
to the implant and alter their phenotype relative to the blood in the context of
tumor-dependent immunomodulation. It is also unclear if these immune cells may be
educated within the scaffold microenvironment and then leave the scaffold and traffic
to other areas of the host, including potential metastatic sites or the primary tumor
itself. These questions can be investigated via labeling of immune cells and adoptive
transfer as a preliminary step [239]. Furthermore they could also be explored by
cell painting approaches [240], optogenetic-like approaches [241], or transplant of a
scaffold containing cells from a labeled host into a non-labeled host. Each of these
approaches has significant experimental considerations and potential pitfalls but be-
ginning with simple adoptive transfer experiments may begin to answer some of these
questions. While of secondary interest to scaffold function as a pre-metastatic niche,
these questions are important toward further the understanding of the foreign body
response in the context of cancer or other immunomodulating conditions.
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8.3.4 Improved understanding of tumor cell dormancy within the scaffold
microenvironment
Although we consistently observe tumor cells arriving to the scaffold implant in
many varied models of cancer metastasis we have never seen secondary tumor forma-
tion at the implant, even over time scales greater than one year for survival studies
after tumor resection. Furthermore we performed preliminary experiments trans-
planting scaffolds containing tumor cells from 4T1-bearing balb/c mice into NSG
immunocompromised mice. In this experiment (data not shown) we did not observe
secondary tumor formation at the transplanted scaffolds and the mice eventually died
of old age. In contrast, in a control experiment to understand if this phenomenon was
simply a result of the low number of cells present within the scaffold, we seeded 20
4T1-tdTomato-luc2 cells on scaffolds and implanted them into NSG mice. We found
all scaffolds implanted demonstrated tumor formation by 4 weeks after implantation.
This result led us to hypothesize that there may be something about the established
foreign body response that prevents these tumor cells from forming a secondary tu-
mor at the implant when they arrive. However, it seems if the tumor cells arrive first
before the foreign body response is established it seems they have an advantage and
are able to subvert the microenvironment to allow their expansion. This is particu-
larly interesting due to the fact that 20 tumor cells is well below the reported number
of tumor cells that is required to form a tumor in limiting dilution assays to identify
cancer stem cell frequency in the 4T1 tumor cell line [242]. The long term fate of
tumor cells recruited to scaffolds is a crucial area for further study as the ability of
the scaffold site to serve as an active site that promotes secondary tumor growth
would be detrimental to clinical translation. Furthermore, enhanced understanding
of the mechanisms of quiescence or dormancy at the implant may help provide basic
answers within the field of tumor dormancy that have been very difficult to study in
animal models.
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8.3.5 Translation of biomaterial scaffolds for detection of metastasis
The first crucial consideration for clinical translation of the platform technol-
ogy discussed herein is device design and fabrication including material, fabrication
method, and size. Scaffold design and size are crucial to scaffold function in humans.
We anticipate that the appropriate size for humans will be a scaffold 13 mm in di-
ameter (instead of the 5 mm used in mouse studies) and 2 mm in height. This size
allows for a large enough implant that it could be biopsied multiple times if needed
but also small enough that it should not be noticeable or cause any discomfort for
the patient. Additionally, fabrication must be conducted in a GMP facility and thus
strides have been made to fabricate PCL scaffolds using a melt-dispersion process
(Youngblood et al., unpublished) which is easily adaptable to GMP practices com-
pared to the synthesis of polymer microparticles. The melt-dispersion process also
allows for a greater level of quality control on the end product as there will no longer
be any batch-to-batch variability in microparticle size.
The method of non-invasive imaging and other analysis techniques are the next
critical components of translation of this platform into humans. This dissertation
reports the use of high frequency ultrasound for monitoring of scaffold tissue pa-
rameters associated with metastasis in mice. Studies to determine the feasibility of
longitudinal monitoring must be performed in patients as well. However, the first
studies in humans with the scaffold will likely be a simple readout of whether tumor
cells were recruited to the scaffold or not via histology and staining for carcinoma
associated markers like pan-cytokeratin. If tumor cells and immune cells associated
with metastasis are recruited to the scaffold implant, the next step will be validating
a protocol for non-invasive imaging and longitudinal monitoring of patient implants.
This dissertation reports on the ability of biomaterial scaffolds to recruit tumor
cells in a variety of different models including orthotopic human 231BR and mouse
4T1 triple negative breast cancer models as well as transgenic models of breast cancer
180
and pancreatic cancer. These results indicate a common mechanism of metastasis in
these models and recruitment of tumor cells and metastasis-associated immune cells
to the scaffold in varied disease models. Transgenic models are the most translatable
implemented in the Shea Lab to date, however more work should be done with other
models of cancer metastasis to determine scaffold function in these models. Current
evidence points to the idea that the scaffold may be suitable for use in a wide array
of metastasizing cancers, but further investigation is warranted.
An emerging method for the detection of metastasis or tumor progression is the
analysis of the scaffold microenvironment and gene signature (Oakes et al., unpub-
lished). These results indicate that the scaffold gene signature is capable of predicting
sensitivity or resistance to an applied therapy, in this case resection of the primary
tumor. These results are an exciting complement to the detection of tumor cells and
provide a platform for detection of tumor-dependent immunomodulation that may
be more sensitive than the detection of tumor cells themselves. However, it remains
to be seen if this information could be gathered from a simple blood test rather than
using the foreign body response to an implanted scaffold. Further work to elucidate
the differential gene expression that may be indicative of tumor progression and/or
metastasis between the immune cells as part of the foreign body response to the
scaffold and those in the blood must be performed.
With the development of new responsive biomaterials, there is an opportunity for
the next generation of scaffolds that recruit metastatic cancer cells and respond to
tumor-dependent immunomodulation to be dynamic and responsive (or smart) [152]
and provide a simple readout as the result of tumor cell recruitment, the presence
of a soluble factor associated with metastasis, or the binding of a specific immune
cell type to a ligand in the material. These next generation smart materials have
the unique opportunity to provide a very simple readout and integrated biochemical
or biomolecular assay within the material, at the cost of increased complexity of the
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material itself and potentially greater barriers to regulation. Clinical implementation
of materials for metastasis detection will require either development of smart materials
or use of simple materials like those described in this dissertation with development
and validation of more complex assays for the analysis of tumor cell arrival and
alteration of immune cell populations and/or gene expression.
Given the significant preclinical findings previously published and presented in
this dissertation, there is sufficient evidence to move forward in a Phase I trial for
safety and efficacy of a poly(ε-caprolactone) scaffold to recruit metastatic tumor cells
in stage IV breast cancer patients. This trial has been designed, approved by the
Institutional Review Board and Tumor Board at University of Michigan and is cur-
rently waiting for approval from the Food and Drug Administration for the scaffold
device. This trial will be the first step toward implementing this technology in pa-
tients for the detection of metastasis and will provide crucial evidence for moving
forward to implementing the scaffold for the early detection of metastasis in patients






[1] E B Ranklin and A J Giaccia. Hypoxic control of metastasis. Science, 352
(6282):175–180, 2016.
[2] S Turajlic and C Swanton. Metastasis as an evolutionary process. Science, 352
(6282):169–174, 2016.
[3] D X Nguyen, P D Bos, and J Massague. Metastasis: from dissemination
to organ-specific colonization. Nat Rev Cancer, 9(4):274–284, 2009. doi:
10.1038/nrc2622. URL http://www.ncbi.nlm.nih.gov/pubmed/19308067.
[4] I J Fidler. The pathogenesis of cancer metastasis: the ’seed and soil’ hypothesis
revisited. Nat Rev Cancer, 3(6):453–458, 2003. doi: 10.1038/nrc1098. URL
http://www.ncbi.nlm.nih.gov/pubmed/12778135.
[5] G P Gupta and J Massague. Cancer metastasis: building a frame-
work. Cell, 127(4):679–695, 2006. doi: 10.1016/j.cell.2006.11.001. URL
http://www.ncbi.nlm.nih.gov/pubmed/17110329.
[6] S Paget. The distribution of secondary growths in can-
cer of the breast. Lancet, 133(3421):98–101, 1889. URL
http://www.ncbi.nlm.nih.gov/pubmed/2673568.
[7] He´ctor Peinado, Masˇa Alecˇkovic´, Simon Lavotshkin, Irina Matei, Bruno
Costa-Silva, Gema Moreno-Bueno, Marta Hergueta-Redondo, Caitlin Williams,
Guillermo Garc´ıa-Santos, Cyrus Ghajar, Ayuko Nitadori-Hoshino, Caitlin Hoff-
man, Karen Badal, Benjamin A Garcia, Margaret K Callahan, Jianda Yuan,
Vilma R Martins, Johan Skog, Rosandra N Kaplan, Mary S Brady, Jedd D
Wolchok, Paul B Chapman, Yibin Kang, Jacqueline Bromberg, David Lyden,
M Aleckovic, Simon Lavotshkin, Irina Matei, Bruno Costa-Silva, Gema Moreno-
Bueno, Marta Hergueta-Redondo, Caitlin Williams, G Garcia-Santos, Cyrus
Ghajar, Ayuko Nitadori-Hoshino, Caitlin Hoffman, Karen Badal, Benjamin A
Garcia, Margaret K Callahan, Jianda Yuan, Vilma R Martins, Johan Skog,
Rosandra N Kaplan, Mary S Brady, Jedd D Wolchok, Paul B Chapman, Yibin
Kang, Jacqueline Bromberg, and David Lyden. Melanoma exosomes educate
bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
Nature medicine, 18(6):883–91, 2012. ISSN 1546-170X. doi: 10.1038/nm.2753.
[8] R N Kaplan, R D Riba, S Zacharoulis, A H Bramley, L Vincent, C Costa, D D
MacDonald, D K Jin, K Shido, S A Kerns, Z Zhu, D Hicklin, Y Wu, J L Port,
184
N Altorki, E R Port, D Ruggero, S V Shmelkov, K K Jensen, S Rafii, and
D Lyden. VEGFR1-positive haematopoietic bone marrow progenitors initiate
the pre-metastatic niche. Nature, 438(7069):820–827, 2005. doi: 10.1038/na-
ture04186. URL http://www.ncbi.nlm.nih.gov/pubmed/16341007.
[9] S C Chafe, Y Lou, J Sceneay, M Vallejo, M J Hamilton, P C Mc-
Donald, K L Bennewith, A Moller, and S Dedhar. Carbonic anhy-
drase IX promotes myeloid-derived suppressor cell mobilization and estab-
lishment of a metastatic niche by stimulating G-CSF production. Can-
cer Res, 75(6):996–1008, 2015. doi: 10.1158/0008-5472.CAN-14-3000. URL
https://www.ncbi.nlm.nih.gov/pubmed/25623234.
[10] J T Erler, K L Bennewith, T R Cox, G Lang, D Bird, A Koong, Q T
Le, and A J Giaccia. Hypoxia-induced lysyl oxidase is a critical me-
diator of bone marrow cell recruitment to form the premetastatic niche.
Cancer Cell, 15(1):35–44, 2009. doi: 10.1016/j.ccr.2008.11.012. URL
http://www.ncbi.nlm.nih.gov/pubmed/19111879.
[11] A J Giles, C M Reid, J D Evans, M Murgai, Y Vicioso, S L High-
fill, M Kasai, L Vahdat, C L Mackall, D Lyden, L Wexler, and
R N Kaplan. Activation of Hematopoietic Stem/Progenitor Cells Pro-
motes Immunosuppression Within the Pre-metastatic Niche. Cancer Res,
76(6):1335–1347, 2016. doi: 10.1158/0008-5472.CAN-15-0204. URL
http://www.ncbi.nlm.nih.gov/pubmed/26719537.
[12] M Kowanetz, X Wu, J Lee, M Tan, T Hagenbeek, X Qu, L Yu, J Ross,
N Korsisaari, T Cao, H Bou-Reslan, D Kallop, R Weimer, M J Ludlam, J S
Kaminker, Z Modrusan, N van Bruggen, F V Peale, R Carano, Y G Meng,
and N Ferrara. Granulocyte-colony stimulating factor promotes lung metas-
tasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad
Sci U S A, 107(50):21248–21255, 2010. doi: 10.1073/pnas.1015855107. URL
https://www.ncbi.nlm.nih.gov/pubmed/21081700.
[13] Y Liu, Y Gu, Y Han, Q Zhang, Z Jiang, X Zhang, B Huang, X Xu, J Zheng,
and X Cao. Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche
Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils.
Cancer Cell, 30(2):243–256, 2016. doi: 10.1016/j.ccell.2016.06.021. URL
https://www.ncbi.nlm.nih.gov/pubmed/27505671.
[14] P B Olkhanud, D Baatar, M Bodogai, F Hakim, R Gress, R L Anderson,
J Deng, M Xu, S Briest, and A Biragyn. Breast cancer lung metastasis re-
quires expression of chemokine receptor CCR4 and regulatory T cells. Can-
cer Res, 69(14):5996–6004, 2009. doi: 10.1158/0008-5472.CAN-08-4619. URL
http://www.ncbi.nlm.nih.gov/pubmed/19567680.
[15] B Z Qian, J Li, H Zhang, T Kitamura, J Zhang, L R Campion, E A Kaiser, L A
Snyder, and J W Pollard. CCL2 recruits inflammatory monocytes to facilitate
185
breast-tumour metastasis. Nature, 475(7355):222–225, 2011. doi: 10.1038/na-
ture10138. URL http://www.ncbi.nlm.nih.gov/pubmed/21654748.
[16] J. Sceneay, M. T. Chow, a. Chen, H. M. Halse, C. S. F. Wong, D. M. Andrews,
E. K. Sloan, B. S. Parker, D. D. Bowtell, M. J. Smyth, and a. Moller. Primary
Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+ Immune Suppressor Cells
and Compromises NK Cell Cytotoxicity in the Premetastatic Niche. Cancer Re-
search, 72(16):3906–3911, 2012. ISSN 0008-5472. doi: 10.1158/0008-5472.CAN-
11-3873. URL https://www.ncbi.nlm.nih.gov/pubmed/22751463.
[17] Bruno Costa-Silva, Nicole M Aiello, Allyson J Ocean, Swarnima Singh, Haiy-
ing Zhang, Basant Kumar Thakur, Annette Becker, Ayuko Hoshino, Mil-
ica Tesˇic´ Mark, Henrik Molina, Jenny Xiang, Tuo Zhang, Till-Martin Theilen,
Guillermo Garc´ıa-Santos, Caitlin Williams, Yonathan Ararso, Yujie Huang,
Gonc¸alo Rodrigues, Tang-Long Shen, Knut Jørgen Labori, Inger Marie Bowitz
Lothe, Elin H Kure, Jonathan Hernandez, Alexandre Doussot, Saya H Ebbesen,
Paul M Grandgenett, Michael a Hollingsworth, Maneesh Jain, Kavita Mallya,
Surinder K Batra, William R Jarnagin, Robert E Schwartz, Irina Matei, He´ctor
Peinado, Ben Z Stanger, Jacqueline Bromberg, and David Lyden. Pancre-
atic cancer exosomes initiate pre-metastatic niche formation in the liver. Na-
ture cell biology, (6), 2015. ISSN 1476-4679. doi: 10.1038/ncb3169. URL
https://www.nature.com/articles/ncb3169.pdf.
[18] Ayuko Hoshino, Bruno Costa-Silva, Tang-Long L Shen, Goncalo Rodrigues,
Ayako Hashimoto, Milica Tesic Mark, Henrik Molina, Shinji Kohsaka, Angela
Di Giannatale, Sophia Ceder, Swarnima Singh, Caitlin Williams, Nadine So-
plop, Kunihiro Uryu, Lindsay Pharmer, Tari King, Linda Bojmar, Alexander E.
Davies, Yonathan Ararso, Tuo Zhang, Haiying Zhang, Jonathan Hernandez,
Joshua M. Weiss, Vanessa D. Dumont-Cole, Kimberly Kramer, Leonard H.
Wexler, Aru Narendran, Gary K. Schwartz, John H. Healey, Per Sandstrom,
K J Labori, Elin H. Kure, Paul M. Grandgenett, Michael A. Hollingsworth,
Maria de Sousa, Sukhwinder Kaur, Maneesh Jain, Kavita Mallya, Surinder K.
Batra, William R. Jarnagin, Mary S. Brady, Oystein Fodstad, Volkmar Muller,
Klaus Pantel, Andy J. Minn, Mina J. Bissell, Benjamin A. Garcia, Yibin
Kang, Vinagolu K. Rajasekhar, Cyrus M. Ghajar, Irina Matei, Hector Peinado,
Jacqueline Bromberg, David Lyden, Knut Jørgen Labori, Elin H. Kure,
Paul M. Grandgenett, Michael A. Hollingsworth, Maria de Sousa, Sukhwinder
Kaur, Maneesh Jain, Kavita Mallya, Surinder K. Batra, William R. Jarna-
gin, Mary S. Brady, Oystein Fodstad, Volkmar Muller, Klaus Pantel, Andy J.
Minn, Mina J. Bissell, Benjamin A. Garcia, Yibin Kang, Vinagolu K. Ra-
jasekhar, Cyrus M. Ghajar, Irina Matei, Hector Peinado, Jacqueline Bromberg,
and David Lyden. Tumour exosome integrins determine organotropic metas-




[19] Sachie Hiratsuka, Akira Watanabe, Hiroyuki Aburatani, and Yoshiro
Maru. Tumour-mediated upregulation of chemoattractants and recruit-
ment of myeloid cells predetermines lung metastasis. Nature Cell Bi-
ology, 8(12):1369–1375, 2006. ISSN 1465-7392. doi: 10.1038/ncb1507.
URL http://www.nature.com/doifinder/10.1038/ncb1507
http://www.ncbi.nlm.nih.gov/pubmed/17128264.
[20] B J Gill and J L West. Modeling the tumor extracellular matrix: Tis-
sue engineering tools repurposed towards new frontiers in cancer biology. J
Biomech, 47(9):1969–1978, 2014. doi: 10.1016/j.jbiomech.2013.09.029. URL
http://www.ncbi.nlm.nih.gov/pubmed/24300038.
[21] David W. Infanger, Maureen E. Lynch, and Claudia Fischbach. Engineered
Culture Models for Studies of Tumor-Microenvironment Interactions. Annual
Review of Biomedical Engineering, 15(1):29–53, 2013. ISSN 1523-9829. doi:
10.1146/annurev-bioeng-071811-150028.
[22] L Gu and D J Mooney. Biomaterials and emerging anti-
cancer therapeutics: engineering the microenvironment. Nat
Rev Cancer, 16(1):56–66, 2016. doi: 10.1038/nrc.2015.3. URL
https://www.ncbi.nlm.nih.gov/pubmed/26694936.
[23] S M Ehsan, K M Welch-Reardon, M L Waterman, C C Hughes, and S C
George. A three-dimensional in vitro model of tumor cell intravasation.
Integr Biol (Camb), 6(6):603–610, 2014. doi: 10.1039/c3ib40170g. URL
http://www.ncbi.nlm.nih.gov/pubmed/24763498.
[24] J S Jeon, S Bersini, M Gilardi, G Dubini, J L Charest, M Moretti,
and R D Kamm. Human 3D vascularized organotypic microfluidic as-
says to study breast cancer cell extravasation. Proc Natl Acad Sci
U S A, 112(1):214–219, 2015. doi: 10.1073/pnas.1417115112. URL
http://www.ncbi.nlm.nih.gov/pubmed/25524628.
[25] J S Jeon, I K Zervantonakis, S Chung, R D Kamm, and J L
Charest. In vitro model of tumor cell extravasation. PLoS
One, 8(2):e56910, 2013. doi: 10.1371/journal.pone.0056910. URL
http://www.ncbi.nlm.nih.gov/pubmed/23437268.
[26] C Y Ko, L Wu, A M Nair, Y T Tsai, V K Lin, and L Tang. The
use of chemokine-releasing tissue engineering scaffolds in a model of in-
flammatory response-mediated melanoma cancer metastasis. Biomateri-
als, 33(3):876–885, 2012. doi: 10.1016/j.biomaterials.2011.10.002. URL
http://www.ncbi.nlm.nih.gov/pubmed/22019117.
[27] Francesca Bersani, Jungwoo Lee, Min Yu, Robert Morris, Rushil Desai, Srid-
har Ramaswamy, Mehmet Toner, Daniel a Haber, and Biju Parekkadan.
Bioengineered implantable scaffolds as a tool to study stromal-derived fac-
tors in metastatic cancer models. Cancer research, 74(24):7229–7238,
187
2014. ISSN 1538-7445. doi: 10.1158/0008-5472.CAN-14-1809. URL
http://www.ncbi.nlm.nih.gov/pubmed/25339351.
[28] D Barkan, H Kleinman, J L Simmons, H Asmussen, A K Kamaraju,
M J Hoenorhoff, Z Y Liu, S V Costes, E H Cho, S Lockett, C Khanna,
A F Chambers, and J E Green. Inhibition of metastatic outgrowth
from single dormant tumor cells by targeting the cytoskeleton. Cancer
Res, 68(15):6241–6250, 2008. doi: 10.1158/0008-5472.CAN-07-6849. URL
http://www.ncbi.nlm.nih.gov/pubmed/18676848.
[29] A de la Fuente, L Alonso-Alconada, C Costa, J Cueva, T Garcia-
Caballero, R Lopez-Lopez, and M Abal. M-Trap: Exosome-Based Cap-
ture of Tumor Cells as a New Technology in Peritoneal Metastasis.
J Natl Cancer Inst, 107(9), 2015. doi: 10.1093/jnci/djv184. URL
http://www.ncbi.nlm.nih.gov/pubmed/26150590.
[30] Shreyas S. Rao, Grace G. Bushnell, Samira M. Azarin, Graham Spicer, Brian A.
Aguado, Jenna R. Stoehr, Eric J. Jiang, Vadim Backman, Lonnie D. Shea,
and Jacqueline S. Jeruss. Enhanced survival with implantable scaffolds that
capture metastatic breast cancer cells in vivo. Cancer Research, 76(18):5209–
5218, sep 2016. ISSN 15387445. doi: 10.1158/0008-5472.CAN-15-2106. URL
http://europepmc.org/abstract/med/27635043.
[31] Samira M Azarin, Ji Yi, Robert M Gower, Brian A Aguado, Megan E Sullivan,
Ashley G Goodman, Eric J Jiang, Shreyas S Rao, Yinying Ren, Susan L Tucker,
Vadim Backman, Jacqueline S Jeruss, and Lonnie D Shea. ARTICLE In vivo
capture and label-free detection of early metastatic cells. Nature Communica-
tions, 6:8094, 2015. doi: 10.1038/ncomms9094.
[32] L Thibaudeau, A V Taubenberger, B M Holzapfel, V M Quent,
T Fuehrmann, P Hesami, T D Brown, P D Dalton, C A Power,
B G Hollier, and D W Hutmacher. A tissue-engineered humanized
xenograft model of human breast cancer metastasis to bone. Dis
Model Mech, 7(2):299–309, 2014. doi: 10.1242/dmm.014076. URL
http://www.ncbi.nlm.nih.gov/pubmed/24713276.
[33] Jodie E Moreau, Kristen Anderson, Joshua R Mauney, Trang Nguyen, David L
Kaplan, and Michael Rosenblatt. Tissue-engineered bone serves as a target
for metastasis of human breast cancer in a mouse model. Cancer Research, 67
(21):10304, 2007. ISSN 1538-7445. doi: 10.1158/0008-5472.CAN-07-2483. URL
http://www.ncbi.nlm.nih.gov/pubmed/17974972.
[34] B A Aguado, J J Wu, S M Azarin, D Nanavati, S S Rao, G G Bushnell, C B
Medicherla, and L D Shea. Secretome identification of immune cell factors me-
diating metastatic cell homing. Sci Rep, 5:17566, 2015. doi: 10.1038/srep17566.
[35] S P Pathi, D D Lin, J R Dorvee, L A Estroff, and C Fischbach. Hydroxyapatite
nanoparticle-containing scaffolds for the study of breast cancer bone metastasis.
188
Biomaterials, 32(22):5112–5122, 2011. doi: 10.1016/j.biomaterials.2011.03.055.
URL https://www.ncbi.nlm.nih.gov/pubmed/21507478.
[36] Jungwoo Lee, Matthew Li, Jack Milwid, Joshua Dunham, Claudio Vinegoni,
Rostic Gorbatov, Yoshiko Iwamoto, Fangjing Wang, Keyue Shen, Kimber-
ley Hatfield, et al. Implantable microenvironments to attract hematopoietic
stem/cancer cells. Proceedings of the National Academy of Sciences, 109(48):
19638–19643, 2012.
[37] S R Vaiselbuh, M Edelman, J M Lipton, and J M Liu. Ectopic
human mesenchymal stem cell-coated scaffolds in NOD/SCID mice: an
in vivo model of the leukemia niche. Tissue Eng Part C Meth-
ods, 16(6):1523–1531, 2010. doi: 10.1089/ten.tec.2010.0179. URL
http://www.ncbi.nlm.nih.gov/pubmed/20586611.
[38] E De Vlieghere, F Gremonprez, L Verset, L Marien, C J Jones, B De Craene,
G Berx, B Descamps, C Vanhove, J P Remon, W Ceelen, P Demetter, M Bracke,
B G De Geest, and O De Wever. Tumor-environment biomimetics delay peri-
toneal metastasis formation by deceiving and redirecting disseminated cancer
cells. Biomaterials, 54:148–157, 2015. doi: 10.1016/j.biomaterials.2015.03.012.
URL http://www.ncbi.nlm.nih.gov/pubmed/25907048.
[39] J A Nemeth, J F Harb, U Barroso Jr., Z He, D J Grignon, and M L
Cher. Severe combined immunodeficient-hu model of human prostate can-
cer metastasis to human bone. Cancer Res, 59(8):1987–1993, 1999. URL
http://www.ncbi.nlm.nih.gov/pubmed/10213511.
[40] T S Xia, G Z Wang, Q Ding, X A Liu, W B Zhou, Y F Zhang, X M Zha,
Q Du, X J Ni, J Wang, S Y Miao, and S Wang. Bone metastasis in a novel
breast cancer mouse model containing human breast and human bone. Breast
Cancer Res Treat, 132(2):471–486, 2012. doi: 10.1007/s10549-011-1496-0. URL
http://www.ncbi.nlm.nih.gov/pubmed/21638054.
[41] F. Philipp Seib, Janice E. Berry, Yusuke Shiozawa, Russell S.
Taichman, and David L. Kaplan. Tissue engineering a surro-
gate niche for metastatic cancer cells. Biomaterials, 51:313–319,
2015. ISSN 18785905. doi: 10.1016/j.biomaterials.2015.01.076. URL
http://www.ncbi.nlm.nih.gov/pubmed/25771021.
[42] B.A. Aguado, J.R. Caffe, D. Nanavati, S.S. Rao, G.G. Bushnell, S.M. Azarin,
and L.D. Shea. Extracellular matrix mediators of metastatic cell colonization
characterized using scaffold mimics of the pre-metastatic niche. Acta Biomate-
rialia, 33, 2016. ISSN 18787568 17427061. doi: 10.1016/j.actbio.2016.01.043.
[43] A V Taubenberger, V M Quent, L Thibaudeau, J A Clements, and D W
Hutmacher. Delineating breast cancer cell interactions with engineered
bone microenvironments. J Bone Miner Res, 28(6):1399–1411, 2013. doi:
10.1002/jbmr.1875. URL http://www.ncbi.nlm.nih.gov/pubmed/23362043.
189
[44] S Bersini, J S Jeon, G Dubini, C Arrigoni, S Chung, J L Charest,
M Moretti, and R D Kamm. A microfluidic 3D in vitro model
for specificity of breast cancer metastasis to bone. Biomaterials, 35
(8):2454–2461, 2014. doi: 10.1016/j.biomaterials.2013.11.050. URL
https://www.ncbi.nlm.nih.gov/pubmed/24388382.
[45] L Yang, C M Edwards, and G R Mundy. Gr-1+CD11b+ myeloid-
derived suppressor cells: formidable partners in tumor metastasis. J
Bone Miner Res, 25(8):1701–1706, 2010. doi: 10.1002/jbmr.154. URL
http://www.ncbi.nlm.nih.gov/pubmed/20572008.
[46] Dmitry I. Gabrilovich and Srinivas Nagaraj. Myeloid-derived sup-
pressor cells as regulators of the immune system. Nat Rev Im-
munol, 9(3):162–174, 2009. ISSN 1474-1733. doi: 10.1038/nri2506.
URL http://www.nature.com/doifinder/10.1038/nri2506
http://www.ncbi.nlm.nih.gov/pubmed/19197294.
[47] S K Sharma, N K Chintala, S K Vadrevu, J Patel, M Karbowniczek,
and M M Markiewski. Pulmonary alveolar macrophages contribute to the
premetastatic niche by suppressing antitumor T cell responses in the lungs.
J Immunol, 194(11):5529–5538, 2015. doi: 10.4049/jimmunol.1403215. URL
http://www.ncbi.nlm.nih.gov/pubmed/25911761.
[48] T R Cox, R M Rumney, E M Schoof, L Perryman, A M Hoye, A Agrawal,
D Bird, N A Latif, H Forrest, H R Evans, I D Huggins, G Lang, R Lind-
ing, A Gartland, and J T Erler. The hypoxic cancer secretome induces pre-
metastatic bone lesions through lysyl oxidase. Nature, 522(7554), 2015. ISSN
0028-0836. doi: 10.1038/nature14492.
[49] A C Monteiro, A C Leal, T Goncalves-Silva, A C Mercadante, F Kestel-
man, S B Chaves, R B Azevedo, J P Monteiro, and A Bonomo. T
cells induce pre-metastatic osteolytic disease and help bone metastases
establishment in a mouse model of metastatic breast cancer. PLoS
One, 8(7):e68171, 2013. doi: 10.1371/journal.pone.0068171. URL
http://www.ncbi.nlm.nih.gov/pubmed/23935856.
[50] W Tan, W Zhang, A Strasner, S Grivennikov, J Q Cheng, R M
Hoffman, and M Karin. Tumour-infiltrating regulatory T cells stimu-
late mammary cancer metastasis through RANKL-RANK signalling. Na-
ture, 470(7335):548–553, 2011. doi: 10.1038/nature09707. URL
http://www.ncbi.nlm.nih.gov/pubmed/21326202.
[51] H Peinado, S Lavotshkin, and D Lyden. The secreted factors responsible for
pre-metastatic niche formation: old sayings and new thoughts. Semin Can-
cer Biol, 21(2):139–146, 2011. doi: 10.1016/j.semcancer.2011.01.002. URL
http://www.ncbi.nlm.nih.gov/pubmed/21251983.
190
[52] H A Smith and Y Kang. The metastasis-promoting roles of tumor-associated
immune cells. J Mol Med (Berl), 91(4):411–429, 2013. doi: 10.1007/s00109-
013-1021-5. URL http://www.ncbi.nlm.nih.gov/pubmed/23515621.
[53] M B Headley, A Bins, A Nip, E W Roberts, M R Looney, A Gerard, and
M F Krummel. Visualization of immediate immune responses to pioneer
metastatic cells in the lung. Nature, 2016. doi: 10.1038/nature16985. URL
http://www.ncbi.nlm.nih.gov/pubmed/26982733.
[54] J M Anderson, A Rodriguez, and D T Chang. Foreign body reaction to bioma-
terials. Semin Immunol, 20(2):86–100, 2008. doi: 10.1016/j.smim.2007.11.004.
URL https://www.ncbi.nlm.nih.gov/pubmed/18162407.
[55] S Franz, S Rammelt, D Scharnweber, and J C Simon. Immune
responses to implants - a review of the implications for the de-
sign of immunomodulatory biomaterials. Biomaterials, 32(28):
6692–6709, 2011. doi: 10.1016/j.biomaterials.2011.05.078. URL
https://www.ncbi.nlm.nih.gov/pubmed/21715002.
[56] A G Mikos, L V McIntire, J M Anderson, and J E Babensee. Host response
to tissue engineered devices. Adv Drug Deliv Rev, 33(1-2):111–139, 1998. URL
https://www.ncbi.nlm.nih.gov/pubmed/10837656.
[57] R M Boehler, J G Graham, and L D Shea. Tissue engineer-
ing tools for modulation of the immune response. Biotechniques, 51
(4):239–40, 242, 244 passim, 2011. doi: 10.2144/000113754. URL
https://www.ncbi.nlm.nih.gov/pubmed/21988690.
[58] Xiao Qing Liu, Rosemarie Kiefl, Claudia Roskopf, Fei Tian, and Rudolf M.
Huber. Interactions among Lung Cancer Cells, Fibroblasts, and Macrophages
in 3D Co-Cultures and the Impact on MMP-1 and VEGF Expression. PLoS
One, 11(5):e0156268, 2016. ISSN 19326203. doi: 10.1371/journal.pone.0156268.
URL https://www.ncbi.nlm.nih.gov/pubmed/27232698.
[59] Yang Liu and Xuetao Cao. Characteristics and Signifi-
cance of the Pre-metastatic Niche. Cancer Cell, 30(5):668–
681, 2016. ISSN 18783686. doi: 10.1016/j.ccell.2016.09.011.
URL http://dx.doi.org/10.1016/j.ccell.2016.09.011
https://www.ncbi.nlm.nih.gov/pubmed/27846389.
[60] S Hiratsuka, A Watanabe, Y Sakurai, S Akashi-Takamura, S Ishibashi,
K Miyake, M Shibuya, S Akira, H Aburatani, and Y Maru. The S100A8-
serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase.
Nat Cell Biol, 10(11):1349–1355, 2008. doi: 10.1038/ncb1794. URL
http://www.ncbi.nlm.nih.gov/pubmed/18820689.
[61] M R Rutkowski, T L Stephen, N Svoronos, M J Allegrezza, A J Tesone,
A Perales-Puchalt, E Brencicova, X Escovar-Fadul, J M Nguyen, M G
191
Cadungog, R Zhang, M Salatino, J Tchou, G A Rabinovich, and J R
Conejo-Garcia. Microbially driven TLR5-dependent signaling governs dis-
tal malignant progression through tumor-promoting inflammation. Can-
cer Cell, 27(1):27–40, 2015. doi: 10.1016/j.ccell.2014.11.009. URL
https://www.ncbi.nlm.nih.gov/pubmed/25533336.
[62] Hannah H. Yan, Michael Pickup, Yanli Pang, Agnieszka E. Gorska, Zhaoyang
Li, Anna Chytil, Yipeng Geng, Jerome W. Gray, Harold L. Moses, and Li Yang.
Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tu-
mor promotion in the premetastatic lung. Cancer Research, 70(15):6139–
6149, 2010. ISSN 00085472. doi: 10.1158/0008-5472.CAN-10-0706. URL
http://www.ncbi.nlm.nih.gov/pubmed/20631080.
[63] V Krishnan, E A Vogler, D M Sosnoski, and A M Mastro. In vitro
mimics of bone remodeling and the vicious cycle of cancer in bone.
J Cell Physiol, 229(4):453–462, 2014. doi: 10.1002/jcp.24464. URL
http://www.ncbi.nlm.nih.gov/pubmed/24022654.
[64] Y Kang, P M Siegel, W Shu, M Drobnjak, S M Kakonen, C Cordon-
Cardo, T A Guise, and J Massague. A multigenic program mediating
breast cancer metastasis to bone. Cancer Cell, 3(6):537–549, 2003. URL
http://www.ncbi.nlm.nih.gov/pubmed/12842083.
[65] S Rafii and D Lyden. S100 chemokines mediate bookmarking of premetastatic
niches. Nat Cell Biol, 8(12):1321–1323, 2006. doi: 10.1038/ncb1206-1321. URL
https://www.ncbi.nlm.nih.gov/pubmed/17139281.
[66] R M Gower, R M Boehler, S M Azarin, C F Ricci, J N Leonard, and L D
Shea. Modulation of leukocyte infiltration and phenotype in microporous
tissue engineering scaffolds via vector induced IL-10 expression. Biomate-
rials, 35(6):2024–2031, 2014. doi: 10.1016/j.biomaterials.2013.11.036. URL
https://www.ncbi.nlm.nih.gov/pubmed/24309498.
[67] H Kwon, H J Kim, W L Rice, B Subramanian, S H Park, I Georgakoudi, and
D L Kaplan. Development of an in vitro model to study the impact of BMP-2 on
metastasis to bone. Journal of Tissue Engineering and Regenerative Medicine,
4(8):590–599, 2010. doi: 10.1002/term.268.
[68] Y Katsuno, A Hanyu, H Kanda, Y Ishikawa, F Akiyama, T Iwase, E Ogata,
S Ehata, K Miyazono, and T Imamura. Bone morphogenetic protein signaling
enhances invasion and bone metastasis of breast cancer cells through Smad
pathway. Oncogene, 27(49):6322–6333, 2008. doi: 10.1038/onc.2008.232. URL
https://www.ncbi.nlm.nih.gov/pubmed/18663362.
[69] Brian T Feeley, Lucie Krenek, Nancy Liu, Wellington K Hsu, Seth C Gamradt,
Edward M Schwarz, Johnny Huard, and Jay R Lieberman. Overexpression
of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Bone, 38(2):154–166, 2006.
192
[70] A S Azmi, B Bao, and F H Sarkar. Exosomes in cancer development,
metastasis, and drug resistance: a comprehensive review. Cancer Metas-
tasis Rev, 32(3-4):623–642, 2013. doi: 10.1007/s10555-013-9441-9. URL
https://www.ncbi.nlm.nih.gov/pubmed/23709120.
[71] B K Thakur, H Zhang, A Becker, I Matei, Y Huang, B Costa-Silva,
Y Zheng, A Hoshino, H Brazier, J Xiang, C Williams, R Rodriguez-
Barrueco, J M Silva, W Zhang, S Hearn, O Elemento, N Paknejad,
K Manova-Todorova, K Welte, J Bromberg, H Peinado, and D Lyden.
Double-stranded DNA in exosomes: a novel biomarker in cancer detec-
tion. Cell Res, 24(6):766–769, 2014. doi: 10.1038/cr.2014.44. URL
https://www.ncbi.nlm.nih.gov/pubmed/24710597.
[72] H Valadi, K Ekstrom, A Bossios, M Sjostrand, J J Lee, and J O Lotvall.
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism
of genetic exchange between cells. Nat Cell Biol, 9(6):654–659, 2007. doi:
10.1038/ncb1596. URL https://www.ncbi.nlm.nih.gov/pubmed/17486113.
[73] L T Brinton, H S Sloane, M Kester, and K A Kelly. Formation and role of ex-
osomes in cancer. Cell Mol Life Sci, 72(4):659–671, 2015. doi: 10.1007/s00018-
014-1764-3. URL http://www.ncbi.nlm.nih.gov/pubmed/25336151.
[74] J S Desgrosellier and D A Cheresh. Integrins in cancer: biological implica-
tions and therapeutic opportunities. Nat Rev Cancer, 10(1):9–22, 2010. doi:
10.1038/nrc2748. URL http://www.ncbi.nlm.nih.gov/pubmed/20029421.
[75] L E Barney, E C Dandley, L E Jansen, N G Reich, A M Mercurio, and
S R Peyton. A cell-ECM screening method to predict breast cancer metas-
tasis. Integr Biol (Camb), 7(2):198–212, 2015. doi: 10.1039/c4ib00218k. URL
http://www.ncbi.nlm.nih.gov/pubmed/25537447.
[76] P M Crapo, T W Gilbert, and S F Badylak. An overview of tissue and whole
organ decellularization processes. Biomaterials, 32(12):3233–3243, 2011. doi:
10.1016/j.biomaterials.2011.01.057.
[77] W D Lu, L Zhang, C L Wu, Z G Liu, G Y Lei, J Liu, W Gao, and Y R Hu. De-
velopment of an Acellular Tumor Extracellular Matrix as a Three-Dimensional
Scaffold for Tumor Engineering. PLoS One, 9(7), 2014. doi: ARTN e103672
10.1371/journal.pone.0103672.
[78] D K Mishra, M J Thrall, B N Baird, H C Ott, S H Blackmon,
J M Kurie, and M P Kim. Human lung cancer cells grown on acel-
lular rat lung matrix create perfusable tumor nodules. Ann Thorac
Surg, 93(4):1075–1081, 2012. doi: 10.1016/j.athoracsur.2012.01.011. URL
https://www.ncbi.nlm.nih.gov/pubmed/22385822.
[79] Aranzazu Villasante, Alessandro Marturano-Kruik, and Gordana Vunjak-
Novakovic. Bioengineered human tumor within a bone niche. Biomaterials, 35
193
(22):5785–5794, 2014. ISSN 18785905. doi: 10.1016/j.biomaterials.2014.03.081.
URL http://dx.doi.org/10.1016/j.biomaterials.2014.03.081.
[80] B M Holzapfel, J C Reichert, J T Schantz, U Gbureck, L Rackwitz, U Noth,
F Jakob, M Rudert, J Groll, and D W Hutmacher. How smart do biomaterials
need to be? A translational science and clinical point of view. Advanced Drug
Delivery Reviews, 65(4):581–603, 2013. doi: 10.1016/j.addr.2012.07.009.
[81] E Lee, E J Fertig, K Jin, S Sukumar, N B Pandey, and A S Popel. Breast
cancer cells condition lymphatic endothelial cells within pre-metastatic niches
to promote metastasis. Nature Communications, 5, 2014. doi: ARTN 4715
10.1038/ncomms5715.
[82] S K Wculek and I Malanchi. Neutrophils support lung colonization
of metastasis-initiating breast cancer cells. Nature, advance on(7582):
1–21, 2015. ISSN 0028-0836. doi: 10.1038/nature16140. URL
http://dx.doi.org/10.1038/nature16140.
[83] R Kalluri. The biology and function of exosomes in cancer. J
Clin Invest, 126(4):1208–1215, 2016. doi: 10.1172/JCI81135. URL
https://www.ncbi.nlm.nih.gov/pubmed/27035812.
[84] Astrid De Boeck, An Hendrix, Dawn Maynard, Mieke Van Bockstal, Annick
Danie¨ls, Patrick Pauwels, Christian Gespach, Marc Bracke, and Olivier De
Wever. Differential secretome analysis of cancerassociated fibroblasts and bone
marrowderived precursors to identify microenvironmental regulators of colon
cancer progression. Proteomics, 13(2):379–388, 2013.
[85] Toshiyuki Yoneda, Paul J Williams, Toru Hiraga, Maria Niewolna,
and R Nishimura. A bone-seeking clone exhibits different biologi-
cal properties from the MDA-MB-231 parental human breast cancer
cells and a brain-seeking clone in vivo and in vitro. J Bone Miner
Res, 16(8):1486–1495, 2001. doi: 10.1359/jbmr.2001.16.8.1486. URL
https://www.ncbi.nlm.nih.gov/pubmed/11499871.
[86] H Hugo, M L Ackland, T Blick, M G Lawrence, J A Clements, E D Williams,
and E W Thompson. Epithelial–mesenchymal and mesenchymal–epithelial tran-
sitions in carcinoma progression. J Cell Physiol, 213(2):374–383, 2007. doi:
10.1002/jcp.21223. URL http://www.ncbi.nlm.nih.gov/pubmed/17680632.
[87] B Ell and Y Kang. Transcriptional control of cancer metastasis. Trends
Cell Biol, 23(12):603–611, 2013. doi: 10.1016/j.tcb.2013.06.001. URL
http://www.ncbi.nlm.nih.gov/pubmed/23838335.
[88] O H Ocana, R Corcoles, A Fabra, G Moreno-Bueno, H Acloque, S Vega,
A Barrallo-Gimeno, A Cano, and M A Nieto. Metastatic colonization re-
quires the repression of the epithelial-mesenchymal transition inducer Prrx1.
194
Cancer Cell, 22(6):709–724, 2012. doi: 10.1016/j.ccr.2012.10.012. URL
http://www.ncbi.nlm.nih.gov/pubmed/23201163.
[89] Cyrus M. Ghajar, He´ctor Peinado, Hidetoshi Mori, Irina R. Matei, Kimberley J.
Evason, He´le`ne Brazier, Dena Almeida, Antonius Koller, Katherine A. Hajjar,
Didier Y R Stainier, Emily I. Chen, David Lyden, and Mina J. Bissell. No Title.
15(7), 2013. doi: 10.1038/ncb2767.
[90] Filippo G Giancotti. Mechanisms governing metastatic dormancy and reacti-
vation. Cell, 155(4):750–764, 2013.
[91] Keith J Luzzi, Ian C MacDonald, Eric E Schmidt, Nancy Kerkvliet, Vincent L
Morris, Ann F Chambers, and Alan C Groom. Multistep Nature of Metastatic
Inefficiency. The American Journal of Pathology, 153(3):865–873, 1998. doi:
10.1016/s0002-9440(10)65628-3.
[92] L Weiss. Metastatic inefficiency. Adv Cancer Res, 54:159–211, 1990. URL
https://www.ncbi.nlm.nih.gov/pubmed/1688681.
[93] L Weiss. Metastatic inefficiency: intravascular and intraperitoneal im-
plantation of cancer cells. Cancer Treat Res, 82:1–11, 1996. URL
https://www.ncbi.nlm.nih.gov/pubmed/8849940.
[94] L Holmgren, M S O’Reilly, and J Folkman. Dormancy of mi-
crometastases: balanced proliferation and apoptosis in the presence
of angiogenesis suppression. Nat Med, 1(2):149–153, 1995. URL
https://www.ncbi.nlm.nih.gov/pubmed/7585012.
[95] S Meng, D Tripathy, E P Frenkel, S Shete, E Z Naftalis, J F Huth, P D
Beitsch, M Leitch, S Hoover, D Euhus, B Haley, L Morrison, T P Fleming,
D Herlyn, L W Terstappen, T Fehm, T F Tucker, N Lane, J Wang, and J W
Uhr. Circulating tumor cells in patients with breast cancer dormancy. Clin
Cancer Res, 10(24):8152–8162, 2004. doi: 10.1158/1078-0432.CCR-04-1110.
URL https://www.ncbi.nlm.nih.gov/pubmed/15623589.
[96] G N Naumov, I C MacDonald, P M Weinmeister, N Kerkvliet, K V Nad-
karni, S M Wilson, V L Morris, A C Groom, and A F Chambers. Per-
sistence of solitary mammary carcinoma cells in a secondary site: a pos-
sible contributor to dormancy. Cancer Res, 62(7):2162–2168, 2002. URL
https://www.ncbi.nlm.nih.gov/pubmed/11929839.
[97] Dalit Barkan, Jeffrey E. Green, and Ann F. Chambers. Extracellular ma-
trix: A gatekeeper in the transition from dormancy to metastatic growth.
European Journal of Cancer, 46(7):1181–1188, 2010. ISSN 09598049. doi:
10.1016/j.ejca.2010.02.027.
[98] C Arrigoni, S Bersini, M Gilardi, and M Moretti. In Vitro Co-
Culture Models of Breast Cancer Metastatic Progression towards Bone.
195
Int J Mol Sci, 17(9), 2016. doi: 10.3390/ijms17091405. URL
https://www.ncbi.nlm.nih.gov/pubmed/27571063.
[99] S Talukdar and S C Kundu. Engineered 3D Silk-Based Metastasis Models:
Interactions Between Human Breast Adenocarcinoma, Mesenchymal Stem Cells
and Osteoblast-Like Cells. Advanced Functional Materials, 23(42):5249–5260,
2013. doi: 10.1002/adfm.201300312.
[100] S Sieh, A V Taubenberger, M L Lehman, J A Clements, C C Nelson, and
D W Hutmacher. Paracrine interactions between LNCaP prostate cancer cells
and bioengineered bone in 3D in vitro culture reflect molecular changes during
bone metastasis. Bone, 63:121–131, 2014. doi: 10.1016/j.bone.2014.02.001.
URL http://www.ncbi.nlm.nih.gov/pubmed/24530694.
[101] B Weigelt, J L Peterse, and L J van ’t Veer. Breast cancer metastasis: markers
and models. Nat Rev Cancer, 5(8):591–602, 2005. doi: 10.1038/nrc1670. URL
http://www.ncbi.nlm.nih.gov/pubmed/16056258.
[102] C A Klein. Parallel progression of primary tumours and metastases.
Nat Rev Cancer, 9(4):302–312, 2009. doi: 10.1038/nrc2627. URL
http://www.ncbi.nlm.nih.gov/pubmed/19308069.
[103] H Esmaeilsabzali, T V Beischlag, M E Cox, A M Parameswaran, and E J
Park. Detection and isolation of circulating tumor cells: principles and methods.
Biotechnol Adv, 31(7):1063–1084, 2013. doi: 10.1016/j.biotechadv.2013.08.016.
URL http://www.ncbi.nlm.nih.gov/pubmed/23999357.
[104] H J Yoon, M Kozminsky, and S Nagrath. Emerging role of nanomaterials in cir-
culating tumor cell isolation and analysis. ACS Nano, 8(3):1995–2017, 2014. doi:
10.1021/nn5004277. URL http://www.ncbi.nlm.nih.gov/pubmed/24601556.
[105] M G Krebs, R L Metcalf, L Carter, G Brady, F H Blackhall, and C Dive.
Molecular analysis of circulating tumour cells-biology and biomarkers. Nat
Rev Clin Oncol, 11(3):129–144, 2014. doi: 10.1038/nrclinonc.2013.253. URL
http://www.ncbi.nlm.nih.gov/pubmed/24445517.
[106] K Pantel, R H Brakenhoff, and B Brandt. Detection, clinical relevance and
specific biological properties of disseminating tumour cells. Nature Reviews
Cancer, 8(5):329–340, 2008. doi: 10.1038/nrc2375.
[107] S Riethdorf, H Fritsche, V Muller, T Rau, C Schindlbeck, B Rack, W Janni,
C Coith, K Beck, F Janicke, S Jackson, T Gornet, M Cristofanilli, and K Pan-
tel. Detection of circulating tumor cells in peripheral blood of patients with
metastatic breast cancer: a validation study of the CellSearch system. Clin
Cancer Res, 13(3):920–928, 2007. doi: 10.1158/1078-0432.CCR-06-1695. URL
http://www.ncbi.nlm.nih.gov/pubmed/17289886.
196
[108] Colette A. Bichsel, Samy Gobaa, Stefan Kobel, Chiara Secondini, George N.
Thalmann, Marco G. Cecchini, and Matthias P. Lutolf. Diagnostic mi-
crochip to assay 3D colony-growth potential of captured circulating tu-
mor cells. Lab on a Chip, 12(13):2313–2316, 2012. ISSN 1473-0197.
doi: 10.1039/c2lc40130d. URL http://xlink.rsc.org/?DOI=c2lc40130d
https://www.ncbi.nlm.nih.gov/pubmed/22565166.
[109] J Lee, N Kohl, S Shanbhang, and B Parekkadan. Scaffold-integrated microchips
for end-to-end in vitro tumor cell attachment and xenograft formation. Technol-
ogy (Singap World Sci), 3(4):179–188, 2015. doi: 10.1142/S2339547815500065.
URL https://www.ncbi.nlm.nih.gov/pubmed/26709385.
[110] M Yu, A Bardia, N Aceto, F Bersani, M W Madden, M C Donaldson, R Desai,
H Zhu, V Comaills, Z Zheng, B S Wittner, P Stojanov, E Brachtel, D Sgroi,
R Kapur, T Shioda, D T Ting, S Ramaswamy, G Getz, A J Iafrate, C Benes,
M Toner, S Maheswaran, and D A Haber. Cancer therapy. Ex vivo culture
of circulating breast tumor cells for individualized testing of drug susceptibil-
ity. Science, 345(6193):216–220, 2014. doi: 10.1126/science.1253533. URL
https://www.ncbi.nlm.nih.gov/pubmed/25013076.
[111] Natalia Bednarz-Knoll, Catherine Alix-Panabie`res, and Klaus Pantel. Clinical
relevance and biology of circulating tumor cells. Breast Cancer Research, 13(6):
1, 2011.
[112] J Yi and V Backman. Imaging a full set of optical scattering proper-
ties of biological tissue by inverse spectroscopic optical coherence tomogra-
phy. Opt Lett, 37(21):4443–4445, 2012. doi: 10.1364/OL.37.004443. URL
http://www.ncbi.nlm.nih.gov/pubmed/23114323.
[113] B J Tauro, D W Greening, R A Mathias, S Mathivanan, H Ji,
and R J Simpson. Two distinct populations of exosomes are released
from LIM1863 colon carcinoma cell-derived organoids. Mol Cell Pro-
teomics, 12(3):587–598, 2013. doi: 10.1074/mcp.M112.021303. URL
https://www.ncbi.nlm.nih.gov/pubmed/23230278.
[114] M S Sosa, P Bragado, and J A Aguirre-Ghiso. Mechanisms
of disseminated cancer cell dormancy: an awakening field. Nat
Rev Cancer, 14(9):611–622, 2014. doi: 10.1038/nrc3793. URL
https://www.ncbi.nlm.nih.gov/pubmed/25118602.
[115] M Cristofanilli, G T Budd, M J Ellis, A Stopeck, J Matera, M C Miller, J M
Reuben, G V Doyle, W J Allard, L W Terstappen, and D F Hayes. Circu-
lating tumor cells, disease progression, and survival in metastatic breast can-
cer. N Engl J Med, 351(8):781–791, 2004. doi: 10.1056/NEJMoa040766. URL
https://www.ncbi.nlm.nih.gov/pubmed/15317891.
[116] Christine L Chaffer and Robert A Weinberg. A Perspec-
tive on Cancer Cell Metastasis. Science, 331(6024):1559–1564,
197
2011. ISSN 0036-8075. doi: 10.1126/science.1203543. URL
http://science.sciencemag.org/content/sci/331/6024/1559.full.pdf
http://www.sciencemag.org/cgi/doi/10.1126/science.1203543.
[117] A F Chambers, A C Groom, and I C MacDonald. Dissemination and growth
of cancer cells in metastatic sites. Nat Rev Cancer, 2(8):563–572, 2002. doi:
10.1038/nrc865. URL http://www.ncbi.nlm.nih.gov/pubmed/12154349.
[118] R Murakami, S Kumita, T Yoshida, K Ishihara, T Kiriyama, K Hakozaki,
K Yanagihara, S Iida, and S Tsuchiya. FDG-PET/CT in the diagnosis of recur-
rent breast cancer. Acta Radiol, 53(1):12–16, 2012. doi: 10.1258/ar.2011.110245.
URL http://www.ncbi.nlm.nih.gov/pubmed/22067206.
[119] K Engelhard, H P Hollenbach, K Wohlfart, E von Imhoff, and F A Fellner.
Comparison of whole-body MRI with automatic moving table technique and
bone scintigraphy for screening for bone metastases in patients with breast
cancer. Eur Radiol, 14(1):99–105, 2004. doi: 10.1007/s00330-003-1968-7. URL
http://www.ncbi.nlm.nih.gov/pubmed/12845463.
[120] T C Lauenstein, S C Goehde, C U Herborn, M Goyen, C Oberhoff, J F De-
batin, S G Ruehm, and J Barkhausen. Whole-body MR imaging: evaluation
of patients for metastases. Radiology, 233(1):139–148, 2004. doi: 10.1148/ra-
diol.2331030777. URL http://www.ncbi.nlm.nih.gov/pubmed/15317952.
[121] S Maheswaran and D A Haber. Circulating tumor cells: a window into cancer
biology and metastasis. Curr Opin Genet Dev, 20(1):96–99, 2010. doi: DOI
10.1016/j.gde.2009.12.002.
[122] M Yu, S Stott, M Toner, S Maheswaran, and D A Haber. Cir-
culating tumor cells: approaches to isolation and characterization. J
Cell Biol, 192(3):373–382, 2011. doi: 10.1083/jcb.201010021. URL
http://www.ncbi.nlm.nih.gov/pubmed/21300848.
[123] S A Joosse and K Pantel. Biologic challenges in the detection of circulating
tumor cells. Cancer Res, 73(1):8–11, 2013. doi: 10.1158/0008-5472.CAN-12-
3422. URL http://www.ncbi.nlm.nih.gov/pubmed/23271724.
[124] P Paterlini-Brechot and N L Benali. Circulating tumor cells
(CTC) detection: clinical impact and future directions. Cancer
Lett, 253(2):180–204, 2007. doi: 10.1016/j.canlet.2006.12.014. URL
http://www.ncbi.nlm.nih.gov/pubmed/17314005.
[125] R N Kaplan, S Rafii, and D Lyden. Preparing the ”soil”: the premetastatic
niche. Cancer Res, 66(23):11089–11093, 2006. doi: 10.1158/0008-5472.CAN-
06-2407. URL http://www.ncbi.nlm.nih.gov/pubmed/17145848.
[126] B Psaila and D Lyden. The metastatic niche: adapting the foreign
soil. Nat Rev Cancer, 9(4):285–293, 2009. doi: 10.1038/nrc2621. URL
http://www.ncbi.nlm.nih.gov/pubmed/19308068.
198
[127] Rosandra N Kaplan, Bethan Psaila, and David Lyden. Bone marrow cells in
the ’pre-metastatic niche’: within bone and beyond. Cancer metastasis reviews,
25(4):521–9, dec 2006. ISSN 0167-7659. doi: 10.1007/s10555-006-9036-9. URL
http://www.ncbi.nlm.nih.gov/pubmed/17186383.
[128] Takanori Kitamura, Bin-Zhi Qian, and Jeffrey W. Pollard. Immune cell promo-
tion of metastasis. Nature Reviews Immunology, 15(2), 2015. ISSN 1474-1733.
doi: 10.1038/nri3789.
[129] Binzhi Qian, Yan Deng, Jae Hong Im, Ruth J Muschel, Yiyu Zou, Jiufeng Li,
Richard a Lang, and Jeffrey W Pollard. A distinct macrophage population medi-
ates metastatic breast cancer cell extravasation, establishment and growth. PloS
one, 4(8):e6562, jan 2009. ISSN 1932-6203. doi: 10.1371/journal.pone.0006562.
[130] J Yi, A J Radosevich, Y Stypula-Cyrus, N N Mutyal, S M Azarin, E Horcher,
M J Goldberg, L K Bianchi, S Bajaj, H K Roy, and V Backman. Spatially
resolved optical and ultrastructural properties of colorectal and pancreatic field
carcinogenesis observed by inverse spectroscopic optical coherence tomogra-
phy. J Biomed Opt, 19(3):36013, 2014. doi: 10.1117/1.JBO.19.3.036013. URL
http://www.ncbi.nlm.nih.gov/pubmed/24643530.
[131] A J Radosevich, N N Mutyal, J Yi, Y Stypula-Cyrus, J D Rogers, M J Gold-
berg, L K Bianchi, S Bajaj, H K Roy, and V Backman. Ultrastructural al-
terations in field carcinogenesis measured by enhanced backscattering spec-
troscopy. J Biomed Opt, 18(9):97002, 2013. doi: 10.1117/1.JBO.18.9.097002.
URL http://www.ncbi.nlm.nih.gov/pubmed/24008865.
[132] A J Radosevich, N N Mutyal, J D Rogers, B Gould, T A Hensing, D Ray,
V Backman, and H K Roy. Buccal spectral markers for lung cancer risk strat-
ification. PLoS One, 9(10):e110157, 2014. doi: 10.1371/journal.pone.0110157.
URL http://www.ncbi.nlm.nih.gov/pubmed/25299667.
[133] Boris M. Holzapfel, Ferdinand Wagner, Daniela Loessner, Nina P.
Holzapfel, Laure Thibaudeau, Ross Crawford, Ming-Tat Ling, Ju-
dith A. Clements, Pamela J. Russell, and Dietmar W. Hutmacher.
Species-specific homing mechanisms of human prostate cancer metasta-
sis in tissue engineered bone. Biomaterials, 35(13):4108–4115, apr
2014. ISSN 01429612. doi: 10.1016/j.biomaterials.2014.01.062. URL
http://linkinghub.elsevier.com/retrieve/pii/S0142961214000921.
[134] Zhaoyang Li, Yanli Pang, Sudheer Kumar Gara, B R Achyut, Christopher
Heger, Paul K Goldsmith, Scott Lonning, and Li Yang. Gr1+ CD11b+ cells
are responsible for tumor promoting effect of TGFβ in breast cancer progression.
International Journal of Cancer, 131(11):2584–2595, 2012.
[135] J Markowitz, R Wesolowski, T Papenfuss, T R Brooks, and W E Car-
son 3rd. Myeloid-derived suppressor cells in breast cancer. Breast Can-
199
cer Res Treat, 140(1):13–21, 2013. doi: 10.1007/s10549-013-2618-7. URL
http://www.ncbi.nlm.nih.gov/pubmed/23828498.
[136] E M Hanson, V K Clements, P Sinha, D Ilkovitch, and S Ostrand-Rosenberg.
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+
and CD8+ T cells. J Immunol, 183(2):937–944, 2009. doi: 10.4049/jim-
munol.0804253. URL http://www.ncbi.nlm.nih.gov/pubmed/19553533.
[137] M Elkabets, V S Ribeiro, C A Dinarello, S Ostrand-Rosenberg, J P Di
Santo, R N Apte, and C A Vosshenrich. IL-1beta regulates a novel myeloid-
derived suppressor cell subset that impairs NK cell development and function.
Eur J Immunol, 40(12):3347–3357, 2010. doi: 10.1002/eji.201041037. URL
http://www.ncbi.nlm.nih.gov/pubmed/21110318.
[138] B Hoechst, T Voigtlaender, L Ormandy, J Gamrekelashvili, F Zhao, H Wede-
meyer, F Lehner, M P Manns, T F Greten, and F Korangy. Myeloid de-
rived suppressor cells inhibit natural killer cells in patients with hepatocellu-
lar carcinoma via the NKp30 receptor. Hepatology, 50(3):799–807, 2009. doi:
10.1002/hep.23054. URL http://www.ncbi.nlm.nih.gov/pubmed/19551844.
[139] Minu K Srivastava, Li Zhu, Marni Harris-White, Upendra Kar, Min Huang,
Ming F Johnson, Jay M Lee, David Elashoff, Robert Strieter, and Steven Du-
binett. Myeloid suppressor cell depletion augments antitumor activity in lung
cancer. PLoS One, 7(7):e40677, 2012.
[140] Gary Kohanbash, Kayla McKaveney, Masashi Sakaki, Ryo Ueda,
Arlan H Mintz, Nduka Amankulor, Mitsugu Fujita, John R
Ohlfest, and Hideho Okada. GM-CSF promotes the immuno-
suppressive activity of glioma-infiltrating myeloid cells through
interleukin-4 receptor-α. Cancer Res, 73(21):6413–6423, 2013. URL
http://cancerres.aacrjournals.org/content/73/21/6413.full.pdf.
[141] C M Diaz-Montero, M L Salem, M I Nishimura, E Garrett-Mayer, D J
Cole, and A J Montero. Increased circulating myeloid-derived suppres-
sor cells correlate with clinical cancer stage, metastatic tumor burden,
and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Im-
munother, 58(1):49–59, 2009. doi: 10.1007/s00262-008-0523-4. URL
http://www.ncbi.nlm.nih.gov/pubmed/18446337.
[142] B Almand, J R Resser, B Lindman, S Nadaf, J I Clark, E D Kwon, D P
Carbone, and D I Gabrilovich. Clinical significance of defective dendritic
cell differentiation in cancer. Clin Cancer Res, 6(5):1755–1766, 2000. URL
http://www.ncbi.nlm.nih.gov/pubmed/10815894.
[143] S Cole, A Montero, E Garret-Mayer, G Onicescu, T Vandenberg, S Hutchens,
and C Diaz-Montero. Elevated Circulating Myeloid Derived Suppressor Cells
(MDSC) Are Associated with Inferior Overall Survival (OS) and Correlate with
200
Circulating Tumor Cells (CTC) in Patients with Metastatic Breast Cancer. In:
Thirty-Second Annual CTRCAACR San Antonio Breast Cancer Symposium:
Cancer Research, San Antonio, TX, 2009.
[144] F Couet, N Rajan, and D Mantovani. Macromolecular bioma-
terials for scaffold-based vascular tissue engineering. Macromol
Biosci, 7(5):701–718, 2007. doi: 10.1002/mabi.200700002. URL
http://www.ncbi.nlm.nih.gov/pubmed/17477449.
[145] H J Sung, C Meredith, C Johnson, and Z S Galis. The effect of scaffold
degradation rate on three-dimensional cell growth and angiogenesis. Bioma-
terials, 25(26):5735–5742, 2004. doi: 10.1016/j.biomaterials.2004.01.066. URL
http://www.ncbi.nlm.nih.gov/pubmed/15147819.
[146] J Kohn, S Abramson, and R Langer. Bioresorbable and Bioerodible Materials.
In B D Ratner, A S Hoffman, F J Schoen, and J E Lemons, editors, Biomaterials
Science: An Introduction to Materials in Medicine, pages 115–127. Elsevier
Academic Press, San Diego, 2004.
[147] J H Jang, C B Rives, and L D Shea. Plasmid delivery in vivo from porous tissue-
engineering scaffolds: transgene expression and cellular transfection. Molec-
ular Therapy, 12(3):475–483, 2005. doi: 10.1016/j.ymthe.2005.03.036. URL
http://www.ncbi.nlm.nih.gov/pubmed/15950542.
[148] J Yi, A J Radosevich, J D Rogers, S C P Norris, I R Capoglu, A Taflove,
and V Backman. Can OCT be sensitive to nanoscale structural alterations
in biological tissue? Optics Express, 21(7):9043–9059, 2013. doi: Doi
10.1364/Oe.21.009043.
[149] Douglas Hanahan and Robert A. Weinberg. Hallmarks of cancer: The next
generation, 2011. ISSN 00928674.
[150] Hector Peinado, Haiying Zhang, Irina R Matei, Bruno Costa-Silva, Ayuko
Hoshino, Goncalo Rodrigues, Bethan Psaila, Rosandra N Kaplan, Jacque-
line F Bromberg, Yibin Kang, Mina J Bissell, Thomas R Cox, Am-
ato J Giaccia, Janine T Erler, Sachie Hiratsuka, Cyrus M Ghajar, and
David Lyden. Pre-metastatic niches: organ-specific homes for metastases.
Nat Rev Cancer, 17(5):302–317, 2017. doi: 10.1038/nrc.2017.6. URL
http://dx.doi.org/10.1038/nrc.2017.6.
[151] Brian A Aguado, Grace G Bushnell, Shreyas S Rao, Jacqueline S Jeruss, and
Lonnie D Shea. Engineering the pre-metastatic niche. 1:77, June 2017.
[152] Brian A Aguado, Joseph C Grim, Adrianne M Rosales, Jana J Watson-
Capps, and Kristi S Anseth. Engineering precision biomaterials for personalized
medicine, 2018. ISSN 19466242.
201
[153] Beverly A Teicher and Simon P Fricker. Cxcl12 (sdf-1)/cxcr4 pathway in cancer.
Clinical cancer research, pages 1078–0432, 2010.
[154] Albert Zlotnik and Osamu Yoshie. Chemokines: a new classification system
and their role in immunity. Immunity, 12(2):121–127, 2000.
[155] Akira Orimo, Piyush B Gupta, Dennis C Sgroi, Fernando Arenzana-Seisdedos,
Thierry Delaunay, Rizwan Naeem, Vincent J Carey, Andrea L Richardson, and
Robert A Weinberg. Stromal fibroblasts present in invasive human breast car-
cinomas promote tumor growth and angiogenesis through elevated sdf-1/cxcl12
secretion. Cell, 121(3):335–348, 2005.
[156] Elena De Falco, Daniele Porcelli, Anna Rita Torella, Stefania Straino,
Maria Grazia Iachininoto, Alessia Orlandi, Silvia Truffa, Paolo Biglioli, Mon-
ica Napolitano, Maurizio C Capogrossi, et al. Sdf-1 involvement in endothelial
phenotype and ischemia-induced recruitment of bone marrow progenitor cells.
Blood, 104(12):3472–3482, 2004.
[157] Magda Kucia, Ryan Reca, Katarzyna Miekus, Jens Wanzeck, Wojtek Wo-
jakowski, Anna Janowska-Wieczorek, Janina Ratajczak, and Mariusz Z Rata-
jczak. Trafficking of normal stem cells and metastasis of cancer stem cells
involve similar mechanisms: pivotal role of the sdf-1–cxcr4 axis. Stem cells, 23
(7):879–894, 2005.
[158] Namita Kundu, Theresa L Beaty, Marian J Jackson, and Amy M Fulton. An-
timetastatic and antitumor activities of interleukin 10 in a murine model of
breast cancer. JNCI: Journal of the National Cancer Institute, 88(8):536–541,
1996.
[159] Yunping Luo, He Zhou, Jo¨rg Krueger, Charles Kaplan, Sung-Hyung Lee, Carrie
Dolman, Dorothy Markowitz, Wenyuan Wu, Cheng Liu, Ralph A Reisfeld, et al.
Targeting tumor-associated macrophages as a novel strategy against breast can-
cer. The Journal of clinical investigation, 116(8):2132–2141, 2006.
[160] Je-In Youn and Dmitry I Gabrilovich. The biology of myeloid-derived suppressor
cells: the blessing and the curse of morphological and functional heterogeneity.
European journal of immunology, 40(11):2969–2975, 2010.
[161] Youjin Lee, Sogyong L Auh, Yugang Wang, Byron Burnette, Yang Wang, Yuru
Meng, Michael Beckett, Rohit Sharma, Robert Chin, Tony Tu, et al. Therapeu-
tic effects of ablative radiation on local tumor require cd8+ t cells: changing
strategies for cancer treatment. Blood, 114(3):589–595, 2009.
[162] Wei Liang and Napoleone Ferrara. The complex role of neutrophils in tumor
angiogenesis and metastasis. Cancer immunology research, 4(2):83–91, 2016.
202
[163] David G DeNardo, Jairo B Barreto, Pauline Andreu, Lesley Vasquez, David
Tawfik, Nikita Kolhatkar, and Lisa M Coussens. Cd4+ t cells regulate pul-
monary metastasis of mammary carcinomas by enhancing protumor properties
of macrophages. Cancer cell, 16(2):91–102, 2009.
[164] Sharon A Williams, Yuka Harata-Lee, Iain Comerford, Robin L Anderson,
Mark J Smyth, and Shaun R McColl. Multiple functions of cxcl12 in a syngeneic
model of breast cancer. Molecular cancer, 9(1):250, 2010.
[165] Purevdorj B Olkhanud, Bazarragchaa Damdinsuren, Monica Bodogai, Ronald E
Gress, Ranjan Sen, Katarzyna Wejksza, Enkhzol Malchinkhuu, Robert P Wer-
sto, and Arya Biragyn. Tumor-evoked regulatory b cells promote breast cancer
metastasis by converting resting cd4+ t cells to t-regulatory cells. Cancer re-
search, 2011.
[166] RM Boehler, R Kuo, S Shin, AG Goodman, MA Pilecki, JN Leonard, and
LD Shea. Lentivirus delivery of il-10 to promote and sustain macrophage po-
larization towards an anti-inflammatory phenotype. Biotechnology and bioengi-
neering, 111(6):1210–1221, 2014.
[167] B Psaila, R N Kaplan, E R Port, and D Lyden. Priming the ’soil’ for breast
cancer metastasis: the pre-metastatic niche. Breast Dis, 26:65–74, 2006. URL
http://www.ncbi.nlm.nih.gov/pubmed/17473366.
[168] Isaiah J Fidler. Metastasis: quantitative analysis of distribution and fate of
tumor emboli labeled with 125I-5-iodo-2-deoxyuridine. Journal of the National
Cancer Institute, 45(4):773–782, 1970.
[169] Ana Maria Gonzalez-Angulo, Flavia Morales-Vasquez, and Gabriel N Horto-
bagyi. Overview of resistance to systemic therapy in patients with breast cancer.
In Breast Cancer Chemosensitivity, pages 1–22. Springer, 2007.
[170] Tathiane M. Malta, Artem Sokolov, Andrew J. Gentles, Tomasz Burzykowski,
Laila Poisson, John N. Weinstein, Boz˙ena Kamin´ska, and Joerg Huelsken. Ma-
chine Learning Identifies Stemness Features Associated with Oncogenic Ded-
ifferentiation. Cell, 173(2):338–354.e15, apr 2018. ISSN 0092-8674. doi:
10.1016/J.CELL.2018.03.034.
[171] Yusuf Emre Erdi. Limits of tumor detectability in nuclear
medicine and PET. Molecular imaging and radionuclide therapy,
21(1):23, 2012. ISSN 21461414. doi: 10.4274/Mirt.138. URL
http://cms.galenos.com.tr/FileIssue/4/509/article/23-28.pdf.
[172] Catherine Alix-Panabie`res and Klaus Pantel. Clinical applications of circulating
tumor cells and circulating tumor DNA as liquid biopsy. 2016. ISSN 21598290.
doi: 10.1158/2159-8290.CD-15-1483.
203
[173] Roy R L Bastien, A´lvaro Rodr´ıguez-Lescure, Mark T W Ebbert, Aleix Prat,
Blanca Muna´rriz, Leslie Rowe, Patricia Miller, Manuel Ruiz-Borrego, Daniel
Anderson, and Bradley Lyons. PAM50 breast cancer subtyping by RT-qPCR
and concordance with standard clinical molecular markers. BMC medical ge-
nomics, 5(1):44, 2012.
[174] Thomas Ried and Indika Rajapakse. The 4D Nucleome, 2017.
[175] Laura Seaman, Haiming Chen, Markus Brown, Darawalee Wangsa, Geoff Pat-
terson, Jordi Camps, Gilbert S Omenn, Thomas Ried, and Indika Rajapakse.
Nucleome Analysis Reveals StructureFunction Relationships for Colon Cancer.
Molecular Cancer Research, 15(7):821–830, 2017.
[176] Fan R K Chung. Spectral graph theory. Number 92. American Mathematical
Soc., 1997. ISBN 0821803158.
[177] Adam A Friedman, Anthony Letai, David E Fisher, and Keith T Flaherty. Pre-
cision medicine for cancer with next-generation functional diagnostics. Nature
Reviews Cancer, 15(12):747, 2015.
[178] A J Minn, G P Gupta, P M Siegel, P D Bos, W Shu, D D Giri, A Viale,
A B Olshen, W L Gerald, and J Massague. Genes that mediate breast cancer
metastasis to lung. Nature, 436(7050):518–524, 2005. doi: 10.1038/nature03799.
URL http://www.ncbi.nlm.nih.gov/pubmed/16049480.
[179] P D Bos, X H Zhang, C Nadal, W Shu, R R Gomis, D X Nguyen,
A J Minn, M J van de Vijver, W L Gerald, J A Foekens, and
J Massague. Genes that mediate breast cancer metastasis to the brain.
Nature, 459(7249):1005–1009, 2009. doi: 10.1038/nature08021. URL
http://www.ncbi.nlm.nih.gov/pubmed/19421193.
[180] A Liberzon, C Birger, H Thorvaldsdottir, M Ghandi, J P Mesirov, and
P Tamayo. The Molecular Signatures Database (MSigDB) hallmark gene set
collection. Cell Syst. 2015; 1 (6): 41725.
[181] B K Linderholm, H Hellborg, U Johansson, G Elmberger, L Skoog, J Lehtio¨,
and R Lewensohn. Significantly higher levels of vascular endothelial growth
factor (VEGF) and shorter survival times for patients with primary operable
triple-negative breast cancer. Annals of oncology, 20(10):1639–1646, 2009.
[182] Brandon L Pierce, Rachel Ballard-Barbash, Leslie Bernstein, Richard N Baum-
gartner, Marian L Neuhouser, Mark H Wener, Kathy B Baumgartner, Frank D
Gilliland, Bess E Sorensen, and Anne McTiernan. Elevated biomarkers of in-
flammation are associated with reduced survival among breast cancer patients.
Journal of Clinical Oncology, 27(21):3437, 2009.
[183] Caitlin D May, Nathalie Sphyris, Kurt W Evans, Steven J Werden, Wenjun
Guo, and Sendurai A Mani. Epithelial-mesenchymal transition and cancer stem
204
cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer
Research, 13(1):202, 2011.
[184] Ming Luo, Michael Brooks, and Max S Wicha. Epithelial-mesenchymal plas-
ticity of breast cancer stem cells: implications for metastasis and therapeutic
resistance. Current pharmaceutical design, 21(10):1301–1310, 2015.
[185] Dongjun Peng, Takashi Tanikawa, Wei Li, Lili Zhao, Linda Vatan, Wojciech
Szeliga, Shanshan Wan, Shuang Wei, Yin Wang, and Yan Liu. Myeloid-
derived suppressor cells endow stem-like qualities to breast cancer cells through
IL6/STAT3 and NO/NOTCH cross-talk signaling. Cancer research, 76(11):
3156–3165, 2016.
[186] Jackie L Johnson, Smitha Pillai, Danielle Pernazza, Sa¨ıd M Sebti, Nicholas J
Lawrence, and Srikumar P Chellappan. Regulation of matrix metalloproteinase
genes by E2F transcription factors: RbRaf-1 interaction as a novel target for
metastatic disease. Cancer research, 72(2):516–526, 2012.
[187] Li Ma, Jennifer Young, Harsha Prabhala, Elizabeth Pan, Pieter Mestdagh,
Daniel Muth, Julie Teruya-Feldstein, Ferenc Reinhardt, Tamer T Onder, and
Scott Valastyan. miR-9, a MYC/MYCN-activated microRNA, regulates E-
cadherin and cancer metastasis. Nature cell biology, 12(3):247, 2010.
[188] Zhibo Yang, Rozita Bagheri-Yarmand, Seetharaman Balasenthil, Gabriel
Hortobagyi, Aysegul A Sahin, Christopher J Barnes, and Rakesh Kumar.
HER2 regulation of peroxisome proliferator-activated receptor gamma (PPAR-
gamma) expression and sensitivity of breast cancer cells to PPAR-gamma ligand
therapy. Clinical Cancer Research, 9(8):3198–3203, 2003.
[189] Regina Berretta and Pablo Moscato. Cancer biomarker discovery: the entropic
hallmark. PLoS One, 5(8):e12262, 2010.
[190] Maxime Tarabichi, Aline Antoniou, Manuel Saiselet, Jaime Miguel Pita, Guy
Andry, Jacques Emile Dumont, Vincent Detours, and Carine Maenhaut. Sys-
tems biology of cancer: entropy, disorder, and selection-driven evolution to in-
dependence, invasion and swarm intelligence. Cancer and Metastasis Reviews,
32(3-4):403–421, 2013.
[191] Christopher R S Banerji, Simone Severini, Carlos Caldas, and Andrew E
Teschendorff. Intra-tumour signalling entropy determines clinical outcome in
breast and lung cancer. PLoS computational biology, 11(3):e1004115, 2015.
[192] Jagdeep K Singh, Bruno M Simo˜es, Sacha J Howell, Gillian Farnie, and
Robert B Clarke. Recent advances reveal IL-8 signaling as a potential key
to targeting breast cancer stem cells. Breast Cancer Research, 15(4):210, 2013.
[193] Andrew R Chin and Shizhen Emily Wang. Cytokines driving breast cancer
stemness. Molecular and cellular endocrinology, 382(1):598–602, 2014.
205
[194] Ina H Benoy, Roberto Salgado, Peter Van Dam, Katrien Geboers, Eric Van
Marck, Simon Scharpe´, Peter B Vermeulen, and Luc Y Dirix. Increased serum
interleukin-8 in patients with early and metastatic breast cancer correlates with
early dissemination and survival. Clinical Cancer Research, 10(21):7157–7162,
2004.
[195] Margit A Huber, Ninel Azoitei, Bernd Baumann, Stefan Gru¨nert, Andreas Som-
mer, Hubert Pehamberger, Norbert Kraut, Hartmut Beug, and Thomas Wirth.
NFkB is essential for epithelial-mesenchymal transition and metastasis in a
model of breast cancer progression. The Journal of clinical investigation, 114
(4):569–581, 2004.
[196] Simi Ali and Gwendal Lazennec. Chemokines: novel targets for breast cancer
metastasis. Cancer and Metastasis Reviews, 26(3-4):401–420, 2007.
[197] Daniele Santini, Gaia Schiavon, Bruno Vincenzi, Laura Gaeta, Francesco Pan-
tano, Antonio Russo, Cinzia Ortega, Camillo Porta, Sara Galluzzo, and Grazia
Armento. Receptor activator of NF-kB (RANK) expression in primary tumors
associates with bone metastasis occurrence in breast cancer patients. PLoS
One, 6(4):e19234, 2011.
[198] Calvin R Justus, Nancy Leﬄer, Maria Ruiz-Echevarria, and Li V Yang. In vitro
cell migration and invasion assays. Journal of visualized experiments: JoVE,
(88), 2014.
[199] Elizabeth Tarasewicz, Robert S Oakes, Misael O Aviles, Joelle Straehla,
Kathryn M Chilton, Joseph T Decker, Jia Wu, Lonnie D Shea, and Jacque-
line S Jeruss. Embryonic stem cell secreted factors decrease invasiveness of
triple-negative breast cancer cells through regulome modulation. Cancer biol-
ogy & therapy, 19(4):271–281, 2018.
[200] Vamsi K Mootha, Cecilia M Lindgren, Karl-Fredrik Eriksson, Aravind Subra-
manian, Smita Sihag, Joseph Lehar, Pere Puigserver, Emma Carlsson, Martin
Ridderstr˚ale, and Esa Laurila. PGC-1alpha-responsive genes involved in oxida-
tive phosphorylation are coordinately downregulated in human diabetes. Nature
genetics, 34(3):267, 2003.
[201] Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee,
Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy,
Todd R Golub, and Eric S Lander. Gene set enrichment analysis: a knowledge-
based approach for interpreting genome-wide expression profiles. Proceedings
of the National Academy of Sciences, 102(43):15545–15550, 2005.
[202] Haiming Chen, Jie Chen, Lindsey A Muir, Scott Ronquist, Walter Meixner,
Mats Ljungman, Thomas Ried, Stephen Smale, and Indika Rajapakse. Func-
tional organization of the human 4D Nucleome. Proceedings of the National
Academy of Sciences, 112(26):8002–8007, 2015.
206
[203] Erik Aronesty. Comparison of sequencing utility programs. The Open Bioin-
formatics Journal, 7(1), 2013.
[204] Thomas J Rosol, Sarah H Tannehill-Gregg, Bruce E LeRoy, Stefanie Mandl,
and Christopher H Contag. Animal models of bone metastasis. Cancer, 97(S3):
748–757, 2003.
[205] Julio A Aguirre-Ghiso. Models, mechanisms and clinical evidence for cancer
dormancy. Nature Reviews Cancer, 7(11):834, 2007.
[206] Jerald J Killion, Robert Radinsky, and Isaiah J Fidler. Orthotopic models are
necessary to predict therapy of transplantable tumors in mice. Cancer and
Metastasis Reviews, 17(3):279–284, 1998.
[207] James E Talmadge, Rakesh K Singh, Isaiah J Fidler, and Avraham Raz. Murine
models to evaluate novel and conventional therapeutic strategies for cancer. The
American journal of pathology, 170(3):793–804, 2007.
[208] Erica Yada, Satoshi Wada, Shintaro Yoshida, and Tetsuro Sasada. Use of
patient-derived xenograft mouse models in cancer research and treatment, 2017.
[209] Samuel Aparicio, Manuel Hidalgo, and Andrew L Kung. Examining the utility
of patient-derived xenograft mouse models. Nature Reviews Cancer, 15(5):311,
2015.
[210] Rebecca L. Siegel, Kimberly D. Miller, and Ahmedin Je-
mal. Cancer statistics, 2018. CA: A Cancer Journal
for Clinicians, 68(1):7–30. doi: 10.3322/caac.21442. URL
https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21442.
[211] Yves Hu¨semann, Jochen B Geigl, Falk Schubert, Piero Musiani, Manfred Meyer,
Elke Burghart, Guido Forni, Roland Eils, Tanja Fehm, Gert Riethmu¨ller, et al.
Systemic spread is an early step in breast cancer. Cancer cell, 13(1):58–68,
2008.
[212] David G DeNardo and Lisa M Coussens. Inflammation and breast cancer.
balancing immune response: crosstalk between adaptive and innate immune
cells during breast cancer progression. Breast cancer research, 9(4):212, 2007.
[213] Andrew D Rhim, Emily T Mirek, Nicole M Aiello, Anirban Maitra, Jennifer M
Bailey, Florencia McAllister, Maximilian Reichert, Gregory L Beatty, Anil K
Rustgi, Robert H Vonderheide, et al. Emt and dissemination precede pancreatic
tumor formation. Cell, 148(1):349–361, 2012.
[214] Andrew D Rhim, Fredrik I Thege, Steven M Santana, Timothy B Lannin,
Trisha N Saha, Shannon Tsai, Lara R Maggs, Michael L Kochman, Gregory G
Ginsberg, John G Lieb, et al. Detection of circulating pancreas epithelial cells in
patients with pancreatic cystic lesions. Gastroenterology, 146(3):647–651, 2014.
207
[215] Suresh T Chari, Kimberly Kelly, Michael A Hollingsworth, Sarah P Thayer,
David A Ahlquist, Dana K Andersen, Surinder K Batra, Teresa A Brentnall,
Marcia Canto, Deborah F Cleeter, et al. Early detection of sporadic pancreatic
cancer: summative review. Pancreas, 44(5):693, 2015.
[216] NABIL Hanna and RC Burton. Definitive evidence that natural killer (nk) cells
inhibit experimental tumor metastases in vivo. The Journal of Immunology, 127
(5):1754–1758, 1981.
[217] Theresa L Whiteside and Ronald B Herberman. The role of natural killer cells in
immune surveillance of cancer. Current opinion in immunology, 7(5):704–710,
1995.
[218] Camille Guillerey, Nicholas D Huntington, and Mark J Smyth. Targeting natu-
ral killer cells in cancer immunotherapy. Nature immunology, 17(9):1025, 2016.
[219] Raquel Tarazona, Beatriz Sanchez-Correa, Ignacio Casas-Avile´s, Carmen Cam-
pos, Alejandra Pera, Sara Morgado, Nelson Lo´pez-Sejas, Fakhri Hassouneh,
Juan M Bergua, Maria Jose Arcos, et al. Immunosenescence: limitations of nat-
ural killer cell-based cancer immunotherapy. Cancer Immunology, Immunother-
apy, 66(2):233–245, 2017.
[220] A. Stathopoulou, I. Vlachonikolis, D. Mavroudis, M. Perraki, Ch Kouroussis,
S. Apostolaki, N. Malamos, S. Kakolyris, A. Kotsakis, N. Xenidis, D. Reppa,
and V. Georgoulias. Molecular detection of cytokeratin-19-positive cells in the
peripheral blood of patients with operable breast cancer: Evaluation of their
prognostic significance. Journal of Clinical Oncology, 2002. ISSN 0732183X.
doi: 10.1200/JCO.2002.08.135.
[221] Anuja Nair, Barry D. Kuban, Nancy Obuchowski, and D. Geoffrey Vince. As-
sessing spectral algorithms to predict atherosclerotic plaque composition with
normalized and raw intravascular ultrasound data. Ultrasound in Medicine and
Biology, 2001. ISSN 03015629. doi: 10.1016/S0301-5629(01)00436-7.
[222] Ernesl Feleppa, Andrew Kalisz, Joan B. Sokil-Melgar, Frederic L. Lizzi, Tian
Liu, Angel L. Rosado, Mary C. Shao, William R. Fair, Yu Wang, Michael S.
Cookson, Victor E. Reuter, and Warren D.W. Heston. Typing of prostate tis-
sue by ultrasonic spectrum analysis. IEEE Transactions on Ultrasonics, Ferro-
electrics, and Frequency Control, 1996. ISSN 08853010. doi: 10.1109/58.503779.
[223] Ronald E. Kumon, Michael J. Pollack, Ashley L. Faulx, Kayode Olowe, Fa-
rees T. Farooq, Victor K. Chen, Yun Zhou, Richard C.K. Wong, Gerard A.
Isenberg, Michael V. Sivak, Amitabh Chak, and Cheri X. Deng. In vivo charac-
terization of pancreatic and lymph node tissue by using EUS spectrum analy-
sis: a validation study. Gastrointestinal Endoscopy, 2010. ISSN 00165107. doi:
10.1016/j.gie.2009.08.027.
208
[224] Madhu Gudur, Rameshwar R. Rao, Yi-Sing Hsiao, Alexis W. Peterson, Cheri X.
Deng, and Jan P. Stegemann. Noninvasive, Quantitative, Spatiotemporal Char-
acterization of Mineralization in Three-Dimensional Collagen Hydrogels Us-
ing High-Resolution Spectral Ultrasound Imaging. Tissue Engineering Part C:
Methods, 2012. ISSN 1937-3384. doi: 10.1089/ten.tec.2012.0180.
[225] Madhu Sudhan Reddy Gudur, Rameshwar R. Rao, Alexis W. Peterson, David J.
Caldwell, Jan P. Stegemann, and Cheri X. Deng. Noninvasive quantification
of in vitro osteoblastic differentiation in 3D engineered tissue constructs us-
ing spectral ultrasound imaging. PLoS ONE, 2014. ISSN 19326203. doi:
10.1371/journal.pone.0085749.
[226] Xiaowei Hong, Jan P. Stegemann, and Cheri X. Deng. Microscale charac-
terization of the viscoelastic properties of hydrogel biomaterials using dual-
mode ultrasound elastography. Biomaterials, 2016. ISSN 18785905. doi:
10.1016/j.biomaterials.2016.02.019.
[227] Jessica Stukel, Monica Goss, Haoyan Zhou, Wenda Zhou, Rebecca Willits,
and Agata Exner. Development of a High-Throughput Ultrasound Technique
for the Analysis of Tissue Engineering Constructs. 44(3):793–802, 2017. doi:
10.1007/s10439-015-1507-0.Development.
[228] William J Gradishar, Benjamin O Anderson, Ron Balassanian, Sarah L Blair,
Harold J Burstein, Amy Cyr, Anthony D Elias, William B Farrar, Andres
Forero, Sharon Hermes Giordano, et al. Nccn guidelines insights: breast cancer,
version 1.2017. Journal of the National Comprehensive Cancer Network, 15(4):
433–451, 2017.
[229] Xiaowei Hong, Ramkumar T Annamalai, Tyler Kemerer, Cheri X Deng,
and Jan P Stegemann. Multimode ultrasound viscoelastography for three-
dimensional interrogation of microscale mechanical properties in heterogeneous
biomaterials. Biomaterials, 2018.
[230] Charles Gawad, Winston Koh, and Stephen R Quake. Single-cell genome se-
quencing: Current state of the science, 2016. ISSN 14710064.
[231] Ja Hye Myung, Cari A Launiere, David T Eddington, and Seungpyo Hong.
Enhanced tumor cell isolation by a biomimetic combination of e-selectin and
anti-epcam: Implications for the effective separation of circulating tumor
cells (CTCs). Langmuir, 26(11):8589–8596, 2010. ISSN 07437463. doi:
10.1021/la904678p.
[232] Eric Lin, Lianette Rivera-Ba´ez, Shamileh Fouladdel, Hyeun Joong Yoon,
Stephanie Guthrie, Jacob Wieger, Yadwinder Deol, Evan Keller, Vaibhav Sa-
hai, Diane M Simeone, Monika L Burness, Ebrahim Azizi, Max S Wicha, and
Sunitha Nagrath. High-Throughput Microfluidic Labyrinth for the Label-free
Isolation of Circulating Tumor Cells. Cell Systems, 5(3):295—-304.e4, 2017.
ISSN 24054720. doi: 10.1016/j.cels.2017.08.012.
209
[233] Ramdane A Harouaka, Ming Da Zhou, Tim Y Yeh, Waleed J Khan, Jeffery
Allerton, and Si Yang Zheng. Viable circulating tumor cell enrichment by flex-
ible micro spring array. In Proceedings of the Annual International Conference
of the IEEE Engineering in Medicine and Biology Society, EMBS, pages 6269–
6272, 2012. ISBN 9781424441198. doi: 10.1109/EMBC.2012.6347427.
[234] Virginia Espina, Julia D Wulfkuhle, Valerie S Calvert, Amy VanMeter, Weidong
Zhou, George Coukos, David H Geho, Emanuel F Petricoin, and Lance A Liotta.
Laser-capture microdissection. Nature Protocols, 1(2):586–603, 2006. ISSN
17542189. doi: 10.1038/nprot.2006.85.
[235] Todd M Gierahn, Marc H Wadsworth, Travis K Hughes, Bryan D Bryson,
Andrew Butler, Rahul Satija, Sarah Fortune, J Christopher Love, and Alex K
Shalek. Seq-Well: portable, low-cost RNA sequencing of single cells at high
throughput. Nature Methods, 2017.
[236] H Piccard, R J Muschel, and G Opdenakker. On the dual roles and polarized
phenotypes of neutrophils in tumor development and progression, 2012. ISSN
10408428.
[237] Justin A Kenkel, William W Tseng, Matthew G Davidson, Lorna L Tolentino,
Okmi Choi, Nupur Bhattacharya, E Scott Seeley, Daniel A Winer, Nathan E
Reticker-Flynn, and Edgar G Engleman. An immunosuppressive dendritic
cell subset accumulates at secondary sites and promotes metastasis in pan-
creatic cancer. Cancer Research, 77(15):4158–4170, 2017. ISSN 15387445. doi:
10.1158/0008-5472.CAN-16-2212.
[238] Alejandro Lo´pez-Soto, Segundo Gonzalez, Mark J Smyth, and Lorenzo Galluzzi.
Control of Metastasis by NK Cells, 2017. ISSN 18783686.
[239] Muthulekha Swamydas and Michail S Lionakis. Isolation, Purification and La-
beling of Mouse Bone Marrow Neutrophils for Functional Studies and Adoptive
Transfer Experiments. Journal of Visualized Experiments, (77), 2013. ISSN
1940-087X. doi: 10.3791/50586.
[240] Mark Anthony Bray, Shantanu Singh, Han Han, Chadwick T Davis, Blake
Borgeson, Cathy Hartland, Maria Kost-Alimova, Sigrun M Gustafsdottir,
Christopher C Gibson, and Anne E Carpenter. Cell Painting, a high-
content image-based assay for morphological profiling using multiplexed flu-
orescent dyes. Nature Protocols, 11(9):1757–1774, 2016. ISSN 17502799. doi:
10.1038/nprot.2016.105.
[241] Xiaoxu Zhou, Jian Wang, Junye Chen, Yuankai Qi, Di Nan, Luhong Jin, Xiao-
han Qian, Xinyi Wang, Qingyong Chen, Xu Liu, and Yingke Xu. Optogenetic
control of epithelial-mesenchymal transition in cancer cells. Scientific Reports,
8(1), 2018. ISSN 20452322. doi: 10.1038/s41598-018-32539-3.
210
[242] Jorg A Kruger, Charles D Kaplan, Yunping Luo, He Zhou, Dorothy Markowitz,
Rong Xiang, and Ralph A Reisfeld. Characterization of stem cell-like can-
cer cells in immune-competent mice. Blood, 108(12):3906–3912, 2006. ISSN
00064971. doi: 10.1182/blood-2006-05-024687.
211
